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- IV  -Preface 
The  Chernobyl  accident,  which  occurred  on  26  April  1986,  presented  major 
challenges to the European Community with respect to the practical and regulatory 
aspects of radiation protection, public information, trade, particularly in food,  and 
international politics.  The Chernobyl accident was also a major challenge to the 
international scientific community which had to evaluate rapidly the radiological 
consequences of  the accident and advise on the introduction of  any countermeasures. 
Prior to the accident at Chernobyl, countermeasures to reduce the consequences of 
radioactive contamination had been conceived largely in the context of relatively 
s1nall  accidental  releases  and  for  application  over  relatively  small  areas.  Less 
consideration had been given to the practical implications of  applying such measures 
in case of a large source term and a spread over a very large area. 
The Radiation Protection Research and Training Programme was influential in a 
number of important initiatives taken within the Community immediately after the 
accident.  Information was  collected  by Community scientists  and,  from  it,  an 
assessment made within days of the possible consequences. This showed that the 
health impact on the population of the European Community was not expected to 
be significant.  About four weeks after the accident, the Programme, together \vith 
the US  Department of Energy, organised a meeting in Brussels during which the 
data on dispersion of radioactive material were discussed and evaluated. Several 
other meetings followed soon after on the transfer of  radio  nuclides in the food chain 
and possible health effects. These meetings were carried out in close co-operation 
w·ith  the  DG  XI  (Directorate  General,  Environment,  Consumer Protection and 
Nuclear Safety) within the CEC, and, externally, with international organisations 
such as  the International Atomic  Energy Agency (IAEA)  and the World Health 
Organisation (WHO). In addition, the Commission convoked a Committee of high-
level independent scientists to assess the scientific evidence from current research 
in  view of recent nuclear incidences, to consider the possible implications for the 
Basic Standards and emergency reference levels and to advise the Commission on 
future action in radiological protection including research. (EUR 11449 EN). 
Soon after the accident,  additional research requirements were identified by the 
Programme; these were mainly better methods to assess accident consequences and 
-v -the further improvetnent of off-site accident management. Several existing contracts 
\Vere reoriented and new contracts were placed; however, the financial means then 
available within the Programme were insufficient to fund the additional research 
identified as necessary. A proposal for a revision of the Programme was, therefore, 
elaborated in 1986. It comprised 10 specific "post-Chernobyl" research actions.  This 
revision,  with an additional budget of 10  MEcu for  a  period of two years,  was 
adopted by the Council of Ministers on 21  December 1987.  With the help of the 
Management and Coordination Advisory Committee (CGC) "Radiation Protection" 
a  number of institutes was identified to carry out the research in a  co-operative 
manner, and the research began in the spring of 1988. 
These post-Chernobyl activities have now been completed. Detailed reports on each 
of these studies and an additional volume containing the executive summaries of all 
reports are now available. 
Evaluation of data on the transfer of radionuclides in the food chain, 
Improvement of reliable long-distance atmospheric transport models, 
Radiological aspects of nuclear accident scenarios, 
A.  Real-time emergency response systems, 
B.  The RADE-AID system, 
Monitoring and surveillance in accident situations, 
Underlying data for derived emergency reference levels, 
Improvement  of  practical  countermeasures  against  nuclear 
contamination in the agricultural environment, 
Improvement  of  practical  countermeasures  against  nuclear 
contamination in the urban environment, 
Improvement of practical countermeasures: preventive medication, 
Treatment and biological dosimetry of exposed persons, 
Feasibility of studies on health effects due to the reactor accident at 
Chernobyl. 
The research undertaken within the "post-Chernobyl" actions has added considerably 
to  the  understanding  of the  basic  underlying  mechanisms  of the  transfer  of 
radionuclides in the environment, of the treatment of accident victims and of ho\v 
the environmental consequences of  accidents may be mitigated. In addition, progress 
has  been  made  in  the  setting  up  environmental  surveillance  program1nes 
development of predictive and decision-aiding techniques, the implementation of 
- VI  -\vhich will lead to significant itnprovements in off-site accident management. Several 
new ideas and lines of theoretical and practical research have originated from the 
post-Chernobyl research and these have already been integrated into the ongoing 
Community Radiation Protection Research Programme. A further important feature 
which should not be  overlooked,  is  the close and effective collaboration of many 
institutes  in  the  research;  this  has  markedly  strengthened  the  ties  between 
Community institutes and scientists. The outcome of all of this work is that the 
Community and all other countries are now better prepared and co-ordinated should 
a significant release of radioactivity ever occur again 
Further research is continuing within the current Radiation Protection Research and 
Training Programme 1990-1991 on a number of the "post-Chernobyl" topics; these 
also form part of the proposal of the specific Programme on "Nuclear Fission Safety" 
1992-1993,  e.g.  real-time  emergency  management  systems,  development  of 
countermeasures in the agricultural environment, treatment of radiation accident 
victims, etc. Moreover, the Community Programme is currently making a significant 
contribution  to  an international  evaluation,  being undertaken by IAEA  at the 
request  of the  Soviet  Government,  on  the  consequences  in  the  USSR  of the 
Chernobyl accident and of the measures being taken to ensure safe living conditions 
for the affected populations. 
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Executive  summary 
1.  Introduction 
The  accident  at  the  Nuclear  Power  Station  at  Chernobyl  was -of  great 
concern  to  all  countries  of  the  E.C.  because  the  radioactive  emission 
was  carried  over  long  distances  and  resulted  in  variable  fall  out  of 
radioactive  isotopes  in  all  areas  of  the  E.C.  Obviously,  radiation 
levels were  the highest inside  the  plant  and  in its immediate vicinity. 
At  least 200  people  involved in  the accident itself at the installation 
or in efforts  to  control  the  catastrophe  by  bringing  the  reactor  under 
control  were  exposed  to  radiation levels  and/or other injuries of such 
extent  that  immediate  medical  care  was  required.  The  information 
concerning  the  acute  victims,  that  was  released  by  the  Russian 
authorities  and  the  subsequent  results  of  the  medical  interventions 
proved  to  be  of  great  interest  to  radiation  experts  of  the  E.C. 
Although  the  radiation  protection  program  of  the  E.C.  had  for  many 
years  included  applied  research  on  the  effects  of  high  dose  radiation 
exposure  and  on  the  treatment  of its consequences,  the  analysis of  the 
acute  :hernobyl  cases  revealed  several  new  issues,  not  foreseen  from 
the  experience of past  reactor accidents,  that  were  all of  a  much  more 
limited extend. 
- XI  -These  problems  were  analysed  by  experts  from  the  Advisory  Committy  as 
the data became  available and  the  most  important ones  were  selected for 
study  in  the  context of  a  crash  research effort,  that is designated  as 
the Post- Ch ernobyl  program. 
The  result  of  the  projects  concerned  with  diagnosis,  prognosis  and 
treatment of acute radiation injuries are  reported in this chapter. 
2.  The  experience of  Chernobyl 
During  the first hours  and or days  of the accident,  several hundreds of 
persons  were  exposed  to  extensive  radiation  from  the  burning  reactor 
and- its  emissions.  A  certain  proportion  of  the  victims  had  also 
suffered  thermal  burns  and  inhalation  of  radioactive  isotipes  of 
unknown  concentration  and  amount  had  occured  as  well.  In  the  majority 
of  the  cases  the  body  dose  received  by  individuals  could  not  be 
reliably  derived  form  personal  dosimeters  carried  by  the  victims.  On 
the  bases of calculated exposures,  using  time,  duration of presence and 
location,  about  200  persons  were  selected  for  immediate hospitalisation 
on  the  likelyhood  of  need  for  treatment.  They  were  transported  to 
specialised  hospitals  in  Moskou  and  Kiew  for  further  diagnostic  and 
prognostic  evaluation.  On  the  bases  of  peripheral  blood  counts,  bone 
marrow  puncture  and  chromosomal  analysis,  19  patients were  treated with 
bone  marrow  or  fatal  liver- cell  transplants.  The  clinical  course  and 
the  results  have  been  reported  in  a  general  way  only  and  the  medical 
community  is  still  awaiting  more  detailed  information.  Anyhow  the 
effects  of  the  transplantations  have  been  disappointing  in  that  a 
benificial influence was  not obser-ved. 
- XII  -In part this  seems  to  be  due  to  the  mixed  type  injuries suffered by  the 
victims  (in particular skin  burns  and  intestinal  damage  in  combination 
with  hemopoietic  injury}.  Other  factors  were  the  lack  of  HLA  identical 
sibling  donors  of  bone  marrow  and  the  fact  that  there  had  been  no 
experience with  bone  marrow  transplantation in Russia. 
This  was  also  the  first  occasion  that  a  large  number  of  heavily 
irradiated  people  had  to  be  treated at  the  same  time  in  one  hospital. 
Owing  to  the  numbers  of  victims  involved  and  the  nature  of  the 
radiation exposure,  these observations  are  obviously of great  interest 
to  the  Commission  on  Radiation Protection of E.C. 
Within  the first few  days  after the accident,  the  Commission  approached 
the  various  bone  marrow  transplantation  teams  in  the  E.C.  and  made  an 
inventory  of  the  number  of  beds  that  could  be  made  available  for 
Russian  patients  possibly  requiring  treatment  with  bone  marrow  grafts. 
The  Russian  authorities  were  then  offered  to  transport  any  number  of 
transplant  candidates  to  these  highly  specialised  teams  in Europe,  but 
this proposal  was  not accepted. 
During  the  months  after  the  accident,  experts  of  the  E.C.  met  on  a 
number  of  occasions  to  evaluate  the  data  coming  from  Russia  and  to 
organise  an  emergency  program  for  research  into  the  new  and  unforeseen 
questions arising from  the  c~ernobyl experience. 
3.  E.C.  crash  program  on  prognostics  and  treatment  of heavily  exposed 
radiation victims. 
The  main  problem  was  the  great  uncertanty  in  establishing  the  risk  of 
the  individual  patient  to  develop  a  fatal  radiation  syndrome.  The 
currently available biological  indicators  were  lowered  peripheral  white 
- XIII  -blood cell counts,  increased chromosomal  abnormalities  and  the severity 
and  rate  of  development  of  clinical  sickness  shortly  after  exposure. 
None  of  their  parameters  provides  a  very  accurate  risk  estimate. 
Therefore,  it  was  decided  to  reanalyse  the  predictive  value  of  the 
changes  in  blood  cell  counts  and  to  perform  in  vitro  studies  on  dose 
effect  relations  of  chromosome  aberrations  with  emphasis  on  the 
influence  of partial  body  irradiation.  In  addition,  a  new  approach  to 
biological  prognostic  dosimetry  was  initiated by  studying  the  possible 
application of the new  Hemopoietic  Growth  Factors  (HGF}  for determining 
the  amount  of  surviving  stem  cells of  the  blood  forming  system.  These 
stem  cells  are  the  only  cells  that  are  important  for  the  recovery  of 
the  blood  formation.  They  may  be  activated  and  stimulated  by  the 
hormonal  action of the  HGF  to produce  progency,  which  should reflect in 
the  peripheral  blood  cell  counts.  If  insufficient  stem  cells  are 
surviving,  administration  of  HGF  would  not  result  in  a  response  and 
this would  then  indicate a  poor prognosis. 
For  patients  with  such  damage  to  the  blood  forming  system  as  was 
hitherto  considered  irreversible.  the  recommended  treatment  was  bone 
marrow  transplantation.  However,  bone  marrow  transplantation  is  thus 
far effective only when  the recipient has  been subjected  to homogeneous 
irradiation of the whole  body  and  when  bone  marrow  from  a  matched  donor 
is  available.  It appears  that  these  conditions  were  not  fulfilled  for 
the majority of the  reactor accident victims. 
Inhomogeneous  exposure  may  leave  a  small  proportion of  the  white  blood 
cells  responsible  for  the  bodies  defence,  intact,  which  is sufficient 
for  a  bone  marrow  graft  from  another person  to  be  rejected. 
The  ne  .... ·  HGF  seemed  to  provide  possibilities  for  stimulating  residual 
autochtonous  stem  cells  following  inhomogeneous  irradiation or  perhaps 
-XIV-even  following  an  otherwise  lethal  dose  of  homogeneous  exposure,  and 
thereby  induce  cures  by  endogeneous  regeneration  of  the  blood  forming 
sys  tern.  Such  investigations  can  obviously  not  be  carried  out  with 
patients,  but  it  is  feasible  to  obtain  certain  essential  pieces  of 
information  like  the of doses  HGF  required  for  a  substantial  response, 
or  the  occurence  of  toxic  side  effects,  from  studying  patients  with 
hematological  diseases  who  are  being  treated  with  HGF.  Other  and  more 
essential  data  can  only  be  acquired  from  experiments  with  subhuman 
primates,  which  greatly  resemble  humans  in  their  responses  to 
irradiation. 
4.  Result  from  the  program 
Prognostic value of blood cell counts 
The  Ulm  Research  group  has  established  a  Radiation  Accident  Data  Bank 
in  which  all  available  data  on  changes  in  blood  cells  and  blood  eel 
forming  tissues  are  being  collected,  in  conjunction  with  clinical 
symptoms,  the  course  of  radiation  sickness  if  developing  and  its 
eventual  outcome.  A  total  of  22  radiation  accidents,  resulting  in  the 
exposure  of  the  whole  body  or  a  large  part  of  the  body  and  involving 
over  600  individuals is being analysed.  At  the  time of  this report more 
than  300 cases  have  been  processed  and  results of calculations  based  on 
the  counts  of peripheral  blood  cells  over  the  observation  period  have 
been  related  to  the  physically  estimated  dose  of  acute  total  body 
irradiation. 
A  computer  based  simulation  model  of  the  formation  of  one  class  of 
\o.'hi te  blood cells  {the granulocytes)  has  been designed  which  allows  the 
-XV-calculation  of  the  number  of  intact  blood  forming  stem  cells  that 
survive  the  irradiation.  The  results  so  far  suggest  that  a  calculated 
surviving  fraction  of  stem  cells  of 8  x  10-6  of  the  normal  number  is 
the  minimum  that  will  allow  spontanous  regeneration  of  the  blood 
formation. 
The  Rijswijk  group  of  researchers  employed  a  somewhat  different 
approach  to  arrive  at  minimal  surviving  stem  cells  numbers  compatable 
with  span  tanous  recovery.  They  compared  in  rhesus  monkeys  the  time 
period required  for spontanous  recovery of peripheral blood cells after 
total  body  irradiation with  a  range  of doses  with  the  time  of-recovery 
seen  in  lethaly  irradiated  monkeys  grafted  with  graded  numbers  of 
autologous  bone  marrow  cells.  Spontanous  recovery  occured  in  monkeys 
with  a  calculated  surviving  fraction of  10-5  of  normal,  which  is  very 
simular  to  the  value  for  humans  of  8  x  10-6  referred  to  above. 
However,  the  dose  of  total  body  irradiation  which  corresponds  to  that 
surviving fraction was  11.5 Gy  gamma  radiation in the  monkeys,  while  in 
the  patients  studied  by  the  Ulm  group  the  corresponding  dose  was  5  Gy 
at  most.  However,  only  2  patients  were  available  in  the  dose  range 
between  10  and  12  Gy  and  the  d?ta  between  10  and  11,5  Gy  total  body 
irradiation were  derived  from  4 monkeys  only.  The  monkey  data  revealed 
that  the  surviving  fraction  of  stem  cells  at  5  Gy  total  body 
irradiation was  10-3. 
Clearly,  there  are  important  as  yet  unresolved  differences  between  the 
results  obtained  from  the  experiments  with  monkeys  and  those  derived 
from  human  victims of radiation accidents.  It can  not  be  excluded  that 
the  human  stem  cells are  more  radiosensitive  than  those  of  the  monkey. 
The  results  with  monkeys  ·have  clearly  shown  that  regeneration  of 
leukocyte  numbers  relate  less  dependably  to  the  radiation  dose  than 
-XVI -regeneration  of  reticulocytes,  the  former  being  disturbed  by  the 
occurrence  of  infections.  It is  advisable  to  take  this  into  account  in 
the  interpretation  of  the  granulocyte  counts  in  humans.  The  most 
important problem however is so far  the  absence of human  data for doses 
between  5  and  10  Gy  and  it is  urgent  to  collect  those,  if available. 
The  major  advantage  of  the  approaches  reported  here  is  that  the 
prognostic  parameters  employed  are not  dependent  on  homogeneity  of  the 
exposure,  since  they  relate  to  the  number  of  surviving  stem  cells 
irrespective of  the location of those cells. 
5.  Prognostic  value  of  administration  of  Hemopoietic  Growth  Factors 
(HGF). 
Recombinant  HGF  have  been  evaluated as  a  means  to  determine  the  number 
of  surviving  stem  cells  in  irradiated  subjects.  The  main  data  were 
obtained  with  GM-CSF  and  interleukin  3.  Since  a  species  barrier  was 
discovered  for r.  hum.  IL-3,  it was  necessary to  produce  r.  Rhesus  IL-3 
for  the  studies  in  irradiated  monkeys.  This  was  accomplished  by  the 
Rijswijk group  under  this program. 
The  French  team  at Fontenay  aux  Roses  has  made  extensive  studies 
in  vitro on  GM-CSF  added  to  long  term  human  bone  marrow  cultures.  They 
observed  no  adverse  effects  on  either  the  stromal  cells  or  on  the 
proliferation  capacity  of  hemopoietic  precursor  cells.  GM-CSF  has  a 
broad  range  of  actions  on  hemopoietic  progenitor  cells,  including 
pluripotent  stem  cells.  It  stimulates  the  proliferation  of  cells  in 
many  of  the  differentiated  lineages.  Therefore  it  was  investigated 
whether  early  post-irradiation  treatment  with  GM-CSF  might  cause  a 
detectable  response of  the  peripheral blood cell counts  and  whether  the 
- XVII  -capacity  for  endogeneous  hemopoietic  recovery  could  be  reliably 
determined  by  such  a  response. 
It  was  found  that  GM-CSF  can  indeed  serve  that  purpose  in  the  dose 
range  between  4 Gy  and 8  Gy  (6  MEV  X-rays).  However,  the variations are 
considerable  and  at  least  8  days  of  observation  are  required  for  a 
reaction.  Responses  were  not  seen  after  doses  greater  than  8  Gy  (more 
than  4  log  cell  kill) ,  although  the  ressidual  stem  cell  numbers  are 
sufficient  for  endogeneous  regeneration.  Preliminary  data  with  IL-3 
treatment of irradiated monkeys  are  simular  to  those  seen  with  GM-CSF. 
Therefore  it  has  to  be  concluded  that  treatment  with  these  factors 
cannot  result  in  a  clear  cut  distinction  between  those  who  will,  and 
those  who  cannot  regenerate spontanously. 
6.  Biological  dosimetry  by  quantitative  analysis  of  chromosomal 
damage. 
a)  As  chromosomal  analysis  is  particularly  labour  intensive  and  time 
consuming  there  are  considerable  logistical  problems  in  dealing  with 
large  numbers  of  patients.  The  new  micronucleus  assay  that  utilises 
cytochalasin  B  to  block  cytokinesis  offers  an  alternative  to  scoring 
for  dicentrics.  Because  the  images  are  far  simpler,  the  analysis  could 
be  completed significantly faster and  by  less skilled technicians.  This 
technique  was  not  available  to  the  Soviet  laboratories  that  responded 
to  the  C~ernobyl accident. 
There  is  usually  an  urgent  need  to  provide  an  estimate  of  dose  as 
quickly  as  possible.  The  present  techniques  are  not  ideal  in  this 
respect  because  for  dicen tric  analysis  the  microscopy  cannot  begin 
until  2  days  after  receipt  of  the  blood  sample.  This  is  because  the 
- XVIII  -'! 
lymphocytes  need  to  be  stimulated  with  a  mitogen  and  cul tered  for  48 
hours  so  that  they  can  be  analysed  at  first  metaphase.  For  the 
micronucleus  assay  the  culture  time  is even  longer,  72  hours;  although 
as  indicated  above  once  the  preparations  are  made  the  analysis  time  is 
much  shorter.  In  practice  therefore  a  dose  estimate  is  not  available 
until  three or four  days  after receipt of a  blood specimen. 
The  relatively  new  method  of  Prematurely  Condensed  Chromosomes  (PCC) 
however  opens  up  the  possibility  of  scoring  aberrations  within  a  few 
hours  of  blood  sampling.  The  technique  is  maintained  at  present  as  a 
routine  test  only  in  Leiden.  It has  the  potential  for  overcoming  the 
complications  of  interphase  death  and  mitotic  delay  which  apply  to 
conventional  metaphase  analysis  with  no  loss  of  sensitivity  or 
accuracy.  The  technique,  being  new,  does  require  further  background 
research. 
b)  The  C:1ernobyl  experience was  notable for highlighting  two  important 
features  of  biological  dosimetry  that  are  particularly  relevant  for 
high  life-threatening  exposures.  Firstly,  for  highly  overexposed 
subjects,  lymphocyte  cultures  yield  a  low  mitotic  index  and  there  are 
two  reasons  for  this;  (a)  the  rapid  decline  in  the  numbers  of 
lymphocytes  in  the  peripheral  circulation  and  (b)  highly  irradiated 
cells  respond  in  culture  less  readily  to  mi togens  and  proceed  more 
slowly  around  the  cell  cycle  to  metaphase.  Thus  in  order  to  increase 
the  number  of  cells  available  for  analysis  there  is  a  need  to  improve 
the  mitotic  index  in  such  circumstances  and  to  quantify  the  mitotic 
delay.  Secondly,  accidental  irradiation  is  usually  inhomogeneous  and 
this  can  often  be  detected  cytogenetically  because  the  distribution  of 
- XIX  -aberrations  among  the scored cells is overdispersed with  respect  to  the 
Poisson distribution that characterises  an  uniform  whole  body  exposure. 
c)  Acute  partial  body  irradiations  to  5  or 8  Gy  x-rays  were  simulated 
at Chilton  by  in vitro  irradiation of blood  which  was  then  mixed  with 
unirradiated blood  from  the same  donor.  The  irradiated fractions of  the 
mixtures  ranged  from  0. 5  to  0 .1.  The  mixtures  were  coded  for  blind 
analysis  and  shared  between  Chilton  and  Leiden  and  cultured  for 
chromosomal  aberrations  and  micronuclei  in  cytokinesis  blocked  cells. 
In  Leiden  only,  prematurely  condensed  chromosomal  fragmeHts  were 
analysed  in mixtures of irradiated and  non-irradiated cells. 
d)  The  analysis  applied  to  the  dicentric  distributions  scored  at  both 
Leiden  and  Chilton  showed  that  for  most  mixtures  both  the  estimates  of 
the  irradiated  fraction  and  their  doses  agreed  well  with  the  true 
values.  It  was  noted  that  even  for  95%  of  cells  irradiated  at  5  Gy 
there  were  still  about  35%  of  cells  seen  that  did  not  contain  any 
aberrations  and  so  were  apparently  undamaged.  At  8.0  Gy  and  99% 
irradiated  about  20%  of  cells  seen  were  normal.  By  contrast  for  100% 
irradiated  at  both  doses  no  cells  were  seen  to  be  free  from 
aberrations.  This  information  in  itself  is  of  immediate  value  as  an 
indication  that  some  proportion  of  the  cells  has  been  spared.  The 
implication  from  this is that  there is likely to  be natural  recovery of 
bone  marrow.  For  the  analysis  for  a  highly  irradiated  subject  this 
would  be  apparent after relatively few  cells had  been  scored. 
e)  Culture  techniques  were  extensively  compared  between  the 
participating teams  in Paris,  Brussels,  Leiden  and  Chilton  and  this  has 
-xx-resulted  in  notable  improvements  and  optimal  standardisation.  Two 
relativily  new  methods  were  also  investigated  in  depth:  the 
micronuclear  technique  and  the  assay  based  on  prematurely  condensed 
chromosomes.  The  latter technique  turned out  to yield comparable values 
to  those  of  the  estimation  of  dicentric  chromosomes  and  to  possess 
several  important  advantages:  results  can  be  scored  within  a  few  hours 
of  blood  sampling  and  there  is  no  interference  from  interphase  death 
and  mitotic delay. 
7.  Therapeutic  implications. 
Our  present  inability  to arrive at a  dependable  estimate of  the  number 
of residual  stem  cells at low  stem  cells numbers,i.e.  at high  doses  of 
irradiation,  implies  that  a  reliable  distinction  can  not  yet  be  made 
between  subjects  with  a  high  probability  of  spontanous  recovery  and 
those  with  a  low  probability.  The  experiments  with  rhesus  monkeys 
indicate  that  spontanous  hemopoietic  regeneration  can  always  be 
expected provided  that intestinal radiation damage  is sublethal.  In  the 
homogeneously  irradiated monkeys  there was  no  significant dose  interval 
between  spontanous  recovery  and  death  from  intestinal  damage.  If these 
observations  apply  to  humans,  it  should  be  safe  not  to  attempt 
treatment  with  bone  marrow  transplants,  in  view  of  the  fact  that  in 
accident  cases  more  marrow  is  spared  because  of  the  inhomogeneous 
distribution of  the  dose  over  the  body.  Treatment  with  the  hemopoietic 
growth  factors  GM-CSF,  possibly in combination with  IL-3  is recommended 
to  be  started  soon  after  the  exposure  in all patients  who  are  expected 
to  develop  pancytopenia.  Such  treatment  will  shorten  the  pancytopenic 
period  and  reduce  the  associated  risks  in  patients  who  will  eventually 
·XXI· recover  spontanously  and  it is not  expected  to  do  any  harm  to  patients 
who  cannot  regenerate  from  their residual stem cells. 
Indications  for  a  substantial  degree  of  inhomogeneous  exposure  can  be 
obtained  from  dicentric  chromosome  counts  and  at  an  early  time  after 
the exposure  from  the  PCC  technique. 
Such  indications  when  obtained  with  high  dose  estimates,  favour  the 
probability  of  endogeneous  recovery  and  should  discourage  the  use  of 
bone  marrow  transplantation.  The  absence  of  signs  of  inhomogeneous 
exposure  in conjunction with high dose  should  favour  attempts at rescue 
with  bone  marrow  grafts.  In such cases,  perhaps  very rare,  rejection of 
the  allogeneic graft is much  less  likely  than  in case of  inhomogeneous 
exposure,  when  surviving  lymphatic  cells  can  react  against  the  graft. 
In case strong indications are present for bone  marrow  transplantation, 
the  chances  of  finding  an  HLA  identical  sibling  donor  will  be  small. 
Other donors  are not  recommanded  because of the high risks of rejection 
or fatal graft versus  host disease. 
~1ost  of  these  dilemmas  would  be  avoided  in  case  the  patients  own 
unirradiated bone  marrow  were  available for  reinfusion. 
Collection  and  storage  of  bone  marrow  from  nuclear  plant  personnel 
prior  to  an  accident is not  feasible.  On  the other hand,  collection of 
stem  cells  from  the  peripheral  blood  of  personnel  that  is  sent  on 
rescue  missions  is worth  considering. 
8.  Recommendations 
The  duration  of  the  special  post- Chernobyl  research  projects  has 
obviously  been  insufficient  to  solve  all  problems  that  were  selected 
for'  study.  However,  the  results  thus  far  obtained  have  permit  ted  a 
·XXII-number  of  conclusions  to  be  drawn  regarding  further  research  and 
organisational  measures  of  high  priority.  These  concern  problems 
related  to  diagnosis  and  prognosis,  treatment  and  logistics  of 
operations  following  the identification of accident victims. 
a.  Diagnostic procedures  with prognostic  relevance 
Further analysis of  the prognostic significance of blood cell counts  is 
reguired  in particular for  total  body  doses  of between  5  Gy  and  12  Gy. 
For  these  purposes  the  data  bank  operated  at Ulm  and  the  mathematical 
models  of myelopoiesis  should  be  further expanded. 
The ·results  so  far  obtained  with  GM-CSF  administration  as  a  means  of 
evaluating  the  size of  the  surviving hemopoietic  stem cell compartment 
should  be  continued  with  IL-3  and  combinations  of  IL-3  and  GM-CSF. 
Separate  studies  should  be  carried  out  in  rhesus  monkeys  subjected  to 
inhomogeneous  total  body  irradiation, 
administration. 
with  and  without  factor 
The  techniques  to determine  chromosome  damage  by counting of dicentrics 
and  prematurely condensed  chromosome  estimates in particular have  to be 
established  in  a  larger  number  of  European  Laboratories  than  were 
involved in  the  present study.  Training courses  have  to be organised  to 
disseminate  the  PCC  technique.  Seperate  investigations  are  needed  for 
the  evaluation  of  these  methods  in  determining  the  degree  of 
inhomogeneity  of  the  exposure,  by  setting  up  in  vivo  experiments 
preferably with  subhuman  primates. 
Finally,  increased  efforts  are  recommended  to  achieve  a  better 
understanding  of  the  interaction  between  extensive  thermal  and  or 
-XXIII· radiation  damage  to  the  skin  and  the  damage  to  hemopoietic  tissues  so 
that prognostic parameters in cases of combined  injury may  be  obtained. 
For  all  the  methods  referred  to  above  it is  necessary  to  increase  our 
knowledge  about  their  usefullness  in  cases  of  protracted  exposure  to 
radiation. 
b.  Improvement  of therapeutic means 
Further  research  both  in preclinical  animal  models  and  in patients  is 
needed  to  improve  the  therapeutic  potential  of  hemopoietic  growth 
factors.  Combinations  of  factors  and  variations  of  the  doses  have  yet 
been  insufficiently explored.  Also  their therapeutic  value  in cases of 
inhomogeneous  exposure has  to be established in vivo.  The  use of HGF  in 
combination  with  allogeneic  bone  marrow  transplantation  also  deserves 
much  attention.  It is possible that HGF  would  promote  the proliferation 
of  the  grafted  cells  and  thereby  overcome  the  problems  of  graft 
rejection  imposed  by  inhomogenous  exposure.  In  this  respect  it  is 
important  to  investigate  in  monkeys  whether  the  residual  immune 
capacity  following  inhomogeneous  exposure  may  be  neutralised  by 
pretreatment  of  the  patient  with  appropriate  anti  lymphocyte 
antibodies,  as  they  have  been  shown  in  rodents  to  allow  a  reduction  of 
approximately  2  Gy  of  the  total  body  dose  required  for  bone  marro"'' 
takes.  Similar  studies  are  recommended  with  some  of  the  ne"'' 
immunosuppressive  drugs.  The  importance  of  continued  research  on  the 
use  of  autologous  stem  cells  derived  from  the  peripheral  blood  can 
hardly  be  overestimated.  If  safe  and  reliable  technology  could  be 
developed  for  harvesting  an  adquate  number  of  stem  cells  from  the 
·XXIV· ~  I 
peripheral  blood of healthy people,  this would  be  a  method  of choice  to 
protect individuals at risk in  the case of a  nuclear accident. 
c.  Organisation and  logistics 
Although  there  is  presently  an  increasing  number  of  well  equiped 
hospitals  where  patients  are  treated  with  high  dose  total  body 
irradiation  and  bone  marrow  transplantation,  on  a  regular  basis,  the 
medical staffs in this places are not usualy  trained in the handling of 
victims  of  radiation  accidents.  It is  recommended  that  the  Commission 
takes  the  initiative  for  organising  courses  in  Europe  to  bring  these 
medical staffs up  to date,  in particular with  regard  to  the handling of 
contaminated  patients  and  to  the  medical  problems  arising in  patients 
with  combined  injuries. 
It  is  recommended  that  these  hospitals  establish  formal  connections 
with  laboratories  capable  of peforming  analysis  of  chromosomal  damage, 
so  that  immediate action can be  taken in case of exposed individuals. 
To  support  such  a  network  of  "stand  by"  medical  and  laboratory 
facilities  to  be  used  in  case of accidents,  an  expert system  should  be 
established  that  is  available  to  all.  A special effort is  required  to 
establish  such  an  international  (European)  expert  system  and  to 
guanrantee  its  maintainance  by  adding  pertinent  new  information  as  it 
becomes  available.  An  exellent  basis  for  this  expert  system  is 
obviously  provided  by  the  data  bank  of  radiation  accidents  which  has 
been established  in Ulm. 
Finally  it  is  recommanded  that  basic  research  on  the  effects  of 
ionising  radiation  on  the  hemopoietic  system  and  factors  that  modify 
this  damage  continues  to  be  stimulated  by  the  Commission. 
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TECHNICAL IMPROVEMENTS OF THE CYTOGENETICAL METHODS USED FOR 
BIOLOGICAL DOSIMETRY IN CASES OF A CHERNOBYL-LIKE ACCIDENT 
B. DUTRILLAUX, A. LEONARD I.  Objectives  of  the  project 
Biological  dosimetry  based  on  the  observation  of  chromosome 
aberrations  in  peripheral  blood  lymphocytes  is  performed  by 
relatively  few  laboratories.  Since  accidental  exposure  to  high 
doses·  of  ionizing  radiation  results  in  a  drastic  decrease  of 
lymphocytes  in  the  peripheral  bl;ood,  the  cultures  are  always 
made  in  very  rich  medium  which  provides  higher·  number  of 
dividing  Ml  44-48  h  after  initiation  of  the  CQltures.  The 
chromosomes,  however,  are  more  contracted  but  anomalies  such  as 
dicentrics  are  easily  detected.  The  low  number  of  laboratories 
doing  biological  dosi~etry  in  routine  contrasts  with  the 
numerous  units  ..  usi.ng,  cytogenetic  methods  for  medical·  purposes. 
The  cu~ture  medium  they  employ  is  relatively  poor  and  the  number 
of  metaphases  obtained  after  48  h  of  cultiv~tion  is  low.  The 
method,  however  permits  the  obtention  of  elongated  prometaphasic 
chromosomes  particularly  appropr,iate  to  high  resolution  banding. 
The  first  part  of  the  programme  had  .the  aim  to  improve  the 
method~  of  cell  synchronisation  which  could  highly  increase  the 
number  of  dividing  and  arialysable  cells  and  which  could  al~~ 
be  easily· applicable  by  medical _cytogenetic  laboratories.  In  the 
eventuality  of  a  serious  nuclear  accident±it  could  be  necessary, 
indeed,· to  perform  biological  dosimetr.y  on  a  larg.e  number  of 
p res  u ma b 1 y  expo  s,e d  i rr d i v i d u a 1 s  "'" i t h i n  a  f e w  d  a y s  f o 11 ow in  g  t he 
accident,  a±programme  which  would  largely  exceed  the  capaci~ies 
of  the  few  existing  specialized  labora~ories. 
The  second  part  of  the  proposal  was  a  complcm·ent.  to  the 
study  of  Dr.D.LLOYD  (Chilton)  and  Dr.NATARAJA~  (Leiden)  on  the 
p r o b 1 ems  r e s u 1 t  i  n g  f rom  i n h orr. o g en eo  u s  or  p a r t i  a 1  bo d y  e x JH> s u r e 
to  ionizing  radiation.  Using  a  chromosome  marker  to  distingui~il 
irradiated  cells  from  noB-irradiated  ones  an  attempt  was  made  to 
estimate  the  i  11  f l u c n c e  o [  m.i tot  i c  del  a y  res  u l  t in g  1 r 0 m 
i r r ad i at  ion  <1 n d  u [  the  d i 1 uti  0 n  of  t h c  i. r radiated  c c 1 1 s  on  t  lH;o 
d o s e  a s  e s t  i m  a t c d  b y  t he  i  n c i  d e n c e  o t  c h r om Q s OJil e  il n om a 1 i ·e s • 
..  3  .. II  •  Progress  achieved 
(1)  Cellular  synchronisation 
Methodology 
The  synch~onisation of  the  lymphocytes  was  obtained ·by 
addition  ·of  thymidine  to  the  culture  medium,  a  treatment 
reported  to  increase  the  number  of  dividing·  cells 
{Viegas-P6rignot  and  Dutrillaux,  Ann.Ginit.,  21,  122-125,  1978). 
In  Fontenay-aux-Roses,  0.3  to  3  mg/ml  thymidine  was-added 
24  to  36  h  after  the  initiation  of  the  cultures  in  TC199·  medium 
additiohed  of  20  % .  human  ;serum,  .  phyto.h:e·ma'gglu'tinin  and 
antibiotics.  This  culture  medium  is  currently  used  by 
laboratories  specialized  in  medical  cytogenetics.  The  block  was 
released  7-8  h  before  harvesting  by  the  addition  of  10  lJ&/ml 
2-deoxycytidine.  The  duration  of  the  thymidine  block  varied  from 
14  to  48  h.  In  some  cultur-es,  5-bromodeoxyuridine  (BrdU)  was 
added  to  the  m·edium  in  order  to  evaluate  the  number  of  cell 
devisions  having  occured  "in  vitro".  A  fluorescence  plus  Giemsa 
( FP.G)  treatment  was  used  to  detect  BrdU  incorporation.  Various 
treatments  by  colchicine  (1  to  5  h)  were  applied  to  ~define  the 
conditions  giving  the  highest  mitotic  index  compatib·le  with  a 
good  quality  of  the  metaphases.  Doses  of  y-radiation  delivered 
by  a  cobalt-60  source  ranged  from  1  to  10  Gy. 
In  Brussels,  blood  samples  from  t\\O  donors  were  given  0, 
1,  3,  or  6  Gy  of  X-irradiation  and  \~·ere  incuhatec  tn  Ham's 
medium,  alone  or  supplemented  with  300  j 1 g  thymidine/r.!l  culture 
medium.  After  an  overnight  exposure  to  thymidine,  the  blocking 
of  the  cell  cycle  was  revers  c d  'by  the  add it  ion  o i  -0.  ·  5  ::1:: 
dco:.:ycitidine/ml  culture  medium.  In  order  to  study  the  cel1 
k i n e t i  c s ,  s om e  c u 1 t u r e s  w  c r e  s u p p 1 c me n t  e d  h' .i t: lt  B r d U  a t  · <·1  d o s <~  o : 
0.05  mg/culturc.  The  culture  time  \o.'as  43  h  for  cells  incubatcl: 
\-."  i  L h o u t  l  h y rn i. d i  n e  a n cl  53  h  [ o r  t  h n s e  c 1  ~ 1 j  s  c u l  L i  \. a t <  ~ d  ~,· i tIt 
• 4.  -
·~  j thymidine.  In  a  second  set  of  experiments  performed  according  to 
the  same  protocol,  the  cultures  were  additioned  with  600  g 
thymidine/ml  culture  medium.  Additional  experiments  were 
performed  to  study  the  effect  of· the  duration  of  exposure  to 
colchicine  (3  to  5  h)  and  of  the  culture  time  (56  to  62  h)  on 
the.  m  i tot  i c  in  d ex ,  on  the  number  of  an  a 1 y sa  b 1 e  c e 11  s  and  the 
cell  cycle  of  human  lymphocytes  cultivated  in  Ham's  medium 
containing  300  u&  thymidine/culture. 
Results 
CEA,  Fontenay-aux-Roses 
Whatever  were  the  conditions,  all  metapha~es were  in  Ml 
after  synchronization  without  thymidine,  the  rate  of  ~12  and  >13 
ranging  from  5  to  more  than  60  %  after  culture  duration  of  48 
and  60  h  respectively  without  synchronisation.  As  the  blocking 
induced  by  thymidine  :was  clearly  efficient  a  53  h  culture .time 
was  selected  for  the  other  experiments. 
In  almost  all  conditions,  mitotic  index  was  increased  by 
thymidine  block. 
The  effect  of  the  dose  of  thymidine  was  studied  in  a  series 
of  4  donors,  and  the  dose  of  0.3  mg/ml  finally  \,•as  selectee:. 
Increase  of  the  duration  of  treatment  by,  colchicine  did  not 
r e s u 1 t  i n  a  s t r o n g  c o n d e n sa t  i on  o f  t h e  c h r o m  o so  m  e s  h u t  i  n c r e a s e (i 
t h e  m  i to  t i c  i n d e x  a n d  a  4  t·o  5  h  t  r e a t me n t  by  c o 1 c h i c i n c  ''a  s 
used  in  further  experiments. 
Two  p r o t o c o i c s  f o r  r e l e a s i  n g  t hy m  i  d i n c  b l o c k i  n ~  \'' (! r  ~.~ 
compared  i.e.  addition  of  2-deoxycitidine  and  to  change  t!it~ 
culture  medium  and  to  rince  the  cells.  Very  similar  re$ults  were 
o I>  l  a j  n e d •  F o r  t It i s  r e a s o n  t  1J e  f o 1 l  tn~· ·j  n g  p r o t o c o l ,  c II '  ~ ;  1 p •· r  ,: '1  , : 
less  time  consuming  was  adopted 
- 5  • - Time  0  initiation  of  the  cultures  (TC  199  medium  + 
human  serum  +  antibiotics  +  PHA)  ; 
- Time  24  to  30  h  addition  of  thymidine  (0.3  mg/ml) 
- Time  45  h  addition  of  2-deoxycitidine  (0.01  mg/ml) 
- Time  49  h  addition  of  colchicine 
- Time  53  h  harvest. 
Using  this  protocol,  mitotic  index  ranging  from  30  to  60 
per  1000  was  obtained  in  non  irradiated  cultures,  all  me~aphases 
being  in  M1.  Such  mitotic  indexes  were  several  folds  higher  than 
those  usually  obtained  without  thymidine.  In  addition,  the 
quality  of  the  metaphases  was  greatly  improved. 
After  exposure  to  ionizing  radiations,  all  metaphases  were 
in  H1  and  treatment  with  thymidine  had  ·co·mparable  effects  ,, 
increase  of  mitotic  index  by  4  to  5  fold,  improvement  of  the 
quality  of  metaphases. 
CES  and  UCL,  Brussels 
T h e  r e s u 1 t s  o f  t h e  o IJ s·e r  v a t i o n s  a r e  s u m  m  a r i  z e d  in  T a b 1 e 5 
I-VIII.  They  sh~w  that  : 
.-.  a  d o s e  o E  3  0 0  11 g  t h y m  i d i n e I rn l  c u l  t  u r e  me d i u m  i n c r  c~ a s <-' s 
g e n e r a 11 y  t  h c  n u m  h c r  o f  3  Il<! 1 y s a h l e  m  e t a p h a s c s  C~' a h 1 c  1 ) 
hut  docs  not  modify  the  cell  ki.nelics  (Tnhle  IE) 
. 6 . - a  dose  of  600  l-18  thymidine/ml  culture  medium  is  much  less 
effective with  respect  to  its effect  on  the  number  of 
analysable  metaphases  (Table  III)  and  could  be  toxic  as 
suggested  by  its effect  on  cell  kinetics  (Table ·IV). 
- the  increase  of  the  duration  of  exposure  to  colchicine 
from  3  to  5  h  does  not  modify  greatly  neither  the  mitotic 
in  d ex  no r  the  number·  of  an  a 1 y sa  b  1 e  met  a phases  (Tab  1 e  V )  ; 
the  cell  kinetics  was  not  modified  all cells  being  in  Ml 
(Table  VI)  ; 
- increase  of· culture  time  from  56  h  to  62  h  does  not 
influence  neither  the  mitotic  ind~xf  nor  th~ nu~ber of 
analysable  metaphases  nor  the  cell kinetics  (Tables  VII 
and  VIII). 
( 2)  Inf  1 uence  of  the  rad.ia  t ion-induced·  mi tot'ic  delay  and  of 
the  dilution  facto~  on  the  dose  estimate 
Biological  dosimetry  based  on  the  observation  of  chromo-
somes  in  peripheral  blood  lymphocytes  provides  only  an  estimate 
on  of  the  average  damage  caused  to  the  entired  lymphocytes 
popu}ation.  One  of  the  .major  difficulties  results  from  the 
inhomogeneity  of  the  dose  and  of  partial  body  exposure.  In 
addition,  selective  elfmination  or  lower  proliferation  rate  of 
irradiated  cells  can  lead·  to  an  important·  underestimate  of  the 
dose. 
In  the  present  study  evaluation  of  survival  and  kinetics 
of  irradiated  cells  was  made  on  mixtures  ·of  male  irradiated 
blood  lyn1phocytes  and  female  control  ones,  the  Y  chromosocc 
being  used  as  marker.  An  attempt  was  made  to  calculate  the  dose 
inhomogeneity  on  the  basis  of  the  dicentric  distribution  and  its 
deviation  from  Poisson's  law. 
.• 7. Methodology 
Fontenay~aux-Roses 
The  two  donor_:;,. one  male  and  one  female,  were  selected  on 
the  b  a sis  0 f  the  i r  hi  g h  number  0 f  1 y mph  0 c y t e s.  per  m  1  0 f  b 1  0 0 d 
( 4 5 7 5  and  3 7 4 4  res  p e c t i v e 1 y )  and  of  the  i r  s i m·i 1 a r  .response  to 
PH A  s t i m  u 1  a t ion •  In  mi xed  c u 1 t u r e s ,  t h e 1  perc  e n  ~  ~  g e s  of 
metaphases  of  each  sexe  were.  roughly  ~roportional  to  the 
respective  quantities  of  male  and  female  blood  which  were 
seeded.  The  blood  from  the  male  donor  received  0,  1,  2,  4,  6,  or 
10  Gy  y-rays  from  a  cobalt  60  source. 
Aliquots  of  irradiated  blood  were  mixed  to  female  blood  samples 
in  the  propor.tions  1:0,  1:1,  1:4,  1:9  and  1:19  before  to  be  put 
in  culture  in  TC  199  medium.  Two  types  of  culture~  were 
developed,  using  or  not  synchronization  technique.  In  addition. 
in  the  non  irradiated  series,. BrdU  was  added  in  order  to  study 
cell  cycles,  in  the  various  conditions  of  dilution.  Cul: ;res 
without  synchronization  were  prolonged  for  48  h,  and  those  with 
synchronization  for  53  h,  including  a  21  h  tr~atment  by 
thymidine,  followed  by  additi.on  of  2-deoxycytidine  (last  8  h) 
and  colchicine  (last  4  h).  Slides  were  stained  by  Giemsa,  except 
for  those  o b t a in  e d  after  B r d U  t rea  t men t  which . were  stained  b.y  a 
modified  FPG  treatment.  Except  for  a  few  cases,  200  metaphases 
h·ere  analysed  for  each  experimental  condition.  Hitotic  indexes 
,,~\.~re  calculated  by  examining  1000  !1uclei  at  least,.  and  100 
metdphascs  ~,.;ere  Rnalyseci  for  the  study  of  cell cycles.· 
I~ r u ~~s e 1 s 
The  experiments  were  performed  \~ith  blood  samples  from  t"-'O 
donors  selected  also  on  the  basis  of  a  high  and  comparable 
- 8 -Ma 1  e  hum a n  peri  ph era  ~  b  ~ o o d  sam p 1  e s  we r e  e. x p o sed  to  0 ,  1 ,  2 ,  4 , 
6  or  10  Gy  of  X-irradiation  by  means  of  a  Philips  RT  250  X-ray 
apparatus  operating  at  250.kV,  15  mA,  0.5  mm  Cu  filtration  and  a 
dose  rat~  of  1  Gy/min.  Before  culturing,  the  irradiated  and 
non-irradiated  male  blood_. were  mixed  in  different  ratios  (1:0·, 
1 : 1 ,  1 : 4 ,  1 : 9  o r  1 : 1 9 )  w  i t h  non - i r r a d i a .t  e d  b l.o  o d  f rom  t he .  f e ~a  1  ~ 
donor.  Culture  were  made  with  and  without  synch.ronisation  by 
thymidine. 
Results 
Figures  1  to  6  summarize  the  results  obtained  in 
Fontenay-aux-Rose~,  figures  7 .to  12  and  tables  IX  to  XXVII,  the 
results  obtained  in  Brussels. 
As  expected,  after  culture  in  TC  199  medium,  the  mitotic 
index  and  the  proporti~n  of  analysable  metaphases  were  greatly 
increased  by  thymidine  block.  Quite  surprisingly  was  the  fact 
that  ,  rna in  1 y  i n  t h e  c u 1 t u res  t rea  t e d  w  i t h  thymi d in  e  b 1 o c k ,  the 
proliferation  of  the  feoalc  non-irradiated  cells . was  increased 
by  the  addition  of  highly  irradiated  (6  and  10  Gy)  cells.  The 
obse~vat~ons  on  the  mixtures  of  irradiated  male  cells.  and 
non-irradiated  ones.  also  confirmed  the  numerous  reports 
indicating.  that  after  ir.radiation  plasm~  contains  a  clastogenic 
factor  induced  or  activated  by  the  radiation.  For  instance,  in 
10  Gy  ·radiation  series  12  to  20  %  female  metaphases  contained 
c h r om a t i  d  1  e s i o n s  i n  s y n  C: h r. o n i  z e d  c u 1 t u r e s •  T h e s e  p e r c e n t a g e ::> 
ranged  from  5  to  12  in  non-synchronized  cultures.  Similar 
effects  of  irradiated  blood  on  non-irradiated  female  cells  wcr0 
observed  after  culture  in  Ham's  medium  but  were  less  marked. 
The  mean  numbers  of  dicentric  and  ring  chromosomes  and  of 
c h r o rn u so  rn c  b r  (~a k s  per  a b norm  a l  me t a ph a s e  we r c  fa i  r 1 y  i  11 d e IH~ n d (! n l 
from  the  diluti0n  and,  as  expected,  were  directly  cnrrt'latcd  to 
the  dose  administered.  For  cells cultivated  without  thymidine  in 
Ham's  medium  t!tP  avPr<t~C  nuruiH!rs  of  diCI)rllri.c  aud  Cl~ntri.c  ring 
- 9  -chromosomes  and  breaks  per  abnormal  cells  were  respectively  0.6 
and  1.6  after  a  Gy,  0.9  and  2.04  after  2  Gy,  1.0  and  3.25  after 
4  G  y ,  2 • 3  and  5 • 7  5  a f t e r  6  G  y , ·  3 • 3  an· d  . 8 • 4  a f t e r  1  0  G  y  ( Tab  1  e -s 
IX  to  XII).  Comparable  results  were  obtained  with  cells' cultured 
in  TC  199  medium.  Very  informative  also  were  the  maximum  number 
of  breaks  and  th~  maximum  number  of  dicentrics  (Tables  XVII 
to  XXVI)  observed  in  abnormal  metaphases  which  were  directly 
related  to  the  doses. 
Irradiation  induced  a  dose-related  mitotic  delay  which 
resulted  in  differences  between  the  numbers  of  dicentrits 
expected  and  observed.  This  effect  was  apparently  not  influenced 
neither  by  the  nature  of  the  culture  medium  nor  the  treatment  by 
thymidine.  It  was,  however,  depending  on  the  dil-ution  mainlly 
when  the  proportion  of  irradiated  cells  to  non-irradiated-ones 
was  low  (1:9  and  1:19)  this  observation  sug_gests  that  the 
probability  for  an  irradiated  cell  to  divid~ is  l6~er when·it  is 
lost among ·numerous  unirradiated  ones  (Tables  XIII  and  XIV). 
Dicentrics  produced  in  male  cells  non-mixed  with  female 
unirradiated  ones  follo\.:ed  the  Poisson  distribution,  the  only 
exception  being  the  cells  given  10  Gy  and  cultivated  in  the 
presence  of  thymidine  (Tables  XIV  and  XV).  As  expected  the 
deviation  of  the  yield  of- dicentric  and  ring  chromosomes  from 
t he  Poisson  d is  t r i b  u t i on  \\~as . s i g n i fica  n t  when  i r r ad i a fed' · c .e 11  s 
were  mixed  to  female  unirradiated  ones  (U  test,  Papw~~tb,  1970). 
Tab 1 e s  XV I I  to  X  X  V  I I  d em on s t r a t e  t h a t  the  con  tam in  a ted  ·poi s son 
., 
. 'i 
me t h o d  d esc  r i b e d  by  Do l p h i n  ( 1  9 6 9 )  c a n  p r o v i  d e  an  v e r y  go o.d  . l 
estimation  of  the  local  dose  administered  and  an  .acceptable  one 
of  the  fraction  exposed.  Since  no  overdispersion  was  observed  irl 
cells  exposed  to  1  Gy  estimate  of  the  fraction ·of  cells 
irradiated  was  not  possible  for  that  dose . 
• 10  • 1.  Conclusions 
I, 
1.  Cell  synchronisation 
Synchronization  improves  citogenetic  analy~is at  various 
degrees~  depending  on  medium  used.  As  far·  as  a  general is  at  ion 
can  be  done,  culture  conditions  developed  by  laboratories 
specialized  in  dosimetry  like  those  of  Brussels  have  been 
optimized,  by  the  use  of  very  rich  medium.  This  given  a 
relatively  high  mitotic  index,  but  a  relatively  low  quality  of 
chromosomes;  as  regards  to  their  elongation  permitting  banding 
analyses.  In  these  conditions,  the  slight  improvement  brought  by 
synchronization  (better  quality  of  metaphases, ·  n·o  second 
generation)  may  not  justify  the  additional  manipulations 
required. 
The  s i t u at  ion  is  q u i t e  d if  fer  en t  f o r  other  c y to  g.e net  i c s 
laboratories,  since  the  quality  (i.e.  elongation)  of  the 
chromosome  is  the  first criteria.  In  most  of  these  laboratories, 
the  medium  used  is  not  very  rich,  and  the  cell  progression  not 
fast.  Synchronization.  without  treatment  by  colchicine  permits 
the  obtention  of  prometaphasic  chromosomes  favorable  for  high 
resolution  chromosome  banding  and  is  currently  used.  The 
modification  proposed  here  permits  to  obtain  mitotic  index  at 
least  as  high  as  this  obtained  by  laboratories  specialized  in 
biological  dosimetry.  All  metaphases  are  at  first  generation  in 
vitro,  and  the  quality  of  their  chromosomes  better. 
In  case  of  accident  most  cytogenetic  laboratori~s can  very 
easily  adopt  the  technique  proposed  h~re.  This  is  certainly  more 
realistic  than  to  ask  for  complete  cll<1nge  of  cuiture  conditions 
;ll!U  the  method  proposed. here  may  permit  a  high  increase  of  the 
cytngenctic  potential,  in  case  of  a  severe  accident. 
J  •  11  -In  summary 
1)  In  laboratories  specialized  in  dosimetry  based  on 
chromosome  observation  synchronization  increases  the  quality  of 
the_metaphases,  but.it  does  not  change  mitotic  index. 
2)  Since  the  technique  is  more  time  consuming,  it probably 
does  not  correspond  to  a  real  improvement  for  specialized 
laborator;i..es. 
3)  In  non  specialized  laboratories,  synchroni~ation 
tech  n i que  c 1 ear  1 y  inc rea  s e s  rn i t o t i c  in  d ex  to  the  .1 e v  e 1. . of  t h a t 
obtained  by  specialized  laboratories.  The ·quality  of  chromosome 
spreads  is  much  improved.  This  techniqu~  can  be  very. easily 
adapted  by  any  laboratory  working  on  medical  diagnosis. 
2.  Influence  of  the  radiation-induced  mitotic  delay  and  of 
the  dilution  on  the  dose  estimate 
T  h.e  use  of  t h e  Y  c h r om o s om e  to  d i s t i n g u i s h  m  a 1 e  c e ll.s 
irradiated  increased  doses  and  mixed  in  different 
proportions  with  unirradiated  female  ones  have  demonstrated 
that  : 
the  mean  and  maximum  numbers  of  dicentric  and  ring 
chromosomes  and  of  break  dre  clarely  dependent  on  the 
doses  but  are  not  influenced  by  the  dJlution  ; 
the  degree  of  dilution  influences  the  probability  of  an 
i r r ad i ate  d  c e 11 s  to  be  o b s  c~ r \'  c~ d  in  met a phase  ; 
- t h c  c o n t a m  i  n a t e d  P o i  s s o n  1:i c t  h o d  c a n  p r o v i  d e  a  g o o d 
e s t  i m  a t  e  o f  t h e  d o s e  r e c e i  v (.' d  1 u c a l l y  ;  1 n d ,  to  so  1r e 
c x t c n t  ,  o £  t h c  f r a c t  i  o 1  1  o f  t  h ('  b o d y  h' it i  c h  h a s  b e e n 
exposed. 
- 12  -
- -, ·.  ~ Table  I. 
Mitotic  index  and  analysable,  metaph.'ises  per  I  000  stimulated  cells 
i n  t h e  p r c s e n c e  o r  a b s e n c e  o f  a  t·  h y m i d i n e  b 1 o G k  ( 3 0 0  )J g I m 1  · 
culture  medium). 
Dose  (Gy)  With  thymidine  l.J it  h 0  u t  thymidine 
Hitotic  Analysable  Mitotic  Analysable 
index  cells  index  cells 
~---··-·--------·-·--·----.. ---
0  133  49  1 4 7  30 
133  40  I 26.  2 1 
3  82  2 1  97  2 1 
6  106  26  57  I 3 
-··---··  ----· 
Table  II. 
Cell  kinetics  (HI  and  M2  per  100  celis)of  lymphocytes  C'lltivated 
in  the  presence  or  absence  of  a  tnymidine  block  (300  ]lg/ml 
culture  medium). 
Dose  (Gy) 
0 
\.J i  t h  t h y rn i d i n e 
Hl 
78 
81 
87 
93 
22 
19 
1 3 
7 
- 13  -
·----------------·------
\·,r i  t h o u t  thy  m i d i 1; t! 
til 
-··· ----·------- ..  ·-·-··-···---------·---
73  27 
74  26 
85  15 
92  '-'  '·' Table  III. 
Mitotic  index  and  analysable  cells  per  I  000  stimulated  cells 
in  the  presence  or  absence  of  a  thymidine  block  (600  lJg/ml 
culture  medium). 
Dose  (Gy)  \~it  h  thymidine  Without  thymidine 
Mitotic  Analysable  Mitotic  Analysable 
index  cells  index  cells 
0  69  4 I  63  34 
42  23  35  1 9 
3  40  20  36  22 
6  1  8  1 0  I 3  5 
.. _______ .  ., __________________ 
Table  IV. 
Cell  kinetics  (HI  and  :12  per  100  cells)  of  lymphocytes 
cultivated  in  the  presence  or  absence  of  a  thymidine  block 
(600  l.lg/ml  culture  medium). 
Dose  (Gy)  \~ i  t h  t h y m  i d i n e  ~ithout  thymidirie 
Nl  M2  Nl  1-12 
0  92  8  72  28 
97  3  ·8 2  1 8 
3  98  2  9.2  8 
6  99  ()j  5 
------- ---·------- --··-····  . ··-- ... ---------·---
•  14  • 
r1{ 
';J.,~ Dose 
{Gy) 
-----·-
0 
3 
6 
Dose 
(Gy) 
0 
3 
6 
Table  V. 
Influence  of  thE!  duration  of  the  exposure  time  to  colchicine  on 
lymphocytes  cultivated  in  the  pre~ence of  ~ thymidine blQck 
(300  ~g/ml culture  medium). 
Cells  were  harvested  52h45  after  initiation  of  the  cultures. 
Duration  of  the  colchicine  treatment 
3  h  4  h  5  h 
Mitotic  Analysable  Mitotic·  Analysable  Mitotic  Analysable 
index  cells  index  cells  index  cells 
1 2 7  30  124  48  162  .  .:.s 
106  30  104  13  152  30 
105  20  92  16  l 05  32 
89  I 5  103  3 J  75  1 3 
Table  VI. 
Influence  of  the  duration  of  the  exposure  to  colchicine  on  t~e 
cell  cycle  of  lymphocytes  cultivated  in  the  presence  of  a  thymi-
dine  block  (300  ~g/ml culture  medium).  Cells  were  harvested 
52h45  after  initiation of  the  cultures. 
Duration  of  the  colchicine  treatment 
3  il  4  h  5  h 
HI  H2  HJ  !'12  HI  .. .., 
_·i-
100  99  100 
99  100  99  1 
100  100  100 
100  99  100 
..  15  -Table  VII. 
Cell  kinetics  after  different  cultivation  times· 
(Thymidine  300  ~Jg/ml  ;  colchicine,  3  h). 
-----------------------------------------------------------------~----~-------------
Cultivation  time 
Dose 
(Gy)  56  h  59  h  62  h 
0 
3 
6 
Ml 
99 
99 
99 
100 
-----·-----·---·--------· 
M2  Ml 
99 
100 
100 
100 
M2  Ml 
99 
99 
99 
100 
----------------------·----------··--·-·. 
Dose 
(Gy) 
0 
3 
6 
Table  VIII. 
Mitotic  index  and  ariilyiable  cells  in  000  stimulated 
cells  after  different  culture  time  (300  ~g/ml  thymidine 
colchicine,  3  h). 
56  h 
Hitotic  .\nalysable 
index  cells 
58  I 5 
72.  34 
43  4 
33  8 
Culture  duration 
Hitotic 
index 
38 
37 
39 
35 
- 16  -
59  h 
.\nalysable 
cells 
10 
5 
8 
I  I 
Hitotic 
index 
4 I 
32 
I  '>  .  -
')I 
-"~ 
H2 
62  h 
A  :1 a l y :: a.Q Le 
celLs 
11 
10 
15 
7 !-
1. 
30~--~--------------~-----------, 
20 
10 
p  .... 
l  '·  :  ....  ..  .  .. 
l  ...... 
1Gy 
.t'  --.......  __ "'  I  u  .  'nS 
0  NS 
o~~------._----~----~----~~~ 
1:0  ,  : 1  1 :4  1:9  1:19 
~~----------------------~------~ 
4Gy 
20  /  .. ///c..  .........  ___  -o....  ... ,  .. ,  ........ 
_...P  ·o s 
.  ·  10  ... ·  I  NS  .. 
..:· 
........ 
. 1:0  1 : 1  1 :4  1 :9 
100~--------------------------~--~ 
80 
60 
..  ······· 
.··_...r:l 
~0 
..  ··· 
20 
............. 
.•· 
1 :0  1 : 1 
lOGy 
pS 
,~l 
/''  .. ·  ..  .. · 
.... JJ···············-o·l  .. ·  .. · 
T: 4  1:9  1: t 9 
30~-------------------------------
20-
10 
2Gy 
ft 
:  \ 
I  \  i  ··  ... 
I  \\  . 
. i  b  s  .. '\  .. '  ...  .1 
_,..···  ·····...  ! 
'  ,,··  ......  .! 
tt•  •• 
d  '  :.  NS  .. d 
..---~~----- -
\  1 :0  1 : 1  1 :4  1 :9  1:19 
100~------------------------------~ 
80 
60 
40 
20 
6Gy 
o· 
..  ·······  s 
p···············O······__. ••  .a·-'"···/ 
... 
.......  .. 
.. l 
...  .. 
_..l 
0 
0~~~----~----~------~----~~ 
'1  : 1  1 :0  1 :4  1 :9  1 : 1 9 
50~------------------------------~ 
40 
30 
20 
10 
O· 
OGy 
... rr············.a.·····.,·,·····u 
..  s  .. ·  .. · 
..•" 
o..........  .·· 
······o····· 
1 :0  1 : 1  1 :4  1 :9 
I 
I 
I 
I 
t~S 1 
1 : 1 9 
!\Htotic  index  (ordi-nate)  in  relation  to  the  dilution of irradiated 
u:lls  from  1 :0  to  1 :1 9  {abscissa). 
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 Table  XXVII 
'  Doses 
administrated 
(Gy) 
2 
4 
I 
I 
I  6  I 
j 
j 
~ 
I 
I 
I 
I 
I 
I 
I 
t  10 
I 
l 
Estimation  of  the  dose  for  cells  treated 
with  and  without  thymidine  by  the  contami-
nated  Poisson. 
(Cultures  in  Ham's  medium). 
Dilution  Doses  estimated  (Gy) 
With  thymidine  Without 
thymidine 
I : 1  2.0)  1 . I 0 
1 : 4  I . 7 1  1. 7 5 
1 : 9  2.24  I . 53 
1 : l 9  0.02  0 
1 :  I  4.24  2.68 
) : 4  3.42  3.63 
1 :  .  .g  4.01  2.78 
I :  I 9  3.87  3.84 
J :  I  6.40  5.56 
I : 4  6.40  6.49 
l  : 9  7. 2 5  6.33 
1 :  I 9  6.73  5.95 
I : I  9. I 4  8.93 
1 : 4  9. 2 6  9.27 
I : 9  10.27  8.46 
I: 19  9.60  5.44 
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BILOGICAL DOSIMETRY APPLIED TO IN VITRO SIMULATED PARTIAL BODY 
IRRADIATION 
D. C.  LLOYD, A. A. EDWARDS, A. T. NATARAJAN, F. DARROUDI. 'i 
Introduction 
The  scientific and  medical  response  to an accidental overexposure  to 
ionising radiation should include an attempt to estimate absorbed doses  to 
irradiated persons.  This  information may  be  gained from  physical and 
biological methods,  although in some  situations,  such as the Chernobyl 
accident,  infor.mation  from  physical  techniques may  be  scant.  At  Chernobyl  the 
initial sorting of casualties was  done  by observations of the  speed of onset 
and  severity of the prodromal  response.  More  precise biological dosimetry was 
then performed using the well established technique of analysing peripheral 
blood lymphocytes  for dicentric chromosomal  aberrations.  In the event of 
another Chernobyl-like accident,  chromosomal  studies would  again be  the method 
of choice for biological dosimetry.  One  could envisage studies needing to be 
carried out on  perhaps a  few  hundred  subjects exhibiting prodromal  reactions 
and  several hundreds more  possibly exposed  to doses below the threshold for 
such early symptoms  (  1  Gy).  As  chromosomal  analysis is particularly labour 
intensive and  time  consuming,  there may  be  considerable logistical problems  in 
dealing with large numbers  of patients.  The  newer  micronucleus assay that 
utilises cytochalsin B to block cytokinesis offers an alternative to scoring 
for dicentrics.  Because  the  images  are far simpler,  the analysis time  could be 
completed significantly faster and by less skilled technicians.  There  is 
usua~ly an urgent need  to provide an estimate of dose as quickly as possible 
and present techniques are not ideal in this respect because of the need  to 
culture lymphocytes  for  two  days  for  chromosomal  aberrations or three days  for 
the micronucleus method.  The  method  of prematurely condensed  chromosomes  (PCC) 
however,  opens up  the possibility of scoring aberrations within a  few  hours of 
blood  sampling. 
Accidental irradiation is usually inhomogeneous.  For  highly irradiated 
patients the clinician requires  information on  the  inhomogeneity of the 
exposure  as management  of casualties may  require an  early decision on  whether 
•  51  • treatment  should include transplantation of allogenic bone  marrow  or treatment 
with growth  factors.  If there is a  likelihood that some  of the patient's own 
marrow will have  survived because of inhomogeneous  exposure,  then transplan-
tation should be  avoided.  Graft rejection was  observed in several of the 
Chernobyl  patients  (Baranov et al 1989)  and  in some  cases probably contributed 
to their deaths. 
Two  methods  have  been proposed for analysing chromosomal  aberration data 
from  inhomogeneously exposed persons with the objective of improving  the dose 
estimates to reflect non-unifor.mity,  rather than quoting an averaged whole  body 
dose  estimate that is obtained simply from  relating a  dicentric yield to an  in 
vitro dose  response  curve.  The  first method  proposed by Dolphin  (  1969) 
considered the over dispersed distribution of aberrations,  particularly 
dicentrics,  among  the scored cells.  The  distribution is considered to be  the 
sum  of a  Poisson distribution which  represents the irradiated fraction of the 
body  and  the  remaining unexposed fraction.  Cells containing aberrations will 
obviously have  been  in the irradiated part of the body.  No~l  undamaged  cells 
will comprise  two  sub-populations,  those  from  the unexposed  fraction and 
irradiated cells representing the first ter.m  of the Poisson series.  This 
assumption enables one  to go  on  to derive,  by a  procedure that is discussed 
more  fully in the Appendix  to this paper,  an estimate of the size of the 
irradiated fraction and its mean  dose.  Previously published data from  in vitro 
simulation of half-body irradiations have  shown  that this procedure is viable 
but of necessity requires a  number  of simplifying assumptions  concerning the 
distribution of lymphocytes  throughout the body  (Lloyd et al 1987,  LAEA  1986). 
Estimates of blood volume  exposed may  not closely reflect the proportion of 
body mass  exposed  (Liniecki et al 1983). 
The  second approach  termed  the Qdr  method  was  proposed by Sasaki  and 
Miyata  (1968).  This considers  the yield of dicentrics and  rings only from 
those cells that contain unstable aberrations and  were  therefore in the 
- 52  -II 
irradiated part of the body.  The  method  circumvents  the problem of dilution by 
undamaged  cells from  an ooexposed  part.  Qdr  is a  function of dose  alone and  so 
permits a  dose  estimate to be  made  for  the irradiated part of the body.  As 
originally published the method  did not go  on  to determdne  the size of the 
irradiated fraction but Sasaki  (1983)  has later shown  that this can  be 
estimated using the same  principle as for the contaminated Poisson  technique. 
The  objective of the present work  is to simulate in vitro high doses  that 
are life threatening if they involve the whole  body.  If however,  they are 
received by  only part of the body and  good  medical  care is provided there are 
hopes  for survival.  Different ratios of irradiated to unirradiated fractions 
are simulated and  the limits of resolution for detecting this by chromosomal 
aberration,  micronucleus and  PCC  endpoints are investigated. 
Materials and  Methods 
Blood  samples  were  taken in Chilton from  two  healthy non-smoking  male 
donors  aged  24  and  46.  The  blood was  placed into a  number  of lithium heparin 
Vacutainer  tubes kept at 37°C  and  some  tubes were  irradiated to 5 or 8  Gy  with 
250  kvp  x-rays HVL  1.22mm  Cu at 1Gy  per min.  one  donor's blood was  used  for 
each dose.  In order to obtain sufficient volumes  of blood at each dose, 
several  tubes were  irradiated placed side by  side.  After exposure  the blood 
from  the  replicate tubes was  allowed to fall to  room  temperature and  pooled 
into glass containers so that any slight variations in dose  between  replicates 
was  equalised.  uncertainties in the stated doses are ± 1.5%.  The  unirradiated 
blood  taken at the same  time  was  treated similarly.  For  each dose  volumes  of 
irradiated and  unirradiated blood  from  the  same  donor  were  mixed  in differing 
proportions in order to simulate the mixing  of blood  that would  occur after 
acute partial body  irradiation.  The  irradiated fractions  range  from  99%  to  10% 
and  are shown  in Tables 1-5. 
The  samples were  coded  for  blind analysis and  shared between  Chilton and 
Leiden.  The  Leiden  specimens  were  sent by  a  commerical  courier service and 
~  53  • arrived during the  following day.  The  Chilton specimens were  kept at room 
temperature  for  24  h  before cultures were  set up  so  that the blood processed in 
each  laboratory was  subject to approximately the  same  delay after irradiation. 
In Chilton the blood was  cultured for  conventional metaphase  aberrations and 
for cytokinesis blocked micronucleus preparations.  In Leiden aberrations and 
micronucleus cultures were  also set up  and  in addition preparations for  PCC 
were  made. 
Aberrations 
Standard 48  hour whole  blood cultures were  set up  and  processed following 
the method  described in an  IAFA  manual  (  1986).  In Chilton the medium  used was 
Eagles  MEM  +  10%  fetal calf serum and  in Leiden  FlO  medium  plus  20%  fetal calf 
serum.  At  each dose  and mixture,  several  replicate cultures were  made.  The 
fixed cells from  the  replicates were  pooled before dropping onto slides. 
Brornodeoxyuridine  was  included in the culture medium  so  that replicate slides 
from  each point were  checked by fluorescence plus Giernsa  staining to ensure 
that the number  of second division cells was  low  (  <5%  and  frequently zero). 
Having  established that second division contaminations were  low,  the  remaining 
slides were  stained with conventional Giemsa  and  scored for unstable 
chromosomal  aberrations; dicentrics,  centric rings and  excess acentrics. 
Micronuclei 
Seventy two  hour cultures for assaying micronuclei  in cytokinesis blocked 
lymphocytes were  made  and,  as described above,  fixed replicates were  pooled 
before placing the cells onto slides.  The  procedure  followed  the general 
method  described by Fenech  and Morley  (1985).  The  exact techniques and  scoring 
criteri~ used at Chilton and  Leiden are given in Prosser et al  (1988)  and 
Ramalho  et al  (1988)  respectively.  Binucleate cells stained with Giemsa  were 
scored  for  the presence of micronuclei. 
Prematurely condensed  chromosomes  (PCC) 
In Leiden,  Ficoll separated lymphocytes  were  fused with mitotic Chinese 
hamster  cells by  the polyethyleneglycol method  (Pantelias and  Maillie 1983) . 
•  54  • The  lymphocytes were  fixed one  hour after fusion according to the standard 
protocol.  The  exact procedure used  in Leiden is described by  Natarajan et al 
(1986).  The  clusters of single stranded human  chromosomes  condensed  in G
0  were 
examdned  and  those comprising  46  or more  objects were  recorded. 
Results and  Discussion 
The  measured yields of chromosomal  aberrations in 48  hour  lymphocyte 
cultures observed by  the  two  laboratories at  the  two  doses are  shown  in Tables 
1  and  2.  The  results for micronuclei  are  shown  in Tables  3 and  4 and  for  PCC 
in Table  5. 
Unstable  chromosomal  aberrations 
Table 6  shows  an  analysis of the dicentric distributions  from  Chilton to 
derive both the fraction irradiated and its dose  compared  with the known  values 
for each mixture.  The  methods  used were  the contaminated Poisson method  as 
described in the Appendix  and  the Qdr  method  or more  strictly the  Qd  method  as 
it has been applied to the dicentrics alone  rather than the dicentrics and 
rings as originally for.mulated.  The  calculations of estimated dose utilised 
dose  response  curves previously published  (Lloyd et al 1986)  by  Chilton for 
dicentrics 
y  = ((3.64 ± 0.53)10-
20  +  (6.67  ±  0.22)10-
20
2
) 
and  for total aberrations 
y  = ((5.10 ± 1.69)10-
20  +  (11.1  ±  0.7)10-
20
2
) 
••• ( 1) 
••• ( 2) 
For  calculating the fraction irradiated from  the  fraction irradiated and  seen 
(see equation 13  in Appendix)  a  D
0  value of 2.5 Gy  was  used.  The  true doses 
and  actual  irradiated fractions as shown  in columns  1  and  2,  are very well 
estimated by  both methods.  At  both doses  the mean  of doses  in colunm  4 are 
within 10%  of the known  values.  The  discrepancy is a  little higher at 8  Gy 
possibly because at this dose  the effects of saturation may  been  seen.  A test 
for  constancy of the estimates of dose  to the  irradiated fraction shows  a  )( 
value a  little greater than the degrees of freedom.  The  data points which 
- 55  -deviate  from  the  known  dose  and  fraction irradiated by  more  than two  standard 
errors are indicated in Table  6.  There  is very little difference between  the 
corresponding estimates  from  the  two  methods.  For  the Qd  method  no  estimates 
of uncertainties are given because  Sasaki does  not give  the method  of deriving 
these and  the analysis is not a  trivial one.  However,  standard errors should 
not be  too different from  those given for  the contaminated Poisson method. 
Leiden  chose  to combine  dicentrics and  centric rings and  in Table  7  the 
results are analysed.  Because  the yield for  the 100%  irradiated sample 
differed from  those of Chilton, it was  not possible to use the yield curve 
(eq 1)  shown  above  as applied in Table  6  to the data from  Chilton.  Therefore, 
estimates of dose  to the irradiated fraction could not be derived for Leiden. 
Neither was  it possible to use the Qdr  method  because a  yield curve for total 
unstable aberrations is reqtiired.  Leiden has not generated its own  dose 
response  data for  this quality of X-rays.  The  present data were  therefore 
analysed using the contaminated Poisson method  but quoting the aberration yield 
in the  irradiated fraction and  the fraction of irradiated cells that was  seen 
(columns  4 and  5).  For  comparison  the true doses  and  fractions were  used 
together with an  assumed  0
0  of 2.5 Gy  to calculate the expected fraction 
irradiated and  seen and  this is shown  in column  3.  Comparison of the values in 
columns  3 and  5  shows  a  reasonable agreement between  expected and the observed 
fraction of irradiated cells that were  seen at metaphase.  The  derived yield of 
dicentrics plus  rings to the irradiated fraction  (column  4)  should be 
independent of the size of the irradiated fraction and  thus the values should 
not change  as one  goes  down  the column.  Weighted  means  of the yields at each 
dose  are  shown  and  also those points that differ from  the mean  by more  than  two 
standard errors are  indicated. 
In Table  8  the  results of an  analysis for  the data for  total aberrations 
is shown.  Because  it is known  that total aberrations are overdispersed 
compared  with Poisson  (Edwards  et al 1979)  and  the  four distributions of total 
- 56  -aberrations for  100%  irradiated samples  shown  in Tables 1  and  2 are all 
overdispersed  (a
2/Y- 1.23,  1.32,  1.24 and  1.48),  the assumption  that the 
Poisson distribution applies to total aberrations in cells which  have  been 
irradiated breaks down.  As  shown  in the Appendix  this deficiency may  be 
overcome  by describing the overdispersion by  the negative binomial.  This may 
be  specified using two  parameters,  the mean  Yanda dispersion parameter,  e. 
The  parameter 1/9 is the  ratio of variance to mean,  so that 6 must  lie between 
zero and  1.  When  analysing the data allowing all the parameters,  Y,  e and  F 
(fraction of cells irradiated)  to float, it was  not always  possible to obtain a 
sensible solution.  By  fixing the value of e it was  possible to obtain sensible 
solutions in most  instances.  The  value chosen  for e was  0.9 based on  our 
previous experience of measured values  for  the ratio of variance to mean  for 
total aberrations produced  by X and  gamma  rays  (Edwards  et al 1979).  This 
corresponds  to a  ratio of variance to mean  for  100%  irradiated samples  of 1.11. 
In practice,  the derived yields and  fractions irradiated were  not ve~ 
dependent upon  the choice of e.  On  three occasions  {5  Gy  Chilton,  100% 
irradiated and  8  Gy  both laboratories 100%  irradiated), it was  not possible to 
arrive at a  solution.  on  three other occasions  (Chilton 8  Gy  97%,  90%  and  70%) 
the numerical minimisation failed  (see Appendix)  but sensible solutions were 
obtained using e = 0.89.  The  reasons  for  these problems  are not yet 
understood,  but they are related to the way  in which  the  NAG  libra~ routine is 
being used.  The  other problem of accounting for a  finite yield at zero dose 
was  solved by using a  background yield of 0.0035  aberrations per cell {see 
Appendix  for details).  If the yield equation for  total aberrations  (eq.  2 
above)  is used  then doses of 5 and  8  Gy  lead to expected yields of 3.0  and  7.5 
aberrations per cell  respectively,  which are in reasonable agreement  with the 
yields  from  Chilton given in Table  8  (column  4).  The  corresponding values  from 
Leiden  (column  6)  are lower  just as  they were  for dicentrics.  Nevertheless, 
the consistency of the yields to the irradiated fractions  in Table  8  and  the 
•  57  • reasonable  consistency between  the expected  (column  3)  and  estimated  (columns  5 
and  7)  fractions of cells irradiated and  seen at metaphase  leads to the 
conclusion that total unstable aberrations as well as dicentrics and  rings,  can 
also be  used to predict the size of the  irradiated fraction and  its dose. 
It is interesting to observe  from  Table  1  that some  cells have  no 
aberrations in them,  even  for  100%  irradiation at 5 Gy  (11  in 171  from  Chilton, 
25  in 300  from  Leiden).  At  8 Gy  however  (Table  2)  then in the  100%  irradiated 
samples  no  cell free of aberrations was  seen but when  only 1%  of cells were 
spared,  then 6 in 33  (Chilton)  and  22  in 100  (Leiden)  were  observed  free  from 
aberrations.  This  raises the possibility that if some  lymphocytes  are seen 
free  from  aberrations it is likely that in vivo  some  stern cells could  remain  to 
multiply and  cause a  host versus graft interaction after a  bone  marrow 
transplant.  It would  appear that the number  of cells seen without aberrations 
could be used as a  simple  indicator of the likelihood of some  cells having been 
spared from  lethal exposure. 
Micronuclei 
Interpretation of the micronucleus data is rather more  difficult than for 
chromosomal  aberrations.  There  has been insufficient experience with the 
technique  to measure  reliable dose  response  curves and  indeed Bauchinger  (1990) 
has  reviewed published data and  showed  considerable disparity.  A quantitative 
estimate of how  overdispersion varies with dose  is not available.  The  only 
information on  this is given by Prosser et al  (1988)  and Littlefield et al 
(1989)  and  the  results are variable.  The  analysis presented here will there-
fore be  to find parameters of the contamdnated  negative binomial distribution 
and  to compare  with estimates derived from  the  known  mixtures.  The  control 
yield of micronuclei  is taken as  0.012 which  is the average of the zero dose 
observations in Tables  3 and  4.  For  the  100%  irradiated specimens  the  ratios 
of variance  to mean  (Tables  3 and  4,  Chilton and  Leiden)  were  respectively 1.37 
±  .13,  1.16 ± .04,  1.04 ± .08,  1.25 ± .04.  These  average out to about  1.2 for 
- 58  -the  four  measurements.  It was  therefore decided  to fix  the parameter  9 at 0.8 
for  the purpose of the analysis of the  results which  is shown  in Table  9. 
For  both laboratories dose effect curves  for micronuclei  exist (Prosser 
et al  (1988)  for Chilton and  the Leiden  curve  is unpublished). 
For  Chilton Y = .0129  +  .1170 +  .00870
2 
For  Leiden Y  =  .024  +  .1570  +  .0310
2 
••• ( 3) 
••• ( 4) 
Table  9  shows  for each dose  and  irradiated fraction the derived yields in 
columns  4 and  7,  the derived doses  in columns  5 and  8 and  the fractions 
irradiated and  seen in columns  6 and  9.  The  yields in columns  4 and  7  should 
depend  only on  the dose  to the irradiated fraction.  Weighted  means  have  been 
calculated and  chi-squared values are considerably greater than the corre-
sponding statistics for  chromosomal  aberrations in Tables  6,  7 and  8.  From  the 
above  dose effect curves,  the dose is poorly predicted.  The  only set that 
predicts the dose within reason is for Chilton at 8 Gy,  although this could be 
spurious because  the curve has been extrapolated beyond  the  range  of the data 
from which it was  derived.  The  Chilton laboratory seriously overestimates the 
5 Gy  dose  and  Leiden  seriously underestimates both doses.  The  deduced 
fractions of cells irradiated and  seen by  Chilton  (column  6)  are in good 
agreement with the expected values in column  3.  The  fractions deduced  by 
Leiden however,  are higher than expected and  at 5 Gy  show  no  smooth  downward 
trend.  Overall the micronucleus  technique does  not give  such  reliable results 
as the aberration endpoint.  It is clear that, at present,  consistency in 
deriving curves is lacking probably because  the  technique is relatively new. 
Details of cell culture still need  to be  standardised both within and  between 
laboratories.  Comparison  of eqns  3 and  4 above  indicate that Leiden  obtains a 
higher dose  response  yet in the present work  at both doses  and all mixtures 
Chilton  reports higher micronucleus yields.  It is notable that by  contrast to 
unstable aberrations even at 8  Gy  100%  irradiated  (Table  4)  both laboratories 
observe a  considerable number  of binucleate cells free  from  micronuclei. 
a  59  a Prematurely condensed  chromosomes 
The  PCC  technique was  carried out only at Leiden where  the group  has 
investigated the dose  response  relationship {unpublished).  With  fusion one  day 
after irradiation a  relationship over  the  range  1-8 Gy  was  obtained that fitted 
best to a  weighted linear regression Y =  {1.45 ± 0.03)0.  The  results of the  PP~ 
ex~eriments using  samples  irradiated at  Chilton  are  shown  in  T~~les Sa,  b. Here 
it may  be  seen that for  zero dose  control values each cell scored contained 46 
chromosomal  pieces corresponding to the human  diploid number.  At both  5 and  8 
Gy  100%  irradiated the number  of cells containing 46  chromosomal  pieces was 
zero.  At  these doses  therefore,  there is good  separation of irradiated and 
unirradiated cells.  At  5.0 Gy  (Table  Sa)  the yield in the irradiated fraction 
(final column)  is constant for each sample.  rrlixture  independant  of  the  fraction 
irradiated.  The  corresponding values at 8.0 Gy  (Table  Sb)  are also quite 
similar although there may  be  a  slight tendency for  the values to rise with 
increasing fraction irradiated.  The  averages of the values in the final 
columns  are 6.26  and  11.35 excess PCC  fragments  per cell which  from  the linear 
regression above  lead to dose estimates of 4.3 and  7.8 Gy.  At  both doses  the 
percentages of cells damaged  (penultimate column)  correspond very closely to 
the percentages of cells irradiated (column 1).  This indicates that with the 
PCC  technique,  there is no  effect corresponding to the interphase death that 
operates with chromosomal  aberrations and micronuclei.  It follows  therefore 
that in the situation of a  small  spared fraction one  would  expect to see more 
undamaged  cells by  the aberration or micronucleus assays and  indeed inspection 
of the  95-99%  irradiated values  in Tables 2 and  4  shows  this to be  so. 
Nevertheless Tables  Sa  and  b  show  that in the  95-97%  irradiated material  PCC 
cells without fragments  were  observed.  It also follows  that in the opposite 
situation of a  localised burn  the  PCC  method  could be  a  more  effective assay 
than aberrations or micronuclei. 
- 60  -Conclusions 
This work  has  been done  by in vitro mixing of irradiated and  unirradiated 
cells to simulate a  partial body  exposure.  It is therefore a  much  more simplified 
situation  tnan  that  which  applies  in  vivo where  the distribution of doses  over 
the body  would  probably form  a  continuum  rather than  two  homogeneous  fractions. 
The  simplification also has  taken no  account of the distribution and 
circulation characteristics of lymphocytes  or any  other physiological processes 
that may  operate on  lymphocyte  populations in vivo.  Nevertheless,  the work  has 
demonstrated that it should be  possible to use biological dosimetry to give a 
more  refined indication of a  high,  but non-unifor.m  irradiation,  than simply 
quoting an  estimate of averaged equivalent whole  body dose.  Potentially the 
methods  described here may  be  able to provide the physician with sufficient 
information to aid in taking decisions  regarding the management  of patients 
thought  to be  at risk of severe depletion or destruction of their bone  marrow. 
It is clearly necessary to follow up  the work  described here by  in vivo studies 
of partially or inhomogeneously irradiated persons. 
We  have  shown  that by analysing the distribution data using the 
contaminated Poisson or Qdr  methods  for dicentrics or the  contaminated negative 
binomial  for  total aberrations,  reasonable estimates of the size of an 
irradiated fraction of lymphocytes  and  its dose,  can be  deduced.  A comparison 
of the deduced  values with the known  yalues shows  no  particular advantage 
whether  the calculations have  been done  on  data for observed dicentric 
aberrations alone,  or all unstable aberrations combined.  On  balance however, 
it is easier to handle  the data on  dicentrics because one  may  assume  an 
underlying Poisson distribution of the aberrations.  The  opportunity has  been 
taken  in this paper  to present in an Appendix  in detail the algebraic steps 
that are  involved  in the calculations of the  contaminated Poisson method.  This 
technique has  been  outlined before  (eg.  lAEA  1986)  but never fully described. 
A contaminated negative binomJal  method  has  been  developed  here  and  is 
•  61  • presented for  the first time  to enable similar calculations for endpoints  such 
as total unstable aberrations or micronuclei  that have  a  natural underlying 
tendency for overdispersed distributions even with homogeneous  irradiation. 
A disturbing feature of the  results in the present work  is the difference 
in aberration yields  reported by  the  two  laboratories that shared aliquots of 
the  same  samples of blood.  This points to the need,  often cited previously, 
(eg.  ~'  1986)  that interpretation of aberration yields in terms of dose 
should be  done  using in vitro curves constructed in the same  laboratory.  The 
lack of appropriate curves from  Leiden has thus limited full derivation of 
values in the present work.  Nevertheless,  presentation of the data from  that 
laboratory in terms of observed aberration yields compared with expected in the 
irradiated fraction and  the calculation of the size of the  fraction has  shown 
that as  for Chilton it is possible to distinguish even a  few  percent of spared 
cells mixed  with cells that have  been highly irradiated.  This esssentially 
arises because of the selective advantage that unirradiated cells have  in 
preferentially reaching metaphase  by  48  hours  in culture. 
It should be  noted that even  for  95%  of cells irradiated at 5 Gy  there  ~~s 
still about  40%  of cells seen that did not contain any aberrations and  so were 
apparently undamaged.  At 8  Gy and  99%  irradiated about 20%  of cells seen were 
normal.  By  contrast for  100%  irradiated, at 5 Gy about  8%  and at 8 Gy  no  cells 
were  seen to be  free  from  aberrations.  This  information in itself is of 
immediate  qualitative value as an indication that some  proportion of the cells 
has  been  spared.  The  implication from  this is that there is likely to be 
natural  recovery of bone  marrow.  For  the analysis of a  highly irradiated 
subject this would  be  apparent after relatively few  cells had  been  scored.  The 
clinician could then be  informed early on  with  the expectation that when  a 
larger sample  has  been  analysed a  more  quantitative estimate of inhomogeneous 
irradiation would  be available using the methods  described in this paper. 
The  analysis of the  results from  the micronucleus measurements  of both 
laboratories indicate that this endpoint is less  reliable than aberrations. 
- 62  -The  data showed  even more  variation both inter and  intra-laboratory and  less 
concordance with the expected values deduced  from  the  known  doses and  sizes of 
irradiated fractions.  Far less  research has gone  into characterising the dose 
response  for  the newer  micronucleus method  compared  with dicentrics and  this is 
reflected in the currently rather disparate published data.  At  present we  see 
no  significant advantage  in using the micronucleus assay as a  biological 
dosemeter  for  the particular purpose addressed by  this paper of determining 
inhomogeneous  exposure. 
Results for  the prematurely condensed  chromosome  assay suggest that there 
is no  selective advantage  for a  small fraction of spared cells being 
preferentially scored.  This is because  the phenomena  of interphase death and 
mitotic delay do  not appear to operate with this assay.  For  detecting. partial 
body  irradiation within two" days of an accident the  PCC  technique  seems  to be 
efficient.  The  number  of normal  cells observed  reflects more  accurately the 
proportion of unirradiated lymphocytes  in the mixture without the need  for 
correction.  PCC  may  be  the method  of choice for  the localised burn. 
Acknowledgement 
We  are indebted to David  Papworth of the UK  Medical  Research Council's 
Radiobiology Unit,  Harwell  who  devised the method  of deriving the fraction 
irradiated and  its mean  from  a  contaminated Poisson distribution.  Although 
this procedure has been available for  several years it has never  formally been 
published.  We  are taking the opportunity here  to present the algebra in full. 
Those  ideas have  also been applied here,  for  the first time,  to the 
contaminated negative binomial distribution.  We  are grateful to David  Papworth 
for critically reviewing this appendix. 
.  63  . ~
 
\
 
o
f
 
c
e
l
l
s
 
i
r
r
A
d
i
a
t
e
d
 
a
t
 
5
 
G
y
 
0
 
3
0
 
s
o
 
7
0
 
8
0
 
9
0
 
9
5
 
1
0
0
 
0
 
3
0
 
s
o
 
7
0
 
8
0
 
9
0
 
9
5
 
1
0
0
 
C
e
l
l
s
 
s
c
o
r
e
d
 
5
0
0
 
4
5
1
 
2
4
7
 
2
0
0
 
2
0
0
 
1
2
0
 
2
5
7
 
1
7
1
 
2
0
0
 
2
0
0
 
2
0
0
 
2
0
0
 
2
0
0
 
2
0
0
 
1
0
0
 
3
0
0
 
D
i
c
e
n
t
r
i
c
s
 
0
 
3
2
 
4
5
 
8
1
 
1
0
2
 
1
0
3
 
2
3
9
 
2
8
2
 
0
 
6
 
3
6
 
4
7
 
5
8
 
9
6
 
s
o
 
3
1
2
 
C
e
n
t
r
i
c
 
r
i
n
q
s
 
0
 
6
 
3
 
5
 
1
3
 
9
 
3
 
1
4
 
T
a
b
l
e
 
1
 
R
o
s
u
l
t
s
 
f
o
r
 
a
b
e
r
r
a
t
i
o
n
s
 
i
n
 
c
e
l
l
s
 
i
r
r
a
d
i
a
t
e
d
 
a
~
 
A
c
e
n
t
r
i
c
s
 
2
8
 
3
2
 
5
9
 
6
7
 
3
8
 
1
8
0
 
2
0
8
 
6
 
1
0
 
7
6
 
7
1
 
1
0
1
 
1
4
0
 
1
0
0
 
4
 
5
4
 
D
i
c
e
n
t
r
i
c
 
d
i
s
t
r
i
b
u
t
i
o
n
 
0
 
1
 
2
 
3
 
4
 
5
0
0
 
4
3
0
 
1
1
 
9
 
2
2
5
 
4
 
1
3
 
s
 
1
6
2
 
1
5
 
1
2
 
6
 
3
 
1
5
4
 
1
7
 
1
2
 
1
1
 
8
0
 
1
2
 
7
 
1
3
 
4
 
1
3
1
 
5
7
 
4
0
 
2
0
 
4
 
3
6
 
5
3
 
4
6
 
1
6
 
1
5
 
(
a
)
 
C
h
i
l
t
o
n
 
2
0
0
 
1
9
5
 
1
8
2
 
4
 
7
 
1
 
4
 
1
6
6
 
2
1
 
1
3
 
1
5
7
 
3
0
 
1
1
 
1
3
1
 
4
6
 
1
9
 
6
5
 
2
2
 
1
1
 
7
 
2
 
4
 
2
 
1
1
2
 
9
2
 
6
9
 
2
6
 
(
h
)
 
t
.
o
l
t
l
o
n
 
1
 
5
 
0
 
3
 
4
 
6
 
7
 
0
 
1
 
4
 
T
o
t
a
l
 
a
b
e
r
r
a
t
i
o
n
 
d
i
s
t
r
i
b
u
t
i
o
n
 
0
 
4
9
9
 
4
2
4
 
1
0
 
2
1
6
 
1
0
 
1
5
8
 
7
 
2
 
5
 
7
 
s
 
9
 
1
1
 
4
 
6
 
6
 
s
 
1
4
4
 
1
3
 
1
1
 
6
 
1
1
 
7
3
 
9
 
1
0
 
1
1
 
8
 
5
 
0
 
4
 
3
 
6
 
3
 
1
0
3
 
4
4
 
3
0
 
2
9
 
3
0
 
1
6
 
1
1
 
2
6
 
4
2
 
4
0
 
2
2
 
1
1
 
1
9
4
 
6
 
1
8
8
 
8
 
1
5
4
 
2
4
 
6
 
5
 
2
 
1
4
4
 
2
1
 
1
7
 
1
0
 
7
 
1
3
2
 
1
9
 
2
6
 
1
0
 
9
 
1
0
7
 
2
4
 
3
3
 
1
0
 
1
8
 
s
o
 
1
2
 
1
4
 
8
 
6
 
3
 
5
 
6
 
0
 
3
 
8
 
2
 
8
 
0
 
2
 
2
5
 
7
1
 
8
8
 
3
3
 
3
7
 
1
9
 
1
6
 
7
 
8
 
3
 
6
 
2
 
7
 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
·
·
-
-
·
-
-
-
-
-
-
-
-
-
-
·
 
9
 
1
0
 e
n
 
c
.
n
 
\
 
o
f
 
c
d
l
s
 
i
r
r
a
d
i
a
t
e
d
 
a
t
 
8
 
G
y
 
0
 
3
0
 
5
0
 
7
0
 
8
0
 
9
0
 
9
5
 
9
7
 
9
9
 
1
0
0
 
0
 
3
0
 
5
0
 
1
0
 
8
0
 
9
0
 
9
5
 
9
7
 
9
9
 
1
0
0
 
C
e
l
l
s
 
s
c
o
r
e
d
 
1
0
0
 
2
0
0
 
3
0
0
 
4
3
8
 
4
0
0
 
J
O
O
 
1
4
6
 
s
o
 
3
l
 
2
1
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
5
0
 
D
i
c
e
n
t
r
i
c
s
 
0
 
1
6
 
3
5
 
1
2
9
 
1
6
1
 
2
J
'
I
 
2
5
3
 
1
0
5
 
1
0
2
 
1
0
0
 
0
 
0
 
7
 
4
2
 
5
2
 
7
6
 
1
1
0
 
9
8
 
1
3
6
 
2
9
2
 
C
e
n
t
r
i
c
 
A
c
e
n
t
r
i
c
s
 
r
i
n
g
s
 
0
 
0
 
8
 
0
 
2
3
 
1
0
1
 
1
1
3
 
I
t
>
 
1
3
.
2
 
u
 
1
4
5
 
4
5
 
4
7
 
4
5
 
3
 
.
2
2
 
5
4
 
6
6
 
8
2
 
1
5
1
 
1
7
1
 
2
2
6
 
.
J
.
I
'
(
)
 
T
a
b
l
e
 
2
 
R
e
s
u
l
t
s
 
f
o
r
 
a
b
e
r
r
a
t
i
o
n
s
 
i
n
 
c
e
l
l
s
 
i
r
r
a
d
i
a
t
e
d
 
a
t
 
8
 
G
y
 
D
i
c
e
n
t
r
i
c
 
d
i
s
t
r
i
b
u
t
i
o
n
 
0
 
3
 
5
 
6
 
7
 
8
 
9
 
1
0
 
1
1
 
1
2
 
1
0
0
 
1
9
6
 
0
 
0
 
0
 
2
9
3
 
0
 
0
 
0
 
4
0
2
 
8
 
1
2
 
5
 
3
5
6
 
6
 
7
 
1
3
 
5
 
6
 
0
 
2
)
9
 
5
 
1
3
 
1
1
 
1
'
1
 
8
 
5
 
8
3
 
5
 
9
 
1
6
 
1
1
 
9
 
8
 
0
 
0
 
2
7
 
0
 
7
 
6
 
5
 
0
 
0
 
4
 
6
 
3
 
0
 
(
a
)
 
C
h
i
l
t
o
n
 
1
0
0
 
0
 
1
0
0
 
0
 
9
6
 
8
1
 
l
 
2
 
8
2
 
5
 
5
 
2
 
7
3
 
a
 
5
8
 
7
 
1
6
 
1
0
 
5
 
4
9
 
1
9
 
2
1
 
3
5
 
2
0
 
2
5
 
1
5
 
1
7
 
3
8
 
5
1
 
2
5
 
1
1
 
(
l
>
)
 
l
.
u
i
d
u
n
 
T
o
t
a
l
 
a
b
e
r
r
a
t
i
o
n
 
d
i
s
t
r
i
b
u
t
i
o
n
 
0
 
2
 
5
 
6
 
7
 
9
 
1
0
 
1
1
 
1
2
 
1
3
 
1
4
 
1
5
 
1
6
 
1
0
0
 
1
9
6
 
0
 
0
 
0
 
0
 
0
 
2
9
2
 
0
 
0
 
0
 
0
 
0
 
3
9
8
 
5
 
6
 
5
 
0
 
3
5
2
 
5
 
7
 
7
 
0
 
0
 
0
 
0
 
2
3
6
 
0
 
6
 
1
1
 
1
0
 
1
3
 
8
0
 
5
 
6
 
1
1
 
1
3
 
0
 
2
6
 
0
 
0
 
5
 
0
 
0
 
0
 
6
 
0
 
5
 
0
 
0
 
0
 
5
 
0
 
9
1
 
9
6
 
9
1
 
0
 
0
 
0
 
1
5
 
6
 
7
0
 
6
 
4
 
5
9
 
7
 
1
0
 
5
 
0
 
1
6
 
9
 
1
 
3
 
4
0
 
6
 
1
0
 
7
 
2
2
 
1
0
 
9
 
1
2
 
1
2
 
1
2
 
6
 
0
 
1
5
 
2
1
 
1
6
 
1
9
 
2
0
 
1
9
 
1
1
 
1
5
 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-T
a
b
l
e
 
3
 
R
e
s
u
l
t
s
 
f
o
r
 
m
i
c
r
o
n
u
c
l
e
i
 
i
n
 
b
i
n
u
c
l
e
a
t
e
 
c
e
l
l
s
 
a
t
 
5
 
G
y
.
 
%
 
o
f
 
c
e
l
l
s
 
C
e
l
l
s
 
D
i
s
t
r
i
b
u
t
i
o
n
 
i
r
r
a
d
i
a
t
e
d
 
s
c
o
r
e
d
 
M
N
 
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
0
 
5
0
0
 
3
 
4
9
8
 
1
 
1
 
3
0
 
5
0
0
 
6
4
 
4
6
4
 
2
0
 
8
 
4
 
4
 
5
0
 
5
0
0
 
1
0
1
 
4
4
5
 
3
1
 
1
1
 
7
 
4
 
1
 
1
 
7
0
 
1
0
0
0
 
3
0
2
 
8
2
5
 
8
6
 
6
4
 
1
5
 
7
 
3
 
8
0
 
1
0
0
0
 
3
9
4
 
7
7
8
 
1
0
8
 
7
2
 
2
9
 
1
1
 
1
 
1
 
9
0
 
5
0
0
 
1
8
5
 
3
7
9
 
7
6
 
2
9
 
1
3
 
.
 
3
 
9
5
 
5
0
0
 
8
1
8
 
1
4
6
 
1
0
1
 
1
0
9
 
9
6
 
3
1
 
1
5
 
2
 
0
>
 
0
>
 
1
0
0
 
3
0
0
 
5
0
6
 
7
9
 
7
3
 
6
8
 
4
8
 
1
7
 
8
 
5
 
1
 
1
 
(
a
)
 
C
h
i
l
t
o
n
 
0
 
1
0
0
0
 
1
4
 
9
8
6
 
1
4
 
3
0
 
1
0
0
0
 
1
1
0
 
9
3
7
 
3
0
 
2
0
 
1
2
 
1
 
5
0
 
1
0
0
0
 
1
9
8
 
8
7
9
 
7
0
 
2
8
 
2
0
 
3
 
7
0
 
1
0
0
0
 
2
7
8
 
7
8
2
 
1
6
6
 
4
4
 
B
 
8
0
 
1
0
0
0
 
4
2
6
 
7
0
6
 
1
8
8
 
8
0
 
2
6
 
9
0
 
1
0
0
0
 
4
5
6
 
6
6
6
 
2
3
0
 
8
6
 
1
0
 
9
5
 
1
0
0
0
 
5
4
2
 
6
3
6
 
2
2
0
 
1
1
2
 
3
0
 
2
 
1
0
0
 
1
0
0
0
 
7
0
5
 
5
2
3
 
3
0
0
 
1
2
3
 
3
5
 
1
0
 
0
 
1
 
(
b
)
 
L
e
i
d
e
n
 T
a
b
l
e
 
4
 
R
e
s
u
l
t
s
 
f
o
r
 
m
i
c
r
o
n
u
c
l
e
i
 
i
n
 
b
i
n
u
c
l
e
a
t
e
 
c
e
l
l
s
 
a
t
 
8
 
G
y
.
 
%
 
o
f
 
c
e
l
l
s
 
C
e
l
l
s
 
D
i
s
t
r
i
b
u
t
i
o
n
 
i
r
r
a
d
i
a
t
e
d
 
s
c
o
r
e
d
 
M
N
 
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
0
 
5
0
0
 
6
 
4
9
4
 
6
 
5
0
 
5
0
0
 
2
6
 
4
8
8
 
6
 
3
 
0
 
2
 
0
 
1
 
7
0
 
5
0
0
 
5
7
 
4
7
7
 
9
 
6
 
1
 
3
 
3
 
1
 
8
0
 
5
0
0
 
1
1
8
 
4
4
5
 
1
8
 
1
6
 
1
6
 
5
 
9
0
 
5
0
0
 
1
8
8
 
4
0
8
 
2
7
 
4
2
 
1
7
 
4
 
2
 
9
5
 
5
0
0
 
3
4
4
 
3
2
8
 
7
1
 
4
9
 
3
9
 
9
 
2
 
2
 
9
7
 
4
0
0
 
3
4
7
 
2
2
5
 
7
3
 
5
7
 
2
9
 
7
 
9
 
0
'
>
 
"
'
 
9
9
 
2
8
3
 
3
4
4
 
1
1
8
 
5
6
 
6
3
 
2
9
 
1
3
 
2
 
1
 
1
 
1
0
0
 
3
0
0
 
5
1
7
 
6
3
 
8
1
 
7
1
 
5
6
 
2
0
 
8
 
1
 
(
a
)
 
C
h
i
l
t
o
n
 
0
 
5
0
0
 
7
 
4
9
3
 
7
 
5
0
 
5
0
0
 
1
0
5
 
4
3
0
 
4
5
 
1
5
 
1
0
 
7
0
 
5
0
0
 
1
7
0
 
4
0
0
 
5
5
 
2
5
 
1
5
 
5
 
8
0
 
5
0
0
 
2
5
0
 
3
7
0
 
6
5
 
3
0
 
2
0
 
1
0
 
5
 
9
0
 
5
0
0
 
2
8
7
 
3
3
1
 
9
0
 
4
0
 
3
9
 
9
5
 
4
0
0
 
2
6
4
 
2
4
8
 
8
4
 
3
6
 
2
0
 
1
2
 
9
7
 
1
0
0
0
 
7
4
6
 
5
6
2
 
2
3
6
 
1
3
2
 
4
4
 
1
8
 
6
 
2
 
9
9
 
1
0
0
0
 
8
2
6
 
4
9
6
 
3
0
2
 
1
2
6
 
4
8
 
1
8
 
4
 
6
 
1
0
0
 
1
0
0
0
 
1
1
8
4
 
3
3
2
 
3
6
0
 
1
8
4
 
7
0
 
3
2
 
1
4
 
8
 
(
b
)
 
L
e
i
d
e
n
 
-
-
·
-
-
-
-
-
-
-
-
-
-
p
-
-
-
-
-
-
·
-
-
-
-
-
-
·
-
-
-
-
-
-
·
-
·
.
 
-
-
·
-
-
-
-
-
-
-
-
-
·
-
-
-
-
-
-
-
-
-
-
-
-
-
-
·
·
-
-
-
-
-
-
-
-
-
-
-
-
·
-
·
-
-
-
-
-
-
-
-
-
-
-
-
-0
)
 
C
X
I
 
\
 
o
f
 
c
e
l
l
s
 
i
r
r
a
d
i
a
t
e
d
 
0
 
1
0
 
3
0
 
s
o
 
1
0
 
8
0
 
9
0
 
9
5
 
9
1
 
9
9
 
1
0
0
 
T
a
b
l
e
 
S
a
 
R
e
s
u
l
t
s
 
f
o
r
 
p
r
e
m
a
t
u
r
e
 
c
h
r
o
m
o
s
o
m
e
 
c
o
n
d
e
n
s
a
t
i
o
n
 
a
t
 
5
 
G
y
 
P
C
C
 
d
i
s
t
r
i
b
u
t
i
o
n
 
4
6
 
4
1
 
4
8
 
4
9
 
s
o
 
5
1
 
5
2
 
5
3
 
5
4
 
5
5
 
5
6
 
5
1
 
5
8
 
5
9
 
6
0
 
6
1
 
6
2
 
6
3
 
6
4
 
6
5
 
6
6
 
6
7
 
6
8
 
6
9
 
9
5
 
9
6
 
0
 
1
 
0
 
2
 
3
 
3
 
2
 
1
 
1
 
1
 
1
3
 
0
 
0
 
1
 
6
 
4
 
3
 
0
 
1
 
2
 
1
 
2
4
 
0
 
0
 
4
 
5
 
3
 
2
 
1
 
1
 
1
 
0
 
1
 
1
3
 
0
 
0
 
0
 
9
 
1
2
 
8
 
1
 
2
 
1
 
3
 
9
 
0
 
0
 
0
 
8
 
9
 
1
0
 
9
 
3
 
1
 
1
 
1
 
1
 
6
 
0
 
0
 
0
 
1
 
1
2
 
1
2
 
1
3
 
4
 
1
 
2
 
2
 
1
 
3
 
0
 
0
 
0
 
1
0
 
1
2
 
9
 
1
 
7
 
3
 
1
 
1
 
2
 
2
 
0
 
0
 
0
 
7
 
8
 
1
1
 
8
 
6
 
3
 
0
 
1
 
1
 
1
 
1
 
0
 
0
 
0
 
0
 
6
 
9
 
1
0
 
1
0
 
6
 
4
 
1
 
2
 
1
 
1
 
0
 
0
 
0
 
1
 
2
1
 
3
3
 
3
0
 
2
0
 
1
1
 
7
 
3
 
3
 
3
 
1
 
2
 
E
x
c
e
s
s
 
C
e
l
l
s
 
C
e
l
l
s
 
P
C
C
 
s
c
o
r
e
d
 
d
a
m
a
g
e
d
 
0
 
9
5
 
0
 
8
4
 
1
1
0
 
1
4
 
1
4
6
 
9
8
 
2
5
 
1
1
5
 
4
3
 
1
9
 
2
4
8
 
5
5
 
4
2
 
2
6
6
 
5
2
 
4
3
 
3
4
6
 
6
0
 
5
4
 
3
3
1
 
5
5
 
5
2
 
3
1
5
 
4
9
 
4
7
 
3
4
0
 
5
0
 
5
0
 
8
8
7
 
1
4
1
 
1
4
1
 
\
 
c
e
l
l
 
d
a
m
a
g
e
 
0
 
1
1
.
3
 
±
 
3
.
2
 
2
0
.
3
 
±
 
4
.
4
 
4
4
.
2
 
±
 
7
.
6
 
7
6
.
4
 
±
 
5
.
7
 
8
2
.
7
 
±
 
5
.
2
 
9
0
.
0
 
±
 
3
.
9
 
9
4
.
5
 
±
 
3
.
1
 
9
5
.
9
 
±
 
2
.
8
 
1
0
0
 
1
0
0
 
m
e
a
n
 
p
e
r
 
d
a
m
a
g
e
d
 
c
e
l
l
 
6
.
0
0
 
±
 
.
6
5
 
5
.
8
4
 
±
 
.
4
8
 
6
.
0
5
 
±
 
.
5
6
 
5
.
9
0
 
±
 
.
3
1
 
6
.
1
9
 
±
 
.
3
8
 
6
.
 
4
1
 
±
 
•
 
3
4
 
6
.
3
7
 
±
 
.
3
5
 
6
.
1
0
 
±
 
.
3
8
 
6
.
8
0
 
±
 
.
3
7
 
6
.
2
9
 
±
 
.
2
1
 0
'
)
 
c
o
 
\
 
o
f
 
c
e
l
l
s
 
i
r
r
a
d
i
a
t
e
d
 
0
 
1
0
 
3
0
 
s
o
 
7
0
 
8
0
 
9
0
 
9
5
 
9
7
 
9
9
 
1
0
0
 
T
a
b
l
e
 
S
b
 
R
e
s
u
l
t
s
 
f
o
r
 
p
r
e
m
a
t
u
r
e
 
c
h
r
o
m
o
s
o
m
e
 
c
o
n
d
e
u
s
a
t
i
o
n
 
a
t
 
8
 
G
y
 
P
C
C
 
d
i
s
t
r
i
b
u
t
i
o
n
 
4
6
 
4
7
 
4
8
 
4
9
 
s
o
 
5
1
 
5
2
 
5
3
 
5
4
 
5
5
 
5
6
 
5
7
 
5
8
 
5
9
 
6
0
 
6
1
 
6
2
 
6
3
 
6
4
 
6
~
 
6
6
 
6
7
 
6
8
 
6
9
 
1
5
6
 
8
7
 
0
 
0
 
0
 
0
 
1
 
1
 
2
 
1
 
1
 
2
 
1
 
1
 
1
 
0
 
1
 
0
 
0
 
0
 
0
 
0
 
1
 
6
5
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
2
 
4
 
4
 
4
 
2
 
0
 
3
 
1
 
2
 
0
 
2
 
1
 
1
 
2
8
 
0
 
0
 
0
 
0
 
0
 
1
 
2
 
s
 
3
 
2
 
0
 
0
 
1
 
0
 
1
 
0
 
0
 
0
 
0
 
1
 
1
 
1
 
1
4
 
0
 
0
 
0
 
0
 
0
 
0
 
5
 
7
 
9
 
7
 
4
 
3
 
1
 
2
 
1
 
2
 
1
0
 
0
 
0
 
0
 
0
 
0
 
2
 
9
 
6
 
3
 
4
 
9
 
4
 
3
 
1
 
2
 
3
 
6
 
0
 
0
 
0
 
0
 
0
 
1
 
9
 
8
 
4
 
3
 
9
 
4
 
2
 
4
 
1
 
4
 
1
 
1
 
3
 
0
 
0
 
0
 
0
 
0
 
1
 
5
 
8
 
3
 
1
 
s
 
3
 
3
 
2
 
4
 
3
 
1
 
2
 
2
 
2
 
0
 
0
 
0
 
0
 
0
 
0
 
s
 
s
 
5
 
4
 
4
 
3
 
4
 
7
 
5
 
2
 
3
 
2
 
0
 
0
 
1
 
1
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
1
 
7
 
4
 
7
 
4
 
4
 
s
 
3
 
1
 
2
 
2
 
1
 
1
 
0
 
2
 
1
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
5
 
1
0
 
9
 
1
3
 
7
 
5
 
5
 
2
 
3
 
4
 
3
 
4
 
1
 
2
 
2
 
2
 
2
 
E
x
c
e
s
s
 
P
C
C
 
0
 
1
3
4
 
3
2
4
 
1
9
8
 
4
1
0
 
4
6
8
 
5
4
2
 
5
3
9
 
6
2
7
 
s
s
o
 
9
7
9
 
C
e
l
l
s
 
C
e
l
l
s
 
s
c
o
r
e
d
 
d
a
m
a
g
e
d
 
1
5
6
 
0
 
1
0
0
 
1
3
 
9
1
 
2
6
 
4
6
 
1
8
 
5
5
 
4
1
 
5
6
 
4
6
 
5
7
 
5
1
 
4
8
 
4
5
 
5
2
 
5
1
 
4
5
 
4
5
 
7
9
 
7
9
 
\
 
c
e
l
l
 
d
a
m
a
g
e
 
0
 
1
3
.
0
 
±
 
3
.
4
 
2
8
.
6
 
±
 
4
.
7
 
3
9
.
1
 
±
 
7
.
2
 
7
4
.
5
 
:
t
 
5
.
9
 
8
2
.
1
 
±
 
5
.
1
 
8
9
.
5
 
±
 
4
.
1
 
9
3
.
8
 
±
 
3
.
5
 
9
8
.
1
 
:
t
 
1
.
9
 
1
0
0
 
1
0
0
 
J
D
e
a
n
 
p
e
r
 
d
a
m
a
g
e
d
 
c
e
l
l
 
1
0
.
3
 
±
 
.
9
 
1
2
.
5
;
t
.
7
 
1
1
.
0
 
±
 
.
8
 
1
0
.
0
 
±
 
.
5
 
1
0
.
2
 
±
 
.
s
 
1
0
.
6
 
±
 
.
5
 
1
2
.
0
 
±
 
.
s
 
1
2
.
3
 
:
t
 
.
5
 
1
2
.
2
 
±
 
.
5
 
1
2
.
4
 
±
 
.
4
 T
a
b
l
e
 
6
 
A
n
a
l
l
s
i
s
 
o
f
 
r
e
s
u
l
t
s
 
f
o
r
 
d
i
c
e
n
t
r
i
c
s
 
f
r
o
m
 
C
h
i
l
t
o
n
 
E
x
p
e
c
t
e
d
 
C
o
n
t
a
m
i
n
a
t
e
d
 
P
o
i
s
s
o
n
 
Q
d
 
T
r
u
e
 
f
r
a
c
t
i
o
n
 
D
o
s
e
 
f
r
a
c
t
i
o
n
 
i
r
r
a
d
i
a
t
e
d
 
E
s
t
i
m
a
t
e
d
 
E
s
t
i
m
a
t
e
d
 
E
s
t
i
m
a
t
e
d
 
E
s
t
i
a
a
t
e
d
 
E
s
t
i
m
a
t
e
d
 
E
s
t
i
~
~
~
a
t
e
d
 
i
r
r
a
d
i
a
t
e
d
 
a
n
d
 
s
e
e
n
 
d
o
s
e
 
f
r
a
c
t
i
o
n
 
f
r
a
c
t
i
o
n
 
d
o
s
e
 
f
r
a
c
t
i
o
n
 
f
r
a
c
t
i
o
n
 
0
0
 
=
 
2
.
5
 
G
y
 
i
r
r
a
d
i
a
t
e
d
 
i
r
r
a
d
i
a
t
o
d
 
i
r
r
a
d
i
a
t
e
d
 
i
r
r
a
d
i
a
t
e
d
 
a
n
d
 
s
e
o
n
 
a
n
d
 
s
e
e
n
 
5
 
G
y
 
1
.
0
0
 
1
.
0
0
 
4
.
8
0
 
±
 
.
1
9
 
.
9
6
 
±
 
.
O
S
 
.
9
9
 
±
 
.
0
1
 
4
.
'
7
0
 
1
.
0
0
 
1
.
0
0
 
0
.
9
5
 
0
.
 
'
7
2
 
4
.
4
0
 
±
 
.
2
0
+
 
.
6
4
 
±
 
.
O
S
 
.
9
1
2
 
±
 
.
0
1
4
+
 
4
.
3
1
 
0
.
6
'
7
 
0
.
9
2
 
0
.
9
 
o
.
s
s
 
S
.
6
3
 
±
 
.
3
4
 
.
3
'
7
 
±
 
.
O
S
 
.
8
S
 
±
 
.
0
3
 
S
.
3
8
 
0
.
4
0
 
0
.
8
5
 
0
.
8
 
0
.
3
5
 
5
.
0
4
 
±
 
.
3
2
 
.
2
1
 
±
 
.
0
4
 
.
7
4
 
±
 
.
0
4
 
4
.
8
0
 
0
.
3
0
 
0
.
'
7
4
 
0
.
7
 
0
.
2
4
 
4
.
8
8
 
±
 
.
3
6
 
.
2
3
 
±
 
.
0
4
 
.
6
8
 
±
 
.
O
S
 
4
.
9
8
 
0
.
2
2
 
0
.
6
8
 
o
.
s
 
0
.
1
2
 
4
.
7
1
 
;
I
;
 
.
4
8
 
.
1
1
 
±
 
.
0
2
 
.
4
S
 
±
 
.
0
6
 
4
.
1
0
 
0
.
1
4
 
0
.
4
6
 
W
e
i
g
h
t
e
d
 
m
e
a
n
 
4
.
8
0
 
-
.
.
.
a
 
x
2
 
1
0
.
6
 
0
 
O
f
'
 
5
 
a
 
G
y
 
1
.
0
0
 
1
.
0
0
 
•
&
.
1
8
 
±
 
.
4
0
 
1
 
1
 
8
.
1
8
 
1
.
0
0
 
1
.
0
0
 
0
.
9
9
 
.
s
o
 
7
.
1
6
 
±
 
.
3
9
+
 
.
8
4
 
±
 
.
0
7
 
.
9
9
 
±
 
.
0
1
 
'
7
.
2
5
 
.
8
2
 
.
9
9
 
0
.
9
7
 
.
5
7
 
1
.
9
6
 
±
 
.
4
1
 
.
4
7
 
±
 
.
0
7
 
.
9
6
 
±
 
.
0
1
 
7
.
8
3
 
.
4
8
 
.
9
6
 
0
.
9
5
 
.
4
4
 
7
.
4
2
 
±
 
.
2
5
+
 
.
4
4
 
±
 
.
0
4
 
.
9
4
 
±
 
.
0
1
 
7
.
3
1
 
.
4
5
 
.
9
4
 
0
.
9
0
 
.
2
7
 
1
.
1
0
 
±
 
.
2
6
+
 
.
2
1
 
±
 
.
0
2
 
.
8
2
 
±
 
.
0
3
+
 
'
7
.
0
1
 
.
2
1
 
.
8
2
 
0
.
8
0
 
.
1
4
0
 
7
.
5
2
 
±
 
.
3
0
 
.
1
1
2
 
±
 
.
0
1
6
 
.
7
2
 
±
 
.
0
4
 
7
.
2
4
 
.
1
2
 
.
7
1
 
0
.
7
0
 
.
0
8
7
 
6
.
9
5
 
±
 
.
3
4
+
 
.
0
8
5
 
±
 
.
0
1
4
 
.
6
0
 
±
 
.
O
S
 
6
.
6
'
7
 
.
0
9
2
 
.
5
9
 
0
.
5
0
 
.
0
3
9
 
8
.
3
6
 
;
t
 
.
1
4
 
.
0
2
3
 
±
 
.
0
0
9
 
.
4
1
 
±
 
.
1
2
 
7
.
8
3
 
.
0
2
1
 
.
3
9
 
W
e
i
g
h
t
e
d
 
m
e
a
n
 
'
7
.
4
2
 
x
2
 
1
0
.
9
 
O
f
'
 
7
 
•
 
T
h
i
s
 
s
a
m
p
l
e
 
W
d
5
 
u
n
d
e
n
l
l
s
p
•
H
s
~
d
 
(
u
2
;
y
 
=
 
O
.
J
l
)
 
a
n
d
 
s
o
 
t
h
e
 
i
r
r
a
d
i
a
t
e
d
 
f
r
a
c
t
i
o
n
 
i
s
 
a
s
s
u
m
o
d
 
t
o
 
b
o
 
1
.
 
•
:
:
;
l
l
l
n
.
.
&
l
u
:
l
 
t
h
.
.
&
t
 
t
l
u
v
i
.
a
l
o
 
{
1
o
m
 
t
l
w
 
l
1
1
1
t
1
 
v
.
a
l
1
1
o
1
1
 
b
y
 
m
o
r
u
 
t
h
a
n
 
2
 
n
t
a
n
d
.
1
r
d
 
o
r
r
o
r
u
.
 
T
h
o
 
l
l
l
l
<
.
:
o
l
l
t
l
l
l
l
l
l
u
:
.
 
:
o
h
•
J
"
I
I
 
J
l
•
J
 
:
o
l
.
1
1
1
d
.
1
1
d
 
u
l
"
l
t
l
l
l
i
,
 Table  7 
Analysis of  results  for dicentrics and  rings  from  Leiden 
Dose 
8  Gy 
5  Gy 
True 
fraction 
irradiated 
1.0 
.99 
.97 
.95 
.90 
.80 
.70 
.50 
1.0 
.95 
.90 
.80 
.70 
.50 
Expected  fraction 
irradiated and  seen 
D  •  2.5 Gy 
0 
1.0 
.80 
.57 
.44 
.27 
.140 
.087 
.039 
Weighted  mean  .;· 
OF 
1.0 
.72 
.55 
.35 
.24 
.12 
Weighted  mean 
i 
DF 
Estimated yield 
to fraction 
irradiated 
*1.95  ±  .11 
1.72 ±  .19 
1.49 ±._.20+ 
2.38  ±  .26 
2.61  ±  .34 
2.70 ±  .42 
3.08 ±  .52+ 
1.25 ±  .67 
1.96 
22.3 
7 
*1.04  ±  .06 
.76  ±  .19 
.70  ±  .13 
.63  ±  .16 
.69  ±  .18 
1.59 ±  .35 
0.93 
16.2 
5 
Estimated fraction 
irradiated and  seen 
1 
.79  ±  .07 
.66  ±  .08 
.46  ±  .06 
.29  ±  .OS 
.19  ±  .04 
.14  ±  .04 
.06  ±  .03 
1 
.66  ±  .14 
.68 ±  .11 
.46  ±  .10 
.34  ±  .08 
.11 ±  .03 
*Distributions were  underdispersed and  so fraction irradiated was  assumed  to be 1. 
+Estimates  that deviate  from  the  true values by  more  than 2  standard errors. 
The  uncertainties shown  are standard errors. 
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 APPENDIX 
The  derivation of the parameters of a  contaminated Poisson 
distribution from  an  observed distribution of dicentrics 
The  problem 
Suppose  that the following distribution of dicentrics is observed  among 
the cells.  The  distribution is tested for conformity with Poisson by a  test 
such as Papworth's  (1970)  'u' test and  shown  to be  overdispersed.  The  variance 
therefore is significantly greater than the mean. 
cells with dicentrics 
0  1 
Let the total number  of cells be  n 
r 
n  =  1:  n. 
i=O 
1 
2 
Let the total number  of dicentrics be x 
1  •••••• 
ni  ••.•. 
r 
n 
r 
The  hypothesis is that the distribution can be  described by a  mixture of a 
fraction p  of a  Poisson distribution of mean  m and  a  fraction  (1-p)  of zeros. 
It is assumed  that unirradiated cells contain no  dicentrics. 
The  expected distribution is: 
P(O)  1-p +  pe-m 
P(i) 
i  -m 
=  prn  e 
i!  for  i  ~ 1 
One  would  wish  to find estimates for  p  and  rn  which  best fit the observed 
·distribution. 
- 75  -The  maximum  likelihood solution 
The  best estimates of p and  m are assumed  to be  those which maximise  the 
likelihood L of the observations.  In practice it is easier to solve  the 
equations which  maximise  the log-likelihood.  Formally the maximum  occurs when 
equations  (1)  and  (2)  are satisfied 
a logL  = 0  (1) 
a P 
and  a logL  ==  0  (2) 
a m 
Further.more,  asymptotic estimates of the variance on  m,  var(m),  the 
variance on  p,  var(p),  and  the covariance of m and  p,  covar(m,p),  can  be 
obtained using equation (  3) 
-1 
var(p)  covar(m,p)  - !_2logL  - !_21~ 
ap2  a  pam 
covar(m,p)  var(m) 
==  - !_2logL  - !_2logL  (3) 
a  pam  am2 
In this case it is possible to solve these equations analytically and  this is 
laid out below. 
The  likelihood L of the observations is 
r 
L  =  n  P( i )ni 
i=O 
( 1-p + pe-• )no 
r 
=  n  (J:IIIie-•ti 
i=1  .  '  J.. 
(1  -m  n  n-n  x  -(n-n  )m  r 
n (. ')n.  =  -p + pe  )  0  p  om  e  0  '/  J..  l. 
i=1 
r 
:.  logL  =  n
0  log( 1-p + pe-m)  +  (n-n
0
) logp +  x  log m -(n-n  )m  - E  ni logi! 
0 
i=1 
alogL  n  (e-
11-1)  n-n 
0  0  ( 4) 
=  +--
ap  1-p+pe 
-m  p 
alogL  n  (-pe-•)  X  (n-n  )  0 
=  +  - - 0 
(5) 
am  1-p+pe -·  m 
- 76  -At  the position of maximum  likelihood expressions  (4)  and  (5)  are zero 
.  .. 
1-p+pe-11 
n-n 
0 
+ -- p  - 0 
no(-pe-
11
)  +  X  - (n-n)  =  0 
0 
1-p+pe-11  m 
Divide  (7)  by p  and  add  to  (6) 
1  - p  +  pe-m  =  mpno 
-- X 
Substitute in equation  (6) 
X  - n-n 
0 
From  (6) 
1- p  (1-e-
111
) 
n  (1-e-m) 
0 
=  _p_ 
n-n 
0 
1  =  _E._  +  .E_ 
n-n  n 
0  0 
Substitute for 1-e-m  from  (9) 
.  .. 
X 
n  (n-n  )m  = 
0  0 
mp  =  ~ 
n 
pn 
n  (n-n  ) 
0  0 
·=  pn 
n  (n-n  ) 
0  0 
(6) 
(7) 
(8) 
(9) 
(10) 
Equations  (9)  and  (10)  can  be  solved to produce  maximum  likelihood estimates m 
and p.  As  far as we  can determine  these equations first appeared in Pershad 
et al  (1961)  but without a  derivation. 
To  estimate variances  on~  and  p,  second derivatives are  required.  From  (4) 
and  (5) 
a
2 logL 
ap2 
a
2 logL 
a  pam 
=-
= 
= 
n  (e-
111-1)2 
0  {n-n  ) 
0  - --
(1-p+pe-m)2  2  p 
• 71  • - nop[ (1-p+pe-111) (-e-111)  - e-111 (-pe-m)] 
(1-p+pe-111)2 
n  p(1-p)e-m 
0 
(1-p+pe-111)2 
- X 
2  m 
The  variance on  ~ and  p  can be  evaluated by  substituting these expressions 
into equation  (3)  using~ and  p for m and  p  respectively. 
Having  derived estimates of the yield ~ and  the fraction of cells which 
were  irradiated and  observed p it is necessary to calculate the dose  D to the 
irradiated fraction and  the fraction of cells irradiated taking into account 
interphase death,  mitotic delay and  any other process that selectively prevents 
an irradiated cell being observed at metaphase  in 48h.  For  brevity,  these will 
in future be  called interphase death. 
The  yield m is related to dose  D by equation  (11)  and  so D can be derived 
m  =  C1  +  o:D  +  130
2  (11) 
The  variance of D,  var(D)  is given by differentiating equation  (11) 
var(D)  =  var(Bl)  (12) 
The  fraction irradiated F  is related to the dose  D  and  the fraction p  by 
equation  (13)  where  D
0  is the dose  required to reduce  the number  of irradiated 
cells by a  factor e  due  to interphase death. 
F  = 
D 
pe  /Do 
D 
1-p+pe  /Do 
= 
0;o  1  e  o  - 1+-
p 
The  variance on  F,  var(F)  is given by differentiating  (13) 
var(F)  (:~f var(p)  +  (a F) 
2 
•  oF  oF  (p,D)  =  oD  var(D)  +  2  op  oD  covar 
In equation  (14) 
D 
oF  e  /Do 
- = 
op  D  2  1  +  e  /Do )
2 
p  <1  -
p 
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(13) 
(14) aF  = 
ao 
D 
( 1-p)e /Do 
COY  (p,D)  =  covar(p,tn) 
X 
cx+2tiD 
This  technique applies very well  to distributions of dicentrics.  However 
if the distribution of total aberrations or micronuclei are used  two  problems 
arise.  Firstly the unirradiated fraction has a  level of aberrations which 
typically may  be  about 1/300  for total aberrations and  1 or 2 in 100  for 
micronuclei.  These  may  not be negligible whereas  for dicentrics a  typical 
background value is 1;'1.000  and  this can be  ignored and  a  yield of zero assumed 
for  the unirradiated fraction.  Secondly the distribution for  the irradiated 
fraction is already overdispersed compared  with Poisson.  These  can be  taken 
into account by  introducing a  non  zero control and  assuming that the 
aberrations in the  irradiated fraction follow a  negative binomial distribution. 
The  negative binomial distribution 
Two  parameters are  required s  and  e 
The  probability that i  aberrations occur in one  cell is given by eq.  15 
p ( i )  =  ( s  +  i  - 1 ) !  9
5 
( 1-8)  i  •..  ( 15} 
i! ( s-1)! 
The  mean  of this distribution m and  its variance  a
2  are as follows 
m  =  s(l-8) 
8 
2  a  =  s( 1-9) 
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The  parameter e lies between  0 and  1 and  will typically lie between  0.7 
and  0.9  for  total aberrations and  micronuclei.  The  parameter  s  ought to be  an 
integer but could be  treated as a  variable if the factorials are  replaced by 
the appropriate r  function. 
At  zero dose,  the yield is so low  that  the  chance  of seeing a  cell with 
two  aberrations is negligible.  The  frequency distribution is given below where 
C is the control yield. 
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P(1)  =  C 
P(i)  =  0  i  ~ 2 
Thus  the  frequency distribution of a  negative binomial  (parameters s  and  9) 
contamdnated with a  fraction  (1-p)  of the control yield C is shown  in equations 
(16) 
P(O)  =  (  1-p) (  1-c)  + p9
5 
) 
P(1)  =  (1-p)C + ps9
5 (1-9) 
P(i)  =  ~(s+i-1)!  e• (1-e)i 
~! ( s-1)! 
The  log-likelihood logL  of the observations n
0
,  n1 ,  n2  etc is 
r 
logL  =  E  ni  log(P(i)) 
i=o 
The  maximum  likelihood equations are:-
alogL  =  o 
ap 
alogL  =  0 
ae 
alogL  =  o 
as 
••• (16) 
Solving these analytically is too complicated.  They  are therefore solved 
numerically.  Second derivatives are also calculated numerically to use an 
equation like  (4)  to estimate variances.  It is easier to interpret the output 
if the mean  yield m of the negative binomial is used  instead of the parameter s. 
This is done  by  replacing s  by m e.  Thus  the variables are m,  e and  p  and  may 
1-e  , 
be  determined using a  minimising  routine such as  the NAG  routine E04JBF.  In 
practice - logL  is minimised.  Having  obtained the yield m and  the fraction p 
then the  same  procedure  to deduce  the dose  D and  the  fraction F irradiated as 
described previously can  be  used again. 
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INTRODUCTION 
The  experience  with  the  treatment  of  heavily  irradiated  victims  of 
Chernobyl  has  led  to  the  identification  of  a  number  of  problems,  some 
of  which  can  most  probably  be  solved  by  limited  investigations 
employing  already  existing  technology,  others  requiring  relatively  new 
approaches  with less certainty in outcome.  At  the  time of  the  Chernobyl 
accident,  it was  thought  that  patients  who  received  a  whole  body  dose 
exceeding the  LD  90  can only be  rescued by  bone  marrow  transplantation. 
At  lower  doses,  e.g.  and  LD  50,  50%  of  the  patients  will  recover 
spontaneously  and  the  others  will  not.  How  to  distinguish  between  the 
th'O  categories?  Obviously  such  a  distinction  is  even  more  important 
h'i th  lower  radiation exposures.  We  propose  to develop  a  prognostic  test 
by  measuring  the  hematological  response  of  heavily  irradiated  rhesus 
monkeys  to  a  short  term  treatment  with  certain  hemopoietic  growth 
factors.  These  factors,  called  GM-CSF,  and  Interleukin  3  {IL-3), 
stimulate  the  proliferation  of  primitive  multipotent  stem  cells  in 
vitro  and  may  be  expected  to  act similarly in vivo.  The  first project 
aimed  at 1/ establishment of  the  relationship  between  irradiation dose 
given  and  growth  factor  response,  and  2/  acceleration  of  hemopoietic 
reconstitution  by  growth  factor  treatment.  In  the  short  duration  of 
this  project,  the  hemopoietic  growth  factor  GM-CSF 
{granulocyte/macrophage  colony-stimulating  factor)  was  studied  most 
extensively,  while  the  growth  factor  that  stimulates  hemopoietic  stem 
cells,  interleukin-3  (IL-3),  was  cloned  specifically  for  monkey 
studies. 
Autologous  BMT  has  many  advantages  over  allogeneic  8~1T,  but  is  only 
feasible  when  the  victims'  stem  cells  have  been  collected  and 
cryopreserved  in  advance.  The  techniques  for  bone  mari."'OW  stem  cell 
preservation  have  been  worked  out  and  are  widely  used  in  the  treatment 
of  leukemia.  In  those  cases  the  stern  cells  are  collected  by  multiple 
bone  marrow  punctures  under  general  anaesthesia.  This  is  not  a 
desirable  practice  to  apply  to  personnel  at  risk  involved  in  reactor 
- 83 -operations.  The  group  of  Fliedner,  Ulm,  has  shown  that  stem  cells  can 
be  collected  from  the  peripheral  blood,  but  in  order  to  collect 
sufficient  cell  numbers,  cell  mobilizing  agents  have  to  be 
administered.  So  far,  this  procedure  is  not  without  side  effects  and 
there  is  a  need  for  the  development  of  non-toxic  mobilizers.  Such 
research  can  best  be  performed  in dogs,  firstly because  the  experience 
has  largely  been  gained  with  that  species  and,  secondly,  because  the 
dog,  due  to  its size,  is  more  suitable  for  large  scale  collection  of 
peripheral blood cells.  A contribution from  the Rijswijk  group  could  be 
to study  the possibility of expanding stem cell populations  in vitro by 
stimulation  with  GM-CSF  or  IL-3.  If  such  expansion  would  yield  a 
substantial increase of the number  of stem cells,  smaller samples  could 
be  collected  from  the  peripheral  blood  obviating  the  need  for 
mobilizing agents.  If that technique is promising it could perhaps  also 
be  applied  to  fetal  liver cells,  which  are  a  potential  source of  donor 
material,  but at the moment  cannot be applied because  the yield of stem 
cells  per  fetus  is  inadequate  to  achieve  the  repopulation  of  an  adult 
recipient. 
The  second  project  thus  aimed  at  expanding  stem  cell  populations  in 
vitro  by  stimulation  with  hemopoietic  growth  factors  to  facilitate 
engraftment  following  transplantation.  This  would  in  principle  allow 
for  relatively  small  samples  of  stem  cells  to  be  grown  in  vitro  to 
full-scale  autologous  (or  perhaps:  allogeneic)  grafts.  To  enable  easy 
handling  of  bone  marrow  cells  and  to  improve  reproducibility  of 
procedures,  we  set  out  with  the  development  of  a  general  method  to 
select hemopoietic  stem  cells by  positive identification. 
I.  Evalution  of  the  potential  for  autogenous  hemopoietic  recovery  of 
patients  thou;ht  to  have  received  a  life-threatening  whole  body 
irradiation by  means  of hemopoietic growth  factors 
In  this  project,  we  have  been  testing  in  vivo  administration  of  the 
hemopoietic  growth  factor  GM-CSF  for  radioprotective  effects, 
pr'ognostic  properties  to  assess  the  residual  number  of  hemopoietic 
cells  following  exposure  to  total  body  irradiation  (TBI),  and  for  its 
capacity  to  accelerate  immunohemopoietic  reconstitution  after 
transplantation  of  low  numbers  or  autologous  BM  cells  in  rhesus 
monkeys.  The  study  is  also  directed  at  dose-finding  and  side-effects. 
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In principle,  there are  three separate potential mechanisms,  by  which  a 
(combination  of}  hemopoietic  growth  factor  ( s}  may  provide 
radioprotection:  1/  administration  of HGFs  before  exposure  to  increase 
the  numbers  of peripheral  blood  cells,  which  results  in  a  later onset 
of  dangerous  pancytopenia  after  exposure;  2/  administration  of  HGFs 
that  increase  the  number  of  stem  cells  before  exposure,  from  which  a 
more  rapid  recovery  of  pancytopenia  may  be  expected;  3/ administration 
of HGFs  immediately after exposure,  which  may  also lead  to  a  more  rapid 
recovery  of  pancytopenia  by  accelaration  of  the  production  rate  of 
blood  cells  {Figure  1}.  Although  only  the  latter mechanism  is  relevant 
in  case  of  accidental  high  dose  exposure,  the  full  evaluation  of  HGFs 
as  radioprotective  agents  involves  experiments  directed  at  all  three 
putative  mechanisms.  To  date,  the  dose-finding  studies  of  GM-CSF  and 
its  radioprotective  properties  and  effects  on  reconstitution  following 
autologous  BMT  are largely completed. 
Studies  on  the  radiation sensitivity of primate  stem  cells,  based  on  a 
comparison  of  the  autogenous  regeneration  rate  after  graded  doses  of 
TBI  with  graded  numbers  of  transplanted  autologous  bone  marrow  cells 
after  high  dose  TBI,  led  to  a  to  a  reappraisal  of  the  D  value 
0 
characterizing  the  radiation  sensitivity of  primate  stem  cells.  A  D 
0 
value  of  0.9  Gy  (confidence  limits  0.8  - 1.1)  for  orthovolt  X-rays  is 
now  assumed  rather  than 0.6  Gy  as  was  earlier calculated.  In principle, 
a  residual  number  of  bone  marrow  stem  cells  capable  of  autogenous 
regeneration  can  now  be  assumed  up  to  doses  of  10  Gy  TBI.  This 
hypothesis  was  prospectively  tested  using  extensive  supportive  care 
(gastrointestinal  decontamination,  antibiotic  treatment,  fluid  and 
electrolyte  administration  and  deliberate  blood  transfusions).  The 
~esults  demonstrated  that  the  LD  50  of  about  5  Gy,  hitherto  reported, 
h'ill  be  shifted  to  about  9. 5  Gy  by  providing  this  extensive  supportive 
care.  Even  at  high  doses  of  TBI,  hemopoiesis  will  ultimately  ( 6  - 8 
h·eeks  after TBI}  regenerate.  This  observation  raises  serious  doubts  on 
the  validity  of  bone  marrow  transplantation  as  a  means  to  rescue 
\'ictims  of high  doses  of accidental  exposure  to  ionizing  radiation  and 
provides  a  scientific  basis  for  attempts  to  accelerate  hemopoietic 
~econstitution by  growth  factor  treatment. 
To  test  the  efficacy  of  the  hemopoietic  growth  factor  0~1-CSF,  rhesus 
::1onkeys  \\'ere  irradiated  with  graded  doses  (4-10  Gy)  of  TBI  (6  MV 
~  85  -X-rays}  and  treated  with  GM-CSF  or  placebo  (days  1-14}.  Another  group 
\~as  given  2  x  6  Gy  TBI  ( 24  h  interval} ,  trans  plan  ted  with  a  very  small 
number  of  purified  autologous  HSC  (equivalent  to  107/kg 
unfractionated  BM)  and  graded  doses  (3-100  ug/kg/day)  of  GM-CSF  {days 
1-30).  All  animals  were  subjected  to  complete  supportive  care.  A 
shortening  of  5  days  on  an  average  pancytopenic  period  of  3  weeks 
resulted  from  the  GM-CSF  treatment  in  the  autologous  BMT  setting. 
Continuation  of  GM-CSF  administration after regeneration  resulted  in  a 
dose-dependent  leukocytosis;  10  - 30  ug/kg/  day  GM-CSF  appeared  to  be 
optimal,  toxic side-effects were  not observed.  Since  these results  were 
rather disappointing,  it was  postulated that the  response of  the  growth 
factor  was  directly  related  to  the  number  of  stem  cells  available  for 
regeneration,  which  purposely  was  kept  limited  in  this  set  of 
experiments.  This  was  approached  by  titrating  TBI  dose  without  BMT. 
Following  TBI  without  BMT,  the  efficacy  of  30  ug/kg/day  GM-CSF 
decreased  sharply  from  5  Gy  TBI  (complete  prevention  of  2  weeks  of 
leukopenia)  to 8  Gy  (no  significant clinical gain).  Further evaluation 
~as done  by  relating cumulated  blood cell counts  (i.e.  the  sum  of blood 
cell  counts  over  the  period  of  observation  to  eliminate  day-to-day 
variations  and  to get  a  fair relative account  of total number  of cells 
produced)  for  GM-CSF  treated  monkeys  and  placebo  controls  to  the  dose 
of radiation given.  From  this evaluation,  it was  clear,  that white cell 
counts  (mainly  neutrophilic  and  eosinophilic  granulocytes)  were  most 
effectively  stimulated  by  GM-CSF,  while  reticulocytes  hardly  showed  a 
response  and  thrombocytes  took  an  intermediate  position.  It was  also 
clear  that  the  response  is directly related  to  the  dose  of irradiation 
given  and,  therefore,  to  the  number  of  residual  stem  cells.  This  also 
explains,  for  instance,  why  the  effectiveness  of  GM-CSF  to  stimulate 
thrombocytes  may  vary  in  various  clinical  trials.  These  data  were 
compared  to  the  blood  cell  regeneration  rates  following  autologous 
transplantation  of  graded  numbers  of  bone  marrow  cells  to  assess  the 
numbers  of  residual  hemopoietic  stem  cells  following  TBI  without  bone 
marrow  transplantation  (Table  I).  The  data  were  fitted  to  a 
mathematical  description  relating  GM-CSF  effectiveness  to  residual 
numbers  of  hemopoietic  cells.  This  relationship  can  be  used  to 
interpret  clinical  data  on  the  use  of  hemopoietic  growth  factors 
following TBI. 
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the  number  of  residual  hemopoietic  stem  cells  and,  therefore,  to  the 
irradiation  dose  received.  As  such,  it  may  serve  as  an  indica  tor  for 
the  need  of  bone  marrow  transplantation  following  accidental  exposure 
to  radiation.  We  therefore  further  analyzed  the  time  point after TBI  at 
~hich  the  GM-CSF  response  can  be  used  to  assess  the  radiation  damage. 
For  that  purpose,  the  effects  of  GM-CSF  on  the  cumulated  white  blood 
cells  {WBC)  were  also  analyzed  for  shorter observation  periods.  During 
the  fist  five  days  following  TBI,  the  white  blood  cells  decrease,  and 
the  cumulated white  blood cells were  not related to  the  radiation dose. 
Although  treatment with  GM-CSF  resulted in an  increase of the  cumulated 
WBC  during  this  episode,  this  effect  was  not  related  to  the  dose  of 
TBI.  Hence  the  cumulated  white  blood  cells  during  the  first  five  days 
following  TBI  cannot  be  used  for  biological  dosimetry.  In  GM-CSF 
treated  monkeys,  the  cumulated  leukocytes  in  the  period  between  day  6 
and  day  8  were  correlated weakly  to  the  dose  of TBI.  This  was  not  the 
case  in  the  control  group.  Therefore,  the  cumulated  leukocytes  in  the 
period  between  day  six  and  day  eight,  allow  for  only  a  very  rough 
estimate of the dose of TBI  {Table II).  Longer observation periods  (day 
6  - 15  or  day  6  - 22)  result  in  a  slight  increase  of  the  accuracy  of 
the  dose  estimate.  Without  GM-CSF,  the  cumulated  cell  counts  can  only 
be  used  for  biological  dosimetry  following  3  weeks  of observation,  and 
the estimate of the irradiation dose is even less accurate. 
The  results  are  summarized  in  Table  II.  A  full  evaluation  awaits 
studies with IL-3.  which  acts on  a  developmentally more  early cell  type 
than  GM-CSF,  and  on  studies  in  which  the  synergism  between  IL-3  and 
GM-CSF  or  other  growth  factors  can  be  explored  in  vivo.  GM-CSF  given 
before irradiation had  no  beneficial effect. 
Human  recombinant  interleukin-3  is  considerably  less  effective  on  the 
BM  cells of  Macaca  species,  including rhesus  monkeys,  than  on  human  or 
chimpanzee  BM  cells.  Hence,  the  molecular  cloning of  the  gene  encoding 
rhesus  monkey  IL-3  \'.'as  accomplished.  The  nucleotide  sequence  of  the 
:.·he sus  monkey  IL-3  gene  compared  with  the  human  IL-3  gene displays  more 
than  90%  homology  and  is,  similar  to  the  human  gene,  divided  into  five 
small  exons;  the  mature  protein  comprises  124  amino  acids,  which  is  9 
residues  shorter  than  the  human  counterpart.  Overall  protein  homology 
is  about  80%.  The  two  cystein  residues  that  play  an  essential  role  in 
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conserved  in  the  rhesus  IL-3.  The  rhesus  IL-3  gene  was  expressed  in 
Bacillus  licheniformis  for  large-scale  production  and  is  currently 
available.  Using  this  material  and  similarly  expressed  human  IL-3,  we 
indeed  established  that  the  affinity of  human  IL-3  for  the  bone  marrow 
IL-3  receptor is about  50-fold  lower  than  that of rhesus  monkey  IL-3. 
Recombinant  rhesus  monkey  IL-3  was  administered  to  normal  rhesus 
monkeys  in  graded  doses  ranging  from  3  to  30  microgram/kg/day 
subcutaneously  for  30  consecutive  days  or  given  as  a  continuous 
intravenous  infusion  at  a  dose  of  30  microgram/kg/day  for  16  days. 
Following  a  lag  phase  of  about  one  week,  a  highly  increased,  dose 
dependent  production  of  bone  marrow  derived  blood  cells  was  observed, 
preceded  by  amplification of  bone  marrow  hemopoietic  progenitor  cells. 
Simultaneously,  peripheral  blood  progenitor  cells  rose.  The  increases 
included  white  cells  ( monocytes  and  the  three  types  of  granulocytes, 
Figure  2) ,  the  red  cell  series  ( normoblasts  and  reticulocytes)  and 
platelets.  The  continuous  intravenous  route of administration proved  to 
be  more  effective  than  subcutaneous  administration,  even  if given  in 
multiple  dayly  injections.  In  the  monkey  which  received  IL-3  by 
continuous  infusion,  white  cells  in  the  second  week  of  treatment  rose 
to  about  75  x  109/1,  while  the  administration  had  to  be  discontinued 
because  of  severity  of  side  effects  at  day  16.  Characteristically,  a 
peripheral  blood  T  lymphocyte  response  was  absent.  Neither  absolute 
cell numbers  nor  the variety of cell types  produced were  precedented in 
studies with  human  IL-3  in Macaca  species.  Analysis of nucleated blood 
cells  revealed,  apart  from  vast  increases  in  numbers  of  eosinophilic 
and  neutrophilic  granulocytes,  monocytes  and  normoblasts,  the 
appearance  of  large  quantities  of  cells  designated  as  atypical 
(basophilic)  granulocytes,  also  reported  in studies  with  human  IL-3  in 
Macaca  species.  Accordingly,  intracellular  histamine  levels  of 
peripheral  blood  cells  rose  directly  proportional  to  the  numbers  of 
these  atypical  basophils.  Dose  related  side effects  included  urticaria 
starting  around  day  10  of  treatment,  prominent  axillary  and  inguinal 
lymph  nodes  from  day  20  onward,  and  at  high  IL-3  doses,  facial  and 
scrotal  oedema  starting  in  the  third  week  of  treatment.  The  skin 
lesions  were  most  numerous  and  prominent  in  monkeys  which  received  30 
::licrogram/kg/day  IL-3.  At  such  high  doses  of  IL-3,  thrombocytopenia 
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developed,  contrasting  thrombocytosis  at  lower  doses.  Thrombocytopenia 
could  not  be  explained  from  decreased  production,  since  megakaryocytes 
in  bone  marrow  and  shift  platelets  in  blood  were  abundant. 
Thrombocytopenia  was  coincident  with  vasculitis  and  hemorrhage  in  the 
generalized  skin  lesions  of  the  monkeys  given  IL-3  in  high  doses. 
\-Ji thdrawal  of  IL-3  not  only  prompted  spontaneous  resolution  of  skin 
lesions.  but  also  of  thrombocytopenia  and  other  side  effects  without 
any  sequeles  within  two  to  four  days.  Recent  sudies  showed  that  the 
side  effects  can  be  almost  completely  prevented  by  simultaneous 
administration  of  histamine  Hl  antagonists  without  affecting  the  bone 
marrow  response. 
Such  results demonstrate  that in vivo administration of homologous  IL-3 
to  rhesus  monkeys  resulted  in  a  dose-dependent  stimulation  of  the 
production  of  all  bone  marrow  derived  cell  lineages.  In  line  with 
existing in vitro data  and  strongly  supported  by  bone  marrow  analyses, 
this  may  be  simply  explained  by  increased  production  of  progenitor 
cells  from  developmentally  early,  multipotential  bone  marrow  cells 
resulting in augmented  production of all bone  marrow  derived blood cell 
lineages.  It may  now  be  predicted  that  many  of  the effects of IL-3  can 
be  selectively  amplified  if  combined  with  lineage  specific  growth 
factors,  such  as  erythropoietin  for  red  cells  and  G-CSF,  M-CSF  or 
GM-CSF  for  cells  of  the  granulocyte/monocyte  series.  Selective 
amplification of the  response  by  other hemopoietic  growth  factors  might 
well  provide  a  most  versatile  use  of  IL-3  and  may  reduce  effective 
single  therapeutic  doses  of  IL-3  and  lineage-specific  hemopoietic 
growth  factors  to  doses  that  more  approach  physiological  requirements, 
thus  reducing  side  effects.  Currently,  IL-3  is  being  tested  in 
irradiated monkeys  similar to  the study completed  for  GM-CSF. 
II.  Expanding stem cell populations  in vitro 
Extensive  studies  in  mice  have  shown  the  possibility  of  stimulating 
murine  repopulating  stem  cells  with  IL-3  and  expand  them  about  3  to  5 
times,  thus  facilitating  engraftment  of  autologous  as  well  as 
allogeneic  bone  marrow  cells.  In  mice,  we  are  in  the  process  of 
identifying  the  non-CFU-S  population  that  is  responsible  for 
hemopoietic  reconstitution  of  irradiated  recipients  and  of 
- 89  • characterizing its HGF  responses.  Since  the  same  HGFs  are  now  available 
for  rhesus  monkeys  as  well  as  humans,  the  mouse  experiments  provide 
guide  lines  for  experiments  on  primate  bone  marrow.  Preluding  on  the 
primate  experiments  with  growth  factors,  we  have  developed  a  simple, 
rapid  and  large-scale  method  for  positive  identification  and 
purification  of  rhesus  monkeys  and  human  stem  cells  and  progenitor 
cells.  The  high  avidity  non-cytotoxic  mouse  IgG2a  anti  human  CD34 
monoclonal  antibody  ICH3  reacts  with  the  HPCA-1  molecule  and  recognizes 
a  similar  epi  tope  on  rhesus  monkey  bone  marrow  (BM)  cells.  In  both 
species  approximately  1-4  % of  the  BM  cells  are  CD34  (ICH3)  positive. 
From  the  regeneration  rate  of  lethally  irradiated  rhesus  monkeys 
transplanted  with  only  2  x  105  autologous  ICH3+  cells/kg  body  weight, 
it was  concluded  that  the  repopulating stem  cells were  40- to  140-fold 
enriched.  To  develop  a  method  for  large scale separation on  this basis, 
Protein  A  was  covalently  bound  to  immunomagnetic  beads  and  ICH3  was 
conjugated  to  the  Protein  A.  Competitive  elution  of  cells  binding  to 
ICH3  was  done  by  excess  soluble  IgG.  The  procedure  may  also serve  as  a 
basis  for  positive  selection of  hemopoietic  stem  cells  for  autologous 
as  well  as  allogeneic  bone  marrow  transplantation.  Approximately  1%  of 
the  original  nucleated cell count  was  recovered  as  rhesus  monkey  ICH3+ 
cells  and  contained  on  the  average  60%  - 70%  of  the  hemopoietic 
progenitor  cells;  this  compares  very  well  with  methods  based  on 
negative  selection  of  stem  cells  by  eliminating  unwanted  cells.  The 
fraction  of  residual  T  lymphocytes  was  less  than  1  % of  the  original 
B~.  Scatter plots  of  whole  bone  marrow  versus  CD34+  cells  isolated  in 
this  way  are  shown  in Figure  3.  Pilot experiments  using stimulation of 
such  purified  cell  suspensions  with  relatively  low  concentrations  of 
rhesus  monkey  IL-3  demonstrated  a  rapid  expansion  of GM-CSF  responsive 
progenitor  cells  and  the  current  availability  of  rhesus  monkey  IL-3 
~ill allow us  to complete  these studies.  Although  prolonged stimulation 
of  murine  stern  cells with  mouse  IL-3  has  been  shown  to  result  in  large 
production  of  commit ted  progenitor  cells  but  a  concomitant  loss  of 
repopulating  stern  cells,  and,  therefore,  success  in  primates  is  not 
guaranteed,  we  will  study varying  time  schedules  of  IL-3  incubation  in 
\"itro,  using  hemopoietic  regeneration  rate  following  autologous 
transplantation  in high  dose  irradiated  monkeys  as  an  end-point.  Since 
novel  hemopoietic  growth  factors,  notably  SCF  (stem  cell  factor).  have 
- 90  -recently  been  identified,  it is not  excluded  that other growth  factors 
than  those  that  are  currently  being  developed  fo~  pharmaceutical 
purposes,  will  be  sui  table  for  the  purpose  of  expanding  stern  cell 
populations. 
The  CD34+  cells  suspensions  produced  in  this  way  have  meanwhile  been 
tested  for  capacity  of  autologous  reconstitution.  The  experiments 
shO\o\1ed,  that  as  little  as  2  x  105  /kg  CD34 +  cells  reconstitute  as 
well  as  107/kg  whole  bone  marrow  cells.  In  addition,  allogeneic 
experiments  demonstrated  that  the  CD34+  cells  reconstitute  myeloid  as 
~ell as  lymphoid  lineages. 
SUMMARY 
The  present work  has  led  to  a  reappraisal  of  the  radiation sensitivity 
of  hemopoietic  stem  cells  of  primates.  If  the  obtained  data  can  be 
extrapolated  to  humans,  intensive  supportive  care  rather  than  bone 
marrow  transplantation  is  the  treatment  of  choice  for  victims  of  high 
doses  of  accidental  irradiation,  since  residual  numbers  of  stem  cells 
can  be  expected  to  ultimately  regenerate  the  blood-producing  system 
even  at  doses  of  10  Gy  TBI  (the  dose  at  which  irreversible 
gastrointestinal  damage  becomes  the  most  important  acute  radiation 
effect). 
The  research  work  done  has  further  given  clues  about  the  use  of 
hemopoietic  growth  factors.  Tested  were  the  possibility  that  the early 
response  to  GM-CSF  can  be  used  as  a  parameter  for  the  number  of 
residual  stem  cells  and,  therefore,  for  the  dose  of  irradiation 
received,  as  well  as  the  efficacy of  this  growth  factor  in  shortening 
or preventing the period of leukopenia.  Although  a  relationship between 
the  early  GM-CSF  response  and  the  dose  of  irradiation  could  be 
established,  the variability of  the  response  and  the  time  required  for 
a  response  did  not  support  the  idea  that  GM-CSF  could  be  used 
practically  for  this  purpose.  However,  G~1-CSF  was  fully  effective  in 
preventing  leukopenia  after  a  dose  of  5  Gy  TBI  (an  about  2-log  stern 
cell depletion).  It became  increasingly  less  effective at  higher  doses 
of  irradiation and  was  clinically ineffective after a  dose  of 8  Gy  TBI 
(an  about  3-log  stem  cell  depletion).  To  enable  studies  with  the  much 
~ore  broadly  acting  growth  factor  IL-3,  it was  necessary  to  clone  and 
express  the  gene  encoding  rhesus  monkey  IL-3  and  to  produce  the 
• 91  • protein,  since  the  species  specificity  of  human  IL-3  made  studies  in 
rhesus  monkeys  with  the  human  growth  factor  unreliable.  During  the 
contract  period,  the  molecular  cloning  and  production  of  rhesus  monkey 
IL-3  was  successfully  achieved  and  preclinical  pilot  studies,  using 
unirradiated monkeys,  have  been  completed. 
The  practical  feasibility  of  in  vitro  expansion  of  hemopoietic  stern 
cells  requires  a  rapid  and  reproducible  method  to  concentrate  stem 
cells.  We  endeavoured  the  positive selection of  hemopoietic  stem  cells 
+  by  developing  a  large-scale  method  based  on  selection  of  CD34  cells. 
The  method  enables  the selection of hemopoietic  stem cells at any  scale 
within a  matter of hours,  yielding preparations  that contain about  60  -
70%  of  the  original  stem  cell  content  of  bone  marrow  concentrated  to 
about  1%  of its original cellular content.  These preparations  have  been 
successfully tested for  autologous  transplantation experiments  and  were 
shown  in  allogeneic  experiments  to  be  capable  of  hemopoietic 
regeneration  of  along  myeloid  as  well  as  lymphoid  regeneration.  The 
availability  of  this  method  as  well  as  the  availability  of  rhesus 
monkey  IL-3  will  enable  us  now  to  study  the  option  of  stem  cell 
expansion in vitro in detail. 
•  92  -Table  I  G~1-CSF EFFECTIVENESS  RELATED  TO  THE  IRRADIATION  DOSE 
cell  type  significant effect observed  no  effect expected at all 
leukocytes* 
thrombocytes 
reticulocytes 
dose of 
TBI 
<8  Gy 
<7  Gy 
<6  Gy 
corresponding fraction  dose of 
of surviving stem cells TBI 
3 X  10-4  10  Gy 
10-3  9.5  Gy 
3  X  10-3  7  Gy 
*  representing neutrophils,  eosinophils  and  monocytes 
- 93  -
corresponding 
fraction of surviving 
stem  cells 
5  X  10-5 
7  X  lo-5 
10-3 Table  II  BIOLOGICAL  DOSIMETRY  BASED  UPON  THE  EFFECT  OF  G~1-CSF  ON  CUMULATED 
WBC  FOLLOWING  TBI 
obser'va tion dose 
pel~iod  (  Gy) 
(days) 
6  - 22  4 
6 
8 
6  - 15  4 
6 
8 
6 - 8  4 
6 
8 
GM-CSF  PLACEBO 
cumulated  wbc  dose  range  cumulated  wbc  dose  range 
(calculated)  (95%  conf lim)  (calculated)  {95%  conf  lim} 
112  <5.0  21  <5.6 
68  4.6  - 7.1  16  <7.2 
28  >6.9  11  >6.4 
61  <5.1  10 
30  4.9- 7.0  8 
0  >7.0  5 
21  <5.1  3 
10  4.8- 7.0  3 
0  >6.8  2 
~be = white  blood cells 
- 94  -Legends  to  Figures 
Figure  1. 
The  three  putative  mechanisms  by  which  hemopoietic  growth  factors  may 
mitigate  cytopenia  following  cytoreductive  irradiation,  here  indicated 
for  therapeutic  purposes,  but  the  same  principles  also  applying  to 
accidental  high  dose  total  body  irradiation.  Upper  panel:  pretreatment 
\vith  HGFs  resulting  in  a  high  peripheral  blood  cell  count  and 
(hypothetically)  an  increase  in  stem  cell  numbers  leading  to  a  later 
onset  of  and  an  earlier  recovery  from  cytopenia.  Lower  panel: 
accelerated reconstitution by  treatment with HGFs. 
Figure 2. 
Peripheral  nucleated  blood  cell  counts  following  administration  of 
graded  doses  of Rh-IL-3,  from  top  to bottom panels:  continuous  infusion 
of  30  microgram/kg/day  during  16  consecutive  days,  and  daily  single 
subcutaneous  injection of  30,  10  and  3  microgram/kg/day,  respectively, 
given  for  30  consecutive  days  and  a  simultaneous  control  monkey,  which 
did  not  receive  IL-3,  but  was  otherwise  treated  identically.  The 
differential  counts  were  cumulated,  from  top  to  bottom:  normoblasts, 
eosinophilic  and  neutrophilic  granulocytes,  neutrophilic  bands, 
atypical granulocytes,  monocytes  and  lymphocytes.  Note  scale difference 
between  upper panel  and  the other panels. 
Figure  3. 
Scatter  plot  of  forward  and  perpendicular  light  scatter  showing  the 
+  selected  CD34  bone  marrow  cell  population  in  comparison  to  whole 
bone  marrow  of  rhesus  monkeys.  The  population  shown  in  the  lower  panel 
contains  60  - 70%  of hemopoietic  stem  cells  and  progenitor cells,  with 
cell  numbers  reduced  to  about  1%  of  the  original  bone  marrow.  E,  L,  G 
and  8  stand  for  respectively  erythrocytes,  lymphocytes,  granulocytes 
and  blast cells. 
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THE ACUTE RADIATION SYNDROME: A CHALLENGE FOR THE MEDICAL 
PROFESSION IN CASE OF RADIATION ACCIDENTS 
T.  M.  FLIEDNER .. 1.  Introduction 
It is  ~he purpose  of  this report to describe  the scientific 
work  that  has  been  conducted  within  the 
"Post-Chernobyl-Programme"  of  the  European  Communities 
between March  1,  1988  and  February  28,  1990  by the Radiation 
Medicine  Research  Group  of  the  Department  of  Clinical 
Physiology,  Occupational  and  Social  Medicine  of  the 
University of  Ulm.  This  group concentrated its efforts  on 
the  "Acute Radiation  Syndrome",  its  pathophysiology as ·well 
as  its  diagnostic  and  therapeutic  implications.  The 
~,~~s·ic~s  ~a n' ~  ~~~··e~od hv  •no  roso~~ch group  ~ay 'no  s-a~oa'  l!l...,._,  t-..-..  .~  - .._.  ...... ._w  ...........  .........._  L..  .......  .......  -~- ~.  _  ·"'- '-"  L- ~....  ...... 
=.s  follo·w-s: 
1.  W~a~ observations were  published about  the  acu't.e 
=adiation  S}~drome  as  a  consequence  of  the 
Chernobyl-accident? 
2.  What  are similarities 
comparison to  other 
1945? 
and  dissimilarities  in 
radiation  accidents  since 
3.  What  are  the  principle  pathophysiological 
mechanisms  leading  to  the  acute  radiation 
syndromes  observed after  accidental whole  body 
exposure? 
4.  Which  are appropriate diagnostic  indicators  to 
predict  course  and  outcome 
radiation  syndromes? 
of  the  acute 
5.  What  is  known  about  possibilities  and 
limitations  to appropriate take care  of  persons 
suffering  from  the acute radiation  syndrome? 
- 101  -6.  What  are  consequences  out of  the analysis  of  the 
"state of  the  arts"  for  further  research work  in 
.order  to  improve  existing  and  develop  new 
strategies  for  medical  radiation  accident 
management  in Europe? 
The  efforts of  the  Ulm  research group represent only part of 
the work  carried out  by  European research  laboratories in 
the  "Post-Chernobyl-Programme".  Through  a  series of meetings 
with the  other groups  it was  possible  to  complement  the 
different activities.  I~  also  became  obvious,  that it is 
c:esi::-able  .1.:  :-to-e  essen-cia:.,  ~o :or:n  c.  "Eurooean  Research 
~e-cwcrk  i~ Radiation  Accide~~  c::der  to  improve 
~~e  scien-cif~c  basis  :cr radia""Cion  accident management  and 
~~  develop  s-cra-ceoies  ~o  cepe  ~ith  radiation  accident 
si-cua-cicns  of  di::£eren-:.  degrees  of  cc:nplexity  from 
medical  viewpoint. 
- 102  -2.  Acute  radiation  syndrome  observations  in the  Chernobyl 
accident 
On  April  26,  1986  a  severe radiation accident  occured  in the 
Chernobyl-Atomic-Power-Plant,  the  health  consequences  of 
which  are still being  explored even  today,  4  years  later. 
In August  1986,  a  conference was  held  at the International 
Atomic  Energy Agency  in Vienna  (IAEA)  in order to inform the 
scientific public about  the  event.  In  the proceedings  of 
this  conference,  Annex  7  describes  the medical-biological 
:?roblems.  It is entitled:  "Data  on  o~e:::-=.tional  a!'ld  emergency 
staff  of  the  nuclear  power  plant  h~o  were  exposed  to 
radiation:  size of  doses  received and  t~e consequences  for 
health.  :2xperience  of  treat::nen"C ''  ( l) . 
Tbis  report allowed to  obtain information on the  signs  and 
symptoms  of  203  exposed persons  who  developed  the  "acute 
radiation  syndrome".  This material  served as  an  important 
input  for  the  further research work  carried  out  at  the 
University of  Ulm  in an  attempt to review  "the state of  the 
arts"  and  to  come  to recommendations  about  the possibilities 
and  limitations  in the  European  Community  to appropriately 
handle radiation accidents  should  they occur  in the  future 
from  the medical  perspective. 
In Table  1,  the  major  signs  and  symptoms  are  listed as 
observed in  203  persons  that received  a  total body radiation 
exposure  in  the  very  early  phase  after  the  radiation 
accident.  These persons  were  classified  into four  groups 
suffering in  different  degrees  from  an  acute  radiation 
syndrome.  105  persons  showed  only  a  mild  syn~rorne.  There 
were  only  a  few  hematological  changes,  but there was  neither 
a  gastrointestinal  symptomatology  nor  skin lesions.  None  of 
these  persons  died  within  the  first  few  months  after 
•  103  • Table  1 
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exposure.  The  estimate dose was  0.8-2.1  Gy.  It is known  from 
previous  analysis,  that such doses  would  be  far below the 
LDS0/60  days  and would  not  require a  special  therapy.  53 
persons were  classified  into  a  group  designated as  ~grad 
II".  In  these patients,  there was  a  general  symptomatology 
with  nausea  and vomitinq  but of  a  mild  type.  It was  reported 
that these patients  showed  some  nausea  and  vomiting,  blood 
cell  chanqes  of  a  mild  to  significant  degree,  some 
alterations  of  the. gastrointestinal  tract  but  no  skin 
lesions.  There were  no  deaths  in this group.  The radiation 
dose estimates  ranged  from  2-4  Gy.  A total  of  23  patients 
were  assigned to the group  "grad III  ...  It is noteworthy that 
there were  7  casualties  in this group  with  death occurrinq 
between  day  14  and  49.  This  fact,  together with the signs 
and  symptoms  - significant  nausea  and  vomiting,  blood cell 
changes  and  a  gastrointestinal  symptomatology  - indicate a 
"hematological  form  of  the acute  radiation syndrome.  There 
were  severe  skin burns  in  6  of  23  patients.  It is quite 
- 104  -possible  that  these burns  were  the  major  reason for  the 
fatal  outcome  in  these  cases  and  not the  hematological  and 
gastrointestinal alterations.  A  total  of  22  patients  were 
assiqned to  the group  "grad  IV''.  19  of  them  died  between 
4-50  days.  There were intensive  evidence  for  nausea  and 
vomiting  early after  the accident.  There were  also severe 
blood cell  changes  and  a  gastrointestinal  symptomatology 
between day  7-9  after  exposure.  All of  them had  extensive 
skin burns  (40·90\  of  the body surface).  The  calculated dose 
was  in excess  of  6  Gy  perhaps  going  up  as  high as  16  Gy. 
It has  been  of interest to analyse  the eigns  and  symptoms  of 
these patients with  an  acute radiation  syndrome  in  some  more 
detail  (Table  2). 
Table  2 
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Aa  can  be  seen,  there is a  correlation  between  the primary 
reactions  (nausea  and  vomiting)  and  the  extend  of  radiation 
exposure:  the earlier the onset of  this  5ymptomatology,  the 
- 105  -higher the  exposure  dose.  Also,  the  time  between  the maximal 
reactions  of  the  organism  and  the  exposure is the  shorter, 
the  higher  the  exposure  dose  has  been.  The  hematological 
parameters  indicate,  that the  patients of  the  group  "grad 
IV"  suffered  from  gastrointestinal  form  of  the radiation 
syndrome  with  little if  any  chance  of  hematopoiesis  to 
recover  spontaneously.  The  patients  classified  into the 
group grad  IV  showed  a  symptomatology  pattern,  compatible 
with  a  severe  form  of  the  hematological radiation syndrome, 
while  those classified  into the  group  "grad  II"  suffered 
:rc~ a  iliilder hematological  fo~.  The  blood cell  changes  in 
:Jersons  assigned  to group  ";rad I"  were  obvious  but  a-:.  no 
~i~e was  there any  evidence  for  an  irreversible  damage  to 
~~e jlood cell  ~rod~ction. 
Unfortunately,  there  has  not  been  - so  far  a  detailed 
report  on  the clinical  signs  and  symptoms  of all these  203 
accident victims.  However,  it will  be of great importance 
for  the  future to  compare  the  clinical course and  outcome 
in these patients  to the course  and  outcome  of patients in 
other radiation accidents.  It  is  only then that  one will 
begin to understand similarities and differences  and whether 
the  skin  burns  in  the Chernobyl  cases  contributed in  what 
way  to the  outcome. 
However  limited the  information  may  be,  it is of  interest 
to at  least  compare  2  reported cases  (August  1986,  IAEA 
conference)  (1)  with  the  hematological  data  in  our 
accidents. 
In  figure  1,  the granulocyte  changes  are depicted for  the  2 
reported Chernobyl  patients  in comparison  to patients  A  and 
C  of  the  Oak  Ridge  accident of  1958  and  to persons  exposed 
in March  1954  on  the Marshall  islands.  In  figure  2,  the data 
are given  for  the platelets  . 
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As  far as  the granulocyte  changes  are concerned  (fig.  2)  it 
is obvious,  that in the  2  Chernobyl  and  in  the  2  Oak  Ridge 
patients,  there was  in all cases  an  "abortive rise"  between 
days  8-18  after exposure  and  a  nadir of values  on  or around 
day  28-30.  This  course of  events  clearly  indicates that in 
these  instances there was  a  spontaneous  granulocyte recovery 
which  means  that the  damage  to  the  stem  cell  pool  was 
reversible  (see  later).  Thus,  one  would  expect that  the 
exposure dose  to·  the  2  Chernobyl  patients  must  have  been 
similar to that calculated for  the Oak  Ridge patients. 
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These  conclusions  are  also  born out by  the observations 
regarding the  platelet  count.  Some  reservations  must  be 
expressed  with respect  to  the platelet numbers  because it 
was  not stated,  which  counting  method  had  been  employed. 
However,  the main  observation  in that the platelets reached 
their lowest  level  between day  20  and  30  which  is support 
for  the notion,  that the megakaryocyte  system did not  cease 
to  support  platelet  production  and  that  there  was  a 
spontaneous platelet recovery beyond day  30.  These patients 
were  treated  by platelet  transfusions  in order to  overcome 
the  consequences  of  thrombocytopenia.  In  Oak  Ridge,  such 
measures  were  not  considered  to be  necessary.  It may  well  be 
that  the  biologically  effective  dose  in  the  Chernobyl 
patients was  a  little higher  than  in Oak  Ridge  but  probably 
- 108  -;j 
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not  more  than  10-20%.  In  any event,  the granulocyte as  well 
as  platelet pattern is  indicative of  a  reversibility of  the 
hemopoietic  damage  requiring  only  "replacement"  therapy as 
described earlier  (2). 
The  similarity  in  the clinical  course  of  the  2  reported 
Chernobyl  cases  and  the  Oak  Ridge  patients is also  born  out 
by the analysis  of early lymphocyte  changes  (Fig.  3). 
Figure  3 
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It  can  be  seen,  that the  lymphocytes  in the Chernobyl  and 
the  Oak  Ridge  cases  decreased  to  30-40%  of  normal  within  2 
days  after  exposure.  This  pattern  is distinctly different 
from  the  case  "Los  Alamos  II"  who  was  exposed  to about  12 
Gy,  a  dose  causing  a  severe  lymphopoiesis  (down  to  10%  of 
normal)  within  24  hours. 
These  studies  lead to the  conclusion,  that it would  be  of 
great  importance  for  radiation  medicine  research  to try to 
obtain  as  much  information  as  possible  on  the  actual 
clinical observations  in radiation accident victims  in order 
to  compare  one  to  the  other  and  to  extract  from  all 
- 109  -observations  the  key 
data  would  then 
differences  and 
form  the  basis 
similarities.  These 
for  a  further 
pathophysiological  analysis  in order to  study the mechanisms 
of  the radiation  syndrome  and  to derive  suggestions  for  an 
improvement  of  existing  and  the  development  of  new 
approaches  to handle  such  patients  in  the most  effective 
way. 
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3.  Establishemnt  and  utilization  of  a  data  base  for 
radiation accident victims 
In  the  course  of  this  "Post-Chernobyl-Project"  it  v..~as 
considered necessary to  try to establish  a  data  base of  as 
many  as  possible radiation  accidents  since  1945.  The  goal 
was  to  register  all accidents  that resulted  in whole  body 
exposurees with penetrating ionizing radiation and  that lead 
to  acute  radiation  syndromes  of  different  degrees  of 
clinical severity.  For  each person  involved,  an  attempt is 
~ade  to collect  as  many  clinical  signs  and  symptoms  as 
Dossible  and  to  t_y to correlate  :::ematolcgical  and  other 
cha~ges  ~o the  course  of disease  a~d its  ou~co~e  i~ order  ~o 
establish a  series  o=  "biolog.:.-::al  i~dicators"  tl'-.. at  a::-e  of 
value  to  ~=edict early after exposure  (i.e.  within l-3  days) 
~he most  likely clinical  course  and  to  establish the most 
optimal  therapeutic  concepts. 
"'umber  Num~  f'llln>ber 
R  ~<fiat  ion Accident  Yf:ar of  Type ol  of  F'f:'I''IOI'tt  oiPf:'l'~  of Of:aths  Relf:l"ences 
No.  Accident  Radiation  ln-.olwf:'d  (•.aluatC'd 
I. Los Alamos I  "u  Carnma,  n  2  2) 
2.  Los Alamos II  1,.,  7  2) 
).  ,..,,~  I'J)2  •  ,,22 
'·USSR  .,))  ?  2  10 
'· Marshall Islands  .,,.  r-at lout  m  2,7  1,9 
'- Oalc  Ride~  .,,,  Co1rnma,  n  a  a  7,U 
7.  Vinca  .,,,  .  a  ' 
2,,27,)2 
I. Los Alamos Ill  .,,,  II  1  )7 
9.  Lockport  .,,0  X-I' a)''  ' 
2  12,2•,n 
10.  Madison  .,,0  ·  Co1mma  12  I  ,, 
II. Hanford  .,u  . 
" 
11  I  II 
12.  ruet'to Rico  .,62  7  ' 
I 
13.  'l'ood Ritoer J\N:tion  "" 
n  )  I  )0 
I'. Mol  19U  .  I  I  ).21,)) 
I). Nf:w  Yf:'l'tf:)'  177'  I  I  2 
''· Tcnnnt.f:e  .,n  I  I  ''·"  11.  Br~scia  177)  I  I  21,)) 
II. N- Yersey  1977  I  I  2 
I'· China'  '"0  I  I  1,.17 
20.  Norway  ICJIZ  I  I  I  31 
21.  Chemobyl  ICJ"  n  X))  ' 
21  ''·"  •  F~llout 
22. China 6  '"' 
Carnrn•  2  16,17  -
)91  321  " 
Table  3 
- 111  -In  table  3,  the  present  state of  the  global  radiation 
accident data base  is  summarized.  The  research group  in Ulm 
was  abie  so  far to  collect  information  on  22  accidents 
between  1945  and  1986  resulting in acute radiation  syndromes 
in  598  persons.  The  most  important  type  of  radiation 
involved was  gamma  radiation alone  or  in combination  with 
neutron  irradiation.  In  a  few  cases,  the  radiation  was 
produced  in  a  X-ray  tube.  The  inhabitants  of  the  Marshall 
Islands  and  the  Chernobyl  victims  were  also  exposed to 
radiative nuclids  resulting  in  cont~~ination  of  the skin 
and/or  incorporation.  Cf  ~he 598  persons  involved,  35  died 
as  a  direct  consequence  of  -::!:e  exposure.  It will  be 
c: interest to  t=Y  i~  ~he future  ~o  :i~d out  ~~at happened 
l~~er (l-30 years)  to  ~~ese  exposed  oersons  a~d  what  was 
-:.l:e  pat-=ern  of  heal  t~  i:npai~ent:s  de-r.Teloping  as  "late 
effects".  A  more  ex~ensive  clincial  and  hematological 
evaluation has  been  performed  so  far in  58  of  321  registered 
individual  case histories.  It became  obvious,  that it will 
not  be  possible to  collect  detailed information  on  many  of 
the  patients.  However,  in collaboration  with  the global 
scientific community,  it might well  be possible  to extend 
the present analysis  to more  cases.  In addition,  although  a 
lot of  information has  been  collected on  the  290  individuals 
exposed  in  1954  on  the Marshall-Islands  (thanks  to the 
collaborative  efforts  of  scientists  at  the  Brookhaven 
National  Laboratory),  these  data  are  not  yet  discussed 
in this report  since most  of  them  belong  to  the exposure 
category  I  (low exposure)  and  their evaluation does  not  add 
much  to  the  present report on  indicators  for  the management 
of  the  severe acute radiation  syndrome. 
In this report,  it appears  of greatest  interest to  ~nalyse 
the  case reports  registered in  the  data  base with  respect 
to  changes  of neutrophils,  platelets and  lymphocytes  in the 
course  of  the  response  to whole  body  irradiation.  The 
analysis  was  performed with  the question in mind,  whether 
• 112  • 'I 
these  changes  would  help  to  answer  the  decisive question 
that  a  physician needs  to  answer:  is  the  damage  to the 
hemopoietic  stem  cell pool  likely to be  reversible  or not, 
does  the patient require replacement or substituion  therapy 
(see  2). 
It was  possible to  form  6  exposure  categories  on  the basis 
of  blood cell response patterns.  This  assignment of patients 
to  "hemopoietic response 
for  each  patient  his 
categories"  was  done  by  plotting 
own  granulocyte,  platelet  and 
l}mphocyte  changes  as  a  function  of  ~ime  after  radiation 
ex~osu=e uo  ~o  50  days. 
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Table  4  shows  the  results  of  a  first  analysis  of  the 
granulocyte  response  pattern  in  68  patients 
radiation accidents  to  whole  body  irradiation. 
exposed  in 
The  first 
"indicator"  is the  "initial granulocytosis".  With  this is 
meant  the  increase  of  granulocytes  in  the first  2-3  days 
after exposure significantly  above  the  normal  level.  It is 
- 113  -of  great  interest  to  note,  that  the  most  intensive 
granulocytosis  was  observed in  2  patients  that  received 
radiation doses  in excess  of  20-30  Gy  and  died within  3  days 
of  exposure  ("CNS-Syndrome").  In  these  patients  the 
granulocytosis  reached  values  of  more  than  900%  within  24 
hours.  In the  response  categories  II to V it  was  always 
possible  to observe  an  initial  granulocytosis within  1-2 
days with  values  of  167  to  200%  of  normal.  This  initial 
granulocytosis  has  been recognized as  an  important parameter 
since  1955  when  our  gro~p established its pathophysiological 
=:techanisms  and  t:.er:ned  .:..~  as  a  "stress-reaction"  of  the  bone 
3ar=ow  caused  by  shi£~  of  granulocytes  from marginal  to 
ci=culat:.i~g pools  ana  :=o~  bone  marrow  into  blocd  as  a 
consequence  of.  si:lt:soidal  reactions  of  the  :rnarrcw 
~icrccirculation. 
A  second  "indicator"  of  importance  and  of  pathophysiological 
significance is the first maximum  of  granulocytes.  In table 
4  it is  of  interest,  that there  is  a  distinct difference 
between patients in category  IV  and  v.  In the latter,  the 
neutrophil  count  drops  to  4%  of  normal  within  7  days. 
Actually,  the major  drop  occurs  between day  4  and  6  due  to 
the fact,  that the maturation time  since the last myelocyte 
division is for  granulocytes  (T  1/2  =  7  hours  in blood)  4-5 
days.  If  all  dividable  precursors  in  the  marrow  are 
radiation  injured then  no  newly produced granulocytes enter 
the  blood  after  4-5  days  so  that  the  steep  drop  in 
granulocyte  counts  is expected to occur at this time.  On  the 
other hand,  if somewhere  in the body  some  myelocytopoiesis 
and  hence granulocyte productions  is left,  the extend of  the 
first granulocytopenia after exposure will not be  excessive. 
This  explains  that  the  first  minimum  for  patients  in 
categories  IV,  III  and  II  reaches  only  22,  50  and  54%  of 
normal  at days  9,  10  or  11  respectively.  The  extend of  this 
first granulocyte  minimum  between  5  and  10  days  can  be 
considered  of  utmost  importance  in  trying to  answer  the 
- 114  -question,  whether  a  spontaneous  recovery of  hemopoiesis  (and 
of  the patient)  is likely or unlikely. 
A  third indicator  is the height  of  the abortive rise.  The 
higher  the  damage,  the  lower is this abortive rise.  There  is 
a  distinct difference between  category  IV  on  the  one  hand 
and  categories II  and  III  on  the  other.  This  corresponds 
actually to the appearance  of  the granulocyte nadir in these 
categories:  the more  extensive the  d~~age,  the shorter the 
duration  of  the abortive rise  and  the  earlier  the nadir 
which  - in cateogry  IV  - is  27  days. 
?~e  pa~hophysiological  mechanisms  jer.ind  ~his  nattern  ~s 
cepic~ed  i~ fiaure  4. 
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Figure  4 
This  concept was  first developed  by  our group  in  1965  (2) 
and  has  now  been  used  to  develop  a  biomathematical  computer 
model  to simulate the granulocyte pattern  after total  body 
exposure  and  to calculate the  "remaining  stem cell units"  in 
the  bone  marrow  from  which  a  spontaneous  recovery  of 
hematopoiesis  could  commence. 
- 115  -This  concept  establishes  the hypothesis,  that  total  body 
exposure results  in  the  damage  of  pluripotent  stem  cells in 
the  body whereever  in the  skeleton they might  be  localized. 
The  exposure will result in a  damage  in accordance with  a  Do 
of  about  80  to  100  cGy.  There  will  then  be  stem cells 
remaining  from which  a  recovery could  commence.  If there are 
unirradiated or repaired stem cells  (»surviving cells'')  then 
they would  be  the origin  of  the eventual  recovery  of  the 
system.  The  biology  of  total  body  irradiation  shows, 
hcwever,  ~hat  ~he  response  to  radiation  can  only  be 
explained  i: cne  assumes  a  f:.:::---:her  category of  s~em cells, 
~~e so  called  inj~=ed  s~em cells.  They would  ~o~ any  lcn;e= 
have  ~he  oo~en~ial of  unlimi~ed replicative  pc~en~ial  ~~~ 
oo£  li~ited ~o~ential.  It is this  group  of  s~em  cells 
......__.., __ 
....  c::.  ._ 
is  ::-esoonsible  foor  an  "abortive"  recovery.  ~~is abor-=ive 
recovery is the less  pronounced  and  the shorter,  the  lo~er 
the  nllillber  of  the  "injured stem cells"  is.  This  hypothesis 
would  lend  support  to  the idea,  that the  abortive rise 
phenomenon  could  be  used  in  the evaluation of  radiation 
exposed  individuals. 
The  radiation accident data base  so  far established provided 
the opportunity to  also analyse  in  detail the significance 
of  lymphocyte  changes  as  an  indicator  for  radiation 
exposure. 
The  lymphocyte  pattern  was  evaluated  in  55  patients 
suffering  from  an  acute radiation syndrome.  The  questions  to 
be  asked were  as  follows:  Are  these characteristic changes 
in  lymphocyte  counts  during  the  observed  postaccidental 
period?  If yes,  do  patterns exist which  are  comparable  to 
the  known  granulocyte patterns?  For  each  person  analysed, 
the  lymphocyte  curve  was  plotted.  Figure  5  shows  the 
lymphocyte  pattern of all  55  persons.  Their physical  dose 
estimated ranged  from  8-8800  cGy.  It is  obvious  that  not 
much  information  can  be  derived  from  this graph except  to 
•  116  • conclude that there is,  in most  of  the patients,  an  early 
lymphocyte  drop after irradiation. 
"" 
60001 
Cl  500~1 
0 - 4000~'  X  ! 
tl)  i 
"'  30001 
...,J 
~ 
(.)  1 
0  2000~  ...  - 1  ,...  - ::  ! 
~ 
1  OOOi. 
; 
oJ .. 
0  j 0  20  30  40  50  50  /J 
11:ne  ( d J 
?iaure  5 
~owever,  if one  takes patient by patient and  t=ies  to bring 
the  individual response  patterns into  response categories, 
it  becomes  obvious,  that  there  are  some  4  distinctly 
different patterns  to  be  recognized. 
Figure  6 
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•  117  • This  category  group  A  contains  all  patients  who 
demonstrated  a  lymphocyte  drop  during  the  first  4  days  but 
who  did.  not reach  values  at  or  below  1000  per  rnm 3 •  This 
pattern corresponds  to  no  or  minimal  effect.  There  was  a 
second  group of  patients:  category group  B  (figure 7). 
Figure  7 
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These patients  showed  an  initial lymphocyte decline and  the 
counts  leveled off at  the  800-1100  per  mrn3  mark.  It  is 
interesting,  that  this  group  contains  patients  whose 
exposure dose was  calculated to be  between  120-240  cGy. 
Figure  8  shows  the  pattern  of  lymphocyte  changes  who 
developed  a  severe  course of  the  acute  syndrome.  There was 
an initial lymphocyte drop  and  a  lymphocyte  level of  200-800 
per  mrn3 •  There was  a  spontaneous  recovery  of  hernopoi~sis, 
including the  lymphocytes. 
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?~gure  9  shows  the  lymphocyte  pattern  i~ the  group  cr 
patients  that  developed  a  very  severe  form  of  the acute 
radiation syndrome.  In all these patients  there was  a  severe 
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70 initial drop.  The  lymphocyte  leveled off  at below  200  per 
mm3.  This  pattern is typical  for  an  irreversible damage  to 
the  hemopoietic  stem cell pool.  The  one  patient who  survived 
in  this  category  was  the  recipient  of  a  stem  cell 
transfusion that was  capable  to restore hematopoiesis. 
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Figure  11 
In  summary  {figure  11)  one  can relate the  lymphocyte  changes 
to the extend of  damage  to hematopoiesis.  One  may  - at this 
point  - confirm  the notion,  that there  is  no  or little 
radiation damage  if  the  lymphocyte  count remains at levels 
above  1000/mm3  within the first  2-4  days  after exposure.  One 
may  also  say,  that  there  was  a  significant  radiation 
exposure if the  lymphocyte  count declines  to  values  below 
1000/rnm3  within  4  days  after  exposure.  However,  it  is 
difficult if not  impossible to use  the degree of  lymphocyte 
depression  within  4  days  of  exposure  to  predict  whether 
hemopoiesis  will  recover  spontaneously  or  not.  If  the 
lymphocyte  evaluation,  however,  is  combined  with  the 
evaluation of  the granulocyte  pattern,  then one  can state 
that a  granulocyte decline  to values  of  less  than  200/mm3 
- 120  -If 
after 4-5  days  and  after an  initial granulocytosis  on  days 
1  and  2,  combined with  a  severe  lymphopenia  as  seen in group 
D of  values  below  200/mm3  is  indicative  of  a  degree  of 
radiation injury that requires  stem cell substitution if it 
is not  a  case that  needs  to  be  considered as  a  CNS-form  of 
the acute radiation  syndrome. 
- 121  -4.  Pathophysiological models  to evaluate the consequences  of 
radiation exposure 
From  the analysis  of  previous  accidents it is evident  that 
the  physician  will  not  be  able  to  obtain information  on 
physical or  chemical  exposure  (stress)  estimates  (measured 
in dose  units).  Such  information would describe at best the 
amount  and  quality  of  external  or  internal  stress 
experienced by the  individual patient.  Since the  physician 
has  to deal  with  an  individual  characterized by age,  sex, 
genetic disposition  and  a  previous  personal health history, 
it ~ust  be  the  objec~ive  to  analyse  and  cete=mine  the 
Figure  12 
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radiation induced  strain.  The  physician has  to rely on  the 
analysis  of  biological  indicators  to  determine  the 
possibilities and  limitations of  a  recovery of  the  organism 
as  such  and  of  the  "critical organs"  such  as  the skin,  the 
central  nervous  system or,  in other cases,  the  hematopoietic 
- 122  -lr 
system.  Based  on  the experience of all accident casualties 
examined,  it is essential to answer  one  single question:  ~ 
there  a  chance  for  a  spontaneous  recovery  of  the 
hematopoietic  stem  cell pool within  a  clinically reasonable 
oeriod of  time  (i.e.  some  2-3  weeks  after exposure).  If the 
answer  is  affirmative,  then  the  therapeutic strategy will 
have  to  i::1.clude  the  so-called  "replacement"  therapy  (to 
replace  temporarily  missing  functions  such  as  that  of 
granulocytes,  platelets,  red-cells,  electrolytes etc.).  If 
the  answer  is negative,  indicati~g  that  a  hematopoietic 
:::ecoverJ  ~s unlikely or  would  be  too  delayed to be  useful, 
then  "su~s-:.itutic!1"  therapy needs  to be  attempted  includir.g 
~ransnla~~~tic~  c=  hematopoietic  s~em  cells  which  nay  be 
available  ~ocav f:::om  a  variety of  sources. 
Inforillatic~  about  the type,  extend and quality of  exposure 
which  dec:::ibes  the  radiation  induced  "stress"  for  the 
individual  is  useful  for  medical  management  but  is  not 
decisive.  It  is  not  only  unnecessary  but  sometimes 
misleading to  use biological  response  patterns describing 
the  "strain''  experienced by  a  patient to extrapolate back  to 
the  "stress"  that can be measured to determine  "a  dose"  in 
air or in tissues. 
The  use  of  hematological  indicators to predict the clinical 
course  in  a  given  patient  after  accidental  exposure to 
ionizing  radiation  is  of critical importance  in  certain 
phases  of  the management  process.  The  "management decision 
tree"  indicates  that  a  number  of  questions  need  to  be 
answered  (Fig.  13).  Initially,  an  answer is needed to the 
question:  "Was  the person exposed  to ionizing  radiation or 
not?"  If the  answer  is affirmative,  then  new questions  need 
to  be  answered,  such as  "Was  there contamination  with or 
without  incorporation of  radioactive nuclides"  or  "was  there 
incorporation alone?"  In all these  instances,  the additional 
question is:  "Was  there total or partial  body  exposure?" 
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~~ese questions will  be  relatively easy to answer  using  t~e 
.i:1for:nation  on  hand  and  using  simple  instrumentation 
(monitors).  However,  it goes  without  saying that the  answers 
to these  questions  will depend  on  anecdotal  evidence  and 
will  only  be  qualitative.  Exposure  doses  will  not  be 
available with any useful  degree of accuracy.  In the  next 
phase,  the medical  personnel will have to determine  the type 
and  degree  of  additional physical,  thermal  or  chemical 
injury present  such  as  wounds  or burns.  The  answers  to these 
questions  are  very  important  in  order  to  initiate 
appropriate  therapy,  such as  management  of  external  burns  or 
surgical  interventions in case of  wounds.  It becomes  obvious 
that  decontamination  and  care  of  wounds  as  well  as 
restoration  of  vital  functions  take  precedent  over 
decontamination  procedures.  Finally,  the  "sequential 
diagnosis  process"  to determine whether  or  not  a  classical 
acutee radiation syndrome will develop,  the type it will be 
and what  type  of clinical management  should  be  used,  will be 
possible. 
- 124  -What  does  "sequential  diagnosis"  mean  or  imply?  The 
experiences  gathered  from  post radiation accidents  indicate 
that there  is a  typical  sequence  of  biological events  and 
changes  that  depend  on  the  type  and  degree  of  damage 
inflicted upon  hematopoietic  and  epithelial  cell  renewal 
systems.  It  is especially important to  know  the  type  and 
degree  of  damage  caused  in the  stem cell  pools.  It  is 
important  to explore whether  the  damage  inflicted  on  the 
stem cell  pools  is reversible or not.  We  have  no  direct 
measure  of  the  stem cell pool  damage  in man.  However,  as  far 
as  hematopoiesis  is  concerned,  the  pattern of  blood cell 
changes  as  a  fu~ction of  time after radiation exposure is  so 
~ypical for  the extend of  stem cell pool  d~~age that one  is 
allowed to  ex~rapolate  back  f=om  the  blood cell  response 
natter~.  Since  this  pool  is  distributed  throughout the 
skeleton  (reportedly consisting  of  more  than  200  individual 
bones),  any degree  of  non-homogenity in irradiation of  the 
body due  to  the radiation pattern or due  to  the  specific 
position of  the  body within the radiation field will affect 
the  cell  pool  damage.  Since  it  is  not  possible  to 
extrapolate  from  .Q.!l§.  "blood  cell count"  back  to the extend 
of  stem cell pool  damage,  one  has  to determine  the pattern 
of  blood  cell  changes  during  the first  5-10  days  after 
exposure  in  order  to  know  whether  one  has  to  assume  a 
reparable or irreparable damage  to the hemopoietic  stem cell 
pool. 
From this logie it follows  that  one  may  have  already gained 
relevant information about  the  probability  of  stem  cell 
damage  by  day  1-2  after  exposure  by  observing 
granulocytosis,  lymphopenia  and  mitotically  connected 
abnormalities  in bone marrow  smears  (Fig.  3).  However,  by 
day  5,  a  definitive  answer  is  possible  regarding  the 
question  whether  a  spontaneous  hemopoietic  recovery can  be 
expected or not  (for pathophysiological  mechanisms  involved 
see ref.  1).  This  answer  can  be  based  on  the pattern of 
- 125  -granulocyte,  lymphocyte,  platelet and  reticulocyte  changes 
during  the  first  5  days  after  radiation  exposure.  During 
that period,  the medical  personnel will  try to assure the 
patients  survival  in case  of  severe injury to the  CNS,  to 
the  cardiovascular  systems  or  to  the  skin  or  injury 
inflicted  by  thermal  burns  or  chemicals.  "Seguential 
diaanosis..  thus  denotes  the  attemot  to determine  by daily 
thorouah  examination  of  the  oatient  the  develooment  of 
chancres  of  the  hemoooietic  and other cell  renewal  systems 
and  the develooment  of  chancres  in other  bodv  svstems  fCNS. 
skin)  wit~  or without theraoeutic  i~terventions.  In  other 
~~ords,  fo=  ~he management  of  individuals  exposed  to  ionizi~g 
=adia~io~  i~  is useful  to have quantitative  info~ation o~ 
~he details  of  external  and  internal stress  (i.e.  dosimetrj) 
~ut this  is  not  essen~ial.  It is essential,  however,  ~o 
determine  the resultant strain and  to analyse by appropriate 
indicators  such  as  the course of  granulocyte and  l}~phocyte 
changes  in the blood,  the extend of reparable injury.  This 
is necessary to  plan  and  perform  appropriate therapeutic 
measures. 
In  order  to 
retrospectively 
establish  at 
the  radiation 
this  point  in  time 
induced  strain  to  the 
hematopoietic  stem cell system as  one  of  the key biological 
indicator to  predict the clinical course  of patients  and  to 
plan intervention strategies accordingly,  a  biomathematical 
model  was  developed  to  determine  the  number  of  stem cell 
units  remaining  from  which  a  spontaneous  regeneration might 
be  expected to occur. 
The  basis  for  this  computer  model  has  been  described 
elsewhere in detail  (3).  It has  been adapted to  simulate the 
granulocyte  pattern observed in radiation accident victims. 
This  computer model  consists of  a  series of  cellular and  two 
regulation  compartments  (Fig.  8).  It has  been  found  to  be 
useful  in dogs  and  man  for  describing  physiological  and 
- 126  -pathological  perturbations  of  the granulocytic cell renewal 
system  such  as  a  leukapheresis  response,  a  response  to 
cyclophosphamid  administration,  a  response  to  total body 
irradiation with or without  stem cell  transplantation.  In 
this model,  to simulate granulocyte  changes  after total body 
exposure,  it is important  to indicate that  the  stem cells 
need  to be  categorized  into  3  groups:  1.  destroyed  stem 
cells  (no  evidence  for repair at all),  2.  damaged  stern cells 
with  limited reparability and,  3.  stem cells intact or with 
complete reparability.  In this model  (fig.  8)  the  stem cell 
pcol  ccn~aining the eliminated  or destroyed  stem cells ist 
::c~  shc\o.-:1..  T~e 2  co::tpa::--:.:nents  sho·wn  con1:.ain  as  "intact ste:n 
Figure  14 
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cells"  those that were  not irradiated  at all (i.e.  because 
they were  localized during whole  body  exposure  in a  shielded 
part of  the  body)  or are capable of  complete reparation.  The 
compartment  "injured  stem cells"  coontain  those  the  damage 
of  which is  partly  reparable  os  that they  are able  to 
undergo  one  or  several  replicative  cell divisions  before 
- 127  -dying  out. 
For  simulating  the  granulocyte  changes  after  total  body 
exposure it had  to  be  assumed  that  the cellular contents  of 
pools  s,  CBM  and  CBL  as  well  as  P  can  be  reduced  by 
radiation exposure  in accordance with  a  Do  of  100  cGy.  It 
was  further  necessary to  assume  that a  certain  fraction of 
stem  cells  already  have  or  have  regained  a  normal 
(essentially unlimited)  replicative  potential while another 
(usually larger)  fraction is  endowed with only a  restricted 
replicative ootential. 
I~ order  to  ~r~ ~o  calc~la~e  t~e ~~~~er  of  ste~ cell  u~ltS 
==em  the  g~anulocyte changes  i~  ~~e  bleed  stre~~  observed 
~uring 50  days  after accicental  ~hole  body  exposure,  :o 
patients  were  selected  cut  of  the  more  than  300  so  far 
incorporated into the Ulm  radiation accident data base.  .;ll 
10  patients  had  a  typical  form  of  an  acute radiation 
syndrome  and  the  course of  clinical events  was  largely 
determined  by  the  hematological  responses.  They  were 
assigned  to several  "granulocyte response categories".  Three 
patients  (from the  Oak  Ridge  accident  1958  and the Tennesse 
University accident  1975)  were  assigned  to  category  II 
(figure 15). 
Figure  15  shows  a  typical but  "mild"  course of events.  It 
can  be  seen that there is an initial granulocytosis,  then  a 
phase  of granulocyte decline  between days  1  and  10.  The 
granulocyte  pattern  between  day  10  and  30  indicates 
continued granulocyte  production  and  release  of  varying 
degrees.  The  granulocyte nadir is reached  between day  30  and 
40  followed  by  a  slow recovery to stable normal  values.  The 
solid  line  is  the  result  of  simulating  the  course of 
granulocyte  changes  by  assuming  a  certain  number  of 
reparable  stem cells that remain  in the  stem cell pools  from 
which  the initial and  the  final  system recovery occurs. 
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60  70 category II but more  pronounced.  There is  a  distinct initial 
granulocytosis  (days  1-3),  a  primary  granulocyte decline 
(days  3-10),  an  abortive  rise  (days  10-25),  a  secondary 
decline with  a  nadir  around  day  30  and  a  final  recovery 
beyond  day  35-40.  The  solid  curve  is the  result  of  a 
computer  simulation 
stem  cells  in  the 
assuming  a  certain number  of reparable 
below).  The  stem  cell  pool  (see 
granulocyte  changes  are  even more  pronounced  in  the  3 
patients  assigned  to category  IV  (from the Vinca  accident 
1958)  (Fig.  17).  This  is  a  pattern very close to failure of 
::.emoooietic  recovery  but  attainable  with  i:1tensive 
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replacement  therapy. 
the  first 10  days  is 
realize  that  between 
LO  so  60  70 
DAYS  AFTER  EXPOSURE 
The  primary granulocyte decline during 
extensive.  But it  is  essential to 
days  5-10,  there  are  day  by  day 
measurable  levels  of  granulocytes  in the peripheral  blood 
(above  200-500  per  mm3 ).  There is evidence  for  an  abortive 
- 130  -rise  between  days  10  and  20  and  a  secondary  decline  and 
final  nadir  around  days  25-35.  There  is,  however,  a 
spontaneous  recovery beyond  day  35.  The  computer  curves 
simulate this pattern and  are based  on  a  certain number  of 
reparable  stem  cells  which  are  present in  the  stem cell 
pools.  There  are  so  far  no  observations  between  this 
category  IV  and  the patients of  category V  characteristic of 
a  response pattern after  an  irreparable  damage  to  the  stem 
cell pool.  The  granulocyte  response  category V  contains  2 
patients  (from the accidentss  in Los  Alamos  1946  and  Brescia 
....  I  ':J  19  ........ )  (
--.·  .::.tg.  18).  ~as  an  initial  n::-onounced 
granulocytosis  during  days  l-3  or  4  and  an  abrunt decline of 
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15 
blood granulocyte concentrations  between  days  4-6.  This  is 
indicative of  a  complete block  in granulocytopoiesis  at the 
myelocyte-promyelocyte  and  stem  cell  level  (granulocyte 
values  below  200  per  rnrn3 ). 
- 131  -There  is  a  severe  granulocytopenia  combined  with  a 
significant thrombocytopenia  and  lymphopenia  present  on  day 
10.  The  clinician would  describe  the  findings  on  day  10  as 
"severe  aplastic anemia"  without  a  chance  of  spontaneous 
recovery.  The  computer  derived  curve  simulates  the 
granulocte  pattern  using certain numerical  assumptions  as 
discussed below. 
It  is  of  interest  to  use  this  computer  model  of 
hew  many  stem cell units  of 
or  unlimited  replicative 
granulocytopoiesis  to calculate 
different  quality  of  limited 
Dotential  must  have  remained  i~  the  four  granulocyte 
=esnonse  categories  show~  to  allow  fo=  regeneration  or 
failure.  In table  5  i~  can  be  seen  that  the  nlli~er  of 
cestroyed or i=raparably  d~~aged  stem cell  units  increases 
as  the granulocyte  response pattern  "gets worse".  This  means 
that  the  granulocyte  pattern  becomes  more  distinct  in 
relation  to  the  initial 
the 
granulocytosis, 
extend  and duration 
the 
of 
primary 
abortive  granulocyte decline, 
rises,  the time  and  duration of  secondary decline  and  the 
granulocyte nadir and  course of  final  recovery. 
Computer  aersved  Calculations  of  St'!111  Cell  Pool  Sizes 
Radiation  ResPOnse  Remaining  Intact  Remaining  InJured  Destroyed  Ranoes  of Phvslcal 
Category  Stem  Cells  :  Stem  Cells  :  Stem  Cells  Dose  Estimates  1n 
<  Ce 11  nllllberl  <Cell  nunberl  :  cGy 
Category  ll  0.008  24.0  76  127  - 236 
Pat.  11,5,38  <1.0  X  105)  (3.0  X  loBl 
Category  Ill  o. 0024  4.8  95  339  - 365 
Pat.  1,  3  (3.0  X  104)  (6.0  X  107) 
Category  IV  0.0008 
I 
2.4  97.6  323  - 426 
Pat.  11,12,13  (1,0  X  1011 >  <3.0  X  107) 
Category  v  0  0.0006  99.9994  1.114  - 1. 200 
Pat.  17,  37  (  0  )  (7 ,7  X 103) 
Table  5 
- 132  -But it is of great interest that in  the  categories  II,  III 
and  IV,  the granulocyte response  pattern is compatible with 
the notion that  there are  stem cell  units  remaining after 
radiation  injury.  Some  are  intact  or  are  completely 
reparable  and  some  are  of  restricted  reparability.  It 
appears  as  if  there  is a  clinical  "threshold"  for  the 
reversibility of  damage  to the  granulocytic  cell renewal 
system.  There  must  be at least 0.0008%  or  8  in 10.000  stem 
cells intact,  or completely repaired to allow a  spontaneous 
recovery.  There must  have  been  between  2.4  and  24.0%  of  stem 
cells  with  restricted  reparability,  responsible  for  the 
~Doearance of  an  abortive rise. 
l.S  cbvious,  tha-:.  this  ~ype  of  aranulocvte resoonse  - - -
c~~e~orization allows  one  -:.o  determine the radiation  induced 
s~rain in a  given  pa-:.ient  (see Fig.  1).  It may well  be  that 
~his strain ~ay be  influenced by  individual  par~ueters such 
as  previous  health  impairments  genetic factors,  age or sex. 
Such  an  analysis  shows  the  potential  in  allowing  the 
quantification of  an  individual strain in terms  of  remaining 
stem cells  which  are  intact or  repaired  completely  from 
which  the final  recovery can  commence. 
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outcome of acute radiation  syndromes 
The  Ulm  radiation accident data base  and  the biomathematical 
simulation model  of  radiation  injured  hematopoietic cell 
renewal  systems will have  to be  completed  and  extended  to 
evaluate more  patient data  and  to include more  cell  systems, 
such  as  megakaryocytopoiesis,  erythropoiesis.  This 
information will eventually be  used  to develop  a  knowledge 
based  expert  system  to  be  useful  in the  management  of 
radiation injured persons.  This  development,  however,  will 
reauire further  i~tensive work  in the  Ulm  Radiation  ~edici~e 
Research  Group. 
However,  on  t~e basis  of  available knowledge  and  experience 
i~  appears  ~ossible  already  today,  to  describe 
constellations of  blood cell changes  early after accidental 
whole  body  irradiation  that are  very useful  in predicting 
the most  likely clinical course of  an irraidated patient and 
to plan the essential therapeutic strategies. 
The  key question  to be  asked in the  "sequential diagnostic 
process"  subsequent  to an accidental total body exposure is: 
"Can  one  ex:Qect  a  s:gontaneous  hemato:Qoietic  recove~  or 
not?"  At  this moment,  there  is  good probability  for  an 
answer  within  6-7  days  after  an  accidental exposure  to 
ionizing irradiation.  but  it  is  possible  to predict the 
course of  events  even earlier,  that is  3-5  days  after an 
accident.  Such predictions will always  have  to be  based  on 
very carefully performed evaluations  and  accurately recorded 
blood cell counts  during  the first 10  days.  Aside  from  the 
granulocyte count,  one  may  take into consideration also the 
concentration of  lymphocytes,  platelets,  reticulocytes  and 
red cells. 
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damage  to the hematopoietic  stem  cell pool  is the result of 
the  pathphysiology  of  the  different  blood  cell  renewal 
systems  (cellular  kinetics,  radiobiological  properties, 
functional  and  regulatory  mechanisms)  and  can  be  described 
as  follows. 
If one  finds  on  day  1  and  2  (24-48  hours  after removal  of 
the  individual  from  the  radiation  field)  a  significant 
granulocytosis  and  at  the  same  time  a  severe 
lymphocytopenia  (less  than  30-50%  of pre-irradiation values) 
one  can  assQ~e  significant damage  ~o  ~he  hematopoietic 
systems.  T~is  ~oticn  ~i:l  je  suppc=~ed by  ex~~ining bone 
narrow  smears  0reDared  :=c~  ~~e nost  i~tense irradiation 
si  -ce.  Cne  ~Tould  excect  a  large  ::w-nbe:!:"  of  injured  cells 
(nuclear  edema,  phagocytosis  c=  cell  nuclei  but  i:1 
particular  ~ito~ically  connected  abnormalities  in 
normoblasts  and  o~her red cell precursors  to  some  extend in 
all cell types  capable of  cellular proliferation)  (2). 
A  high  probability  of  an  irreversible  damage  to  the 
hemopoietic  stem cell pool  can  be  attached to the  following 
observation to be made  on  day  5  after exposure:  if  on this 
day the granulocytes  have declined  or are declining to very 
low values  (less  than  200  per  mm3  on  day  5  or  6)  and if the 
lymphocyte  concentration is also  very  low  (less  than  10-30% 
of  normal)  and if the platelets  show  a  progressive fall with 
values  on  this  day  of  some  40-60%  of  normal,  then  a 
spontaneous  recovery of  hemopoisis within reasonable periods 
of  time is unlikely  (see category v,  figure  18). 
It  is  possible  to predict  whether or not  reversible  or 
irreversible damage  to  hematopoiesis  can  be  expected  on  day 
10.  If on  this  day  the granulocytes  are still below  300  per 
mm 3 ,  the  lymphocytes  still  low or absent  and  the platelets 
- 135  -approaching very  low  levels  (less  than  50.000/mrn3 ),  then  the 
hemopoietic  tissue must  be  injured to  such  an  extend that  a 
sponta~eous recovery is unlikely. 
In reverse,  if  the early pattern of  blood cell changes  is 
similar to the patients described in category  IV  (see  figure 
17)  (some  granulocyte  and  platelet production continuously 
present on  the basis of cell kinetic considerations)  then it 
can  be  assumed  that the  stem cell pool  has  a  fair chance  to 
=ecover  and  that the  final  hemopoietic  recovery will  become 
apparent  (depending  on  the  extend  of  stem cell  pool  d~~age) 
je~ween days  30-40  after exposure. 
~hese  above  considera~ions  have  i~portant  ~~erapeutic 
~~nlica~ions.  All  patien~s desc=ibed in cateqories  II,  III 
a~d IV  experienced  a  soontaneous  hematopoietic reecover1. 
~~eir  therapy,  however,  had  to  take care of  the transient 
electrolyte  imbalance  (due  -to  damage  to  the intestinal 
surfaces:  "radiation induced burns  of  the inner surfaces of 
the body"),  the transient granulocytopenia  (with infections 
complications  requ~r~ng  antibiotics  or  even  granulocyte 
transfusions)  and  the  transient thrombocytopenia  resulting 
in bleeding episodes  requiring  platelet  transfusions.  In 
all these instances  (supported  in  many  instances  by strict 
isolation or even bacterial decontamination to sterilize the 
g ..  t  and  the  skin  flora)  hemopoiesis  recovered 
spontaneously.  It is likely,  that these patients would  have 
been  able  to  recover faster if they  had  had  an  identical 
twin  to serve as  a  stem  cell donor  or if there  would  have 
been  a  bank  of  cryopreserved  autologous  hemopoietic  stem 
cells  (from blood or  from  bone  marrow). 
In patients with  a  blood  cell response pattern dentical or 
similar to that described  for  category v,  there is only one 
possible  curative  therapeutic  approach.  These  patients 
should  be  treated  as  if  they  were  patients  with  "severe 
- 136  -aplastic anemia".  For these patients  one  would  look  for  a 
suitable  stem cell donor  (allogeneic  bone  marrow  or blood 
stem cells).  Since  in many,  if not all instances,  one  would 
not  be  able  to  judge  the  degree  and  sufficiency  of 
immunological  suppression  by  the  radiation exposure,  one 
would  have  to  "condition"  the patient  by appropriate means 
(chemotherapy  as  in  the  preparation  for  stem  cell 
transplantation for  severe aplastic anemia) . 
..  137  .. 6.  Possibilities and  limitations to treat persons  suffering 
from  acute radiation syndromes 
The  work  performed within this  EC-contract did not  cover all 
aspects  to treat radiation injured  persons.  The  Chernobyl 
experience added  a  new  dimension  to  the  management  of 
radiation injured  persons,  skin  burns  in addition  to the 
total body exposure  by  penetrating ionizing radiation.  In 
this report emphasis will be  on  the question of establishing 
a  blood  stem cell bank  as  a  means  to treat  persons at high 
risk  of  being  exposed  as  a  consequence  of  radiation 
accidents. 
:~ the  ~revicus  c~ap~er 4  i~ was  poi~ted cut that one  m~st 
co~sider  i~  pri~ciple  situations:  radiation  exposure 
ca~egories  resul~i~g  ~~ a  reversible  hema~opoietic  d~~age 
and  those  resul~i~g  i~ an  irreversible hematopoietic  damage. 
The  Chernobyl  accident  (see  tables  1  and  2)  providul 
evidence that all persons  in Grades  I  through III need to be 
considered as  having  been  exposed  to such  an  extend that the 
hemopoietic  damage  was  reversible.  The  fatal  casualties 
observed in grad III are attributable to the severe burns  of 
the  skin. 
Aside  from  considering  the  therapeutic  strategies  with 
respect  to  skin  burns  and  incorporation  of radioactive 
nuklides,  the therapy of  choice  for  taking  care of  the 
consequences  of  the  transient  hemopoietic  failure,  in 
particular  infection  and  bleeding  has  been described as 
replacement  therapy  (4).  It  consists essentially of  trying 
to  remove  exogenous  and  endogenous  bacteria  and  other 
microbial  organisms  from  the  skin  and  the gastrointetinal 
tract  by  antibiotic  therapy.  It is  in cases  of  severe 
granulocytopenia  advisable to  induce  a  "gnotobiotic  state" 
and  to  treat  the  patient  in a  sterile isolation  system 
- 138  -(reverse isolation).  In  this way,  one  can  wait  for  the 
granulocytes  to recover  on  or around  day  30  after total  body 
irradiation and  one  can  also tolerate low platelet counts 
without high risk of  bleeding.  This  form  of  therapy has  been 
described previously. 
If  there  is  a  severe  thrombocytopenia  with  a  risk  of 
bleeding,  it  may  be  necessary  to  perform  platelet 
replacement therapy  as  was  done  in  one  of  the Chernobyl 
cases  (see  figure  2). 
It may  also  be  necessar~  to  take  snecial  ca=e  of  the 
elec-crolyte  balance,  especially  so:ne  for:n  cf 
gastrintesti~al damage  becomes  obvious  '  .~ ;  ~  ,... ,... ;,  r:::. a ) 
\ ------·- . 
~n  ~his report,  sufficient evidence was  given  for the  fact, 
that there is,  after acute radiation exposure,  the onset of 
spontaneous  granulocyte  and platelet  recovery on or around 
day  30.  It is thus  necessary to provide optimal  care during 
this transient  phase of  hematopoietic failure  (gnotobiotic 
care,  provision  of  adequate  fluids,  platelet  support if 
necessary). 
What  about  stem cell substitution?  If there is evidence of 
an  irreversible damage  to the  stem cell system as described 
above,  it is essential to provide hematopoietic  stem cells 
for restoring the hematopoietic  function of  the bone  marrow. 
Other  research  institutes  participating  in  this 
Post-Chernobyl  programme  have  concentrated  their efforts on 
the  improvement  of  bone marrow transplantation. 
The  Ulm  Research  Group  together with the Group  of Professor 
Hunstein  in the  Medical  Department  of  the University of 
Heidelberg  has  established the  concept  of  a  blood  stem cell 
bank.  This  approach  may  become  useful if  there are  persons 
at  high  risk for radiation exposure  who  are  prepared to 
•  139  • allow  their  pluripotent hematopoietic  stem  cells  to  be 
collected  from  the  peripheral  blood,  stored  at ultralow 
temperatures  and  being  antotransfused 
unexpectedly high radiation  exposure. 
evident after a  radiation accident when 
if 
This 
the 
necessary after 
risk may  become 
necessity arises 
the  Chernobyl 
situation,  there was  evidence  for radiation exposure  in the 
teams  of  technicians  participating  in rescue  and  clean-up 
operations. 
to  engage  in  clean-up  operations.  In 
The  blood  stem cell  bank  concept has  been  developed  at the 
precli~ical level  (dog  model)  at  the University of  Ulill  and 
~~  ~~9 cliaical level at  t~e University of  ~eidelberg. 
The  c~~cept  or  a~  au~ologous  bleed  ste~  cell  bank  ~as 
as  a  means  patier..ts  acu~e 
':"""y.oloaonous  1 oukem; ~  ( "'f/.j )  ..  6-L_  - ., .......  -......  ...  ..._....  r-~  •  _;ll  t::-ansplants  performed 
in the  fi=st  remission  following  conventional  induction 
chemotherapy. 
The  patients data are listed in table  6. 
Table  6 
no  pattents 
male 
female 
age  (medfan,  range) 
WBC  at  dhgnosts 
(medhn,  range) 
tfme  between  start of 
CR  precedfng  transplant, 
and  transplant 
(medhn,  range J 
fAB  Hl 
HZ 
HJ 
H4 
HS 
ASSCT 
20 
12 
8 
41  (5-48) 
5300/ul  (500-268,000) 
3,5  months  (2-12) 
4 
5 
2 
7 
2 
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ABHT 
23 
14 
9, 
33  lU-soJ 
17600/ul  (700-277,000) 
4 months  (2-6) 
5 
2 
3 
9 
4 
p value 
n.s. 
p •  0.05 
n.s. 
n.s. 
n.s. 
___  , _____ _ Blood  stem cell collection 
Blood  ·derived  hemopoietic  stern  cells  were  collected by 
continuous  flow  cytopheresis  using  a  Fenwal  CS  3000  blood 
cell separator  (BAxter  Deutschland  GmbH,  Mlinchen,  Federal 
Republic  of  Germany).  For  mobilizing  stem  cells  from 
extravascular sites  into  the circulation,  aphereses  were 
performed  at the  time  of  bone  marrow  recovery following 
chemotherapy-induced transient myelosuppression.  The  regimen 
used was  identical  to  the  consolidation  treatment  of  ~~~= 
~~~~-C  100  mg/m 2  q  12  ~r s.c.,  days  1-5;  Dauno~ubicin  45 
-g/~ 2  d~vs  ~~~a.·~  t1i'  Stem cell  a~hereses were initiated  .aL  ·••  I  ......... ...  .._~  ..........  •  \  - - I  •  .._, 
·w-hen  the  pa"Cient  had  =eached  a  peripheral  1"1"SC  count  o: 
1,000/ul,  and  a  oeripheral platelet count of  40,000/ul.  The 
~oa'iMn  nu.:~~~r 0;  a~·no~ 0 5°S  0°~ DC.~ion~ WaS  10  (ranao  ·•L- --•  •  ... ~e  .J...  !:"  • ._. __  ._  _  ,_.~  _  '-'-"-...  ~  ...  .,-1  6-14); 
the  time  in~erval between  aphereses  was  1-3  days. 
The  MNC-enriched  peripheral  leukocytes  were  collected 
according to  a  program designed  by the Baxter  Company  (12). 
The  median  percentage of  MNC  collected  from  199  aphereses 
was  91,7%  (range,  50.8-100). 
The  harvested  MNC-enriched  leukocyte suspension  was  then 
pelleted and  resuspended with ABO  compatible  human  plasma  to 
a  final  volume  of  50  ml,  and  transferred to  a  freezing  bag 
(Delmed,  Canton,  Mass.).  50  ml  of  cold  S-MEM  supplementted 
with  20%  DMSO  were  added  to  end  up with  a  final  DMSO 
concentration of  10%. 
Marrow  collection and  orocessing 
The  technical  aspect  of  bone  marrow  collection  and 
processing has  been  described  in  detail  elsewhere  (10). 
Briefly:  marrow was  collected by multiple aspiration  from 
the  posterior  iliac  crest  and  the  sternum.  The  cell 
suspension was  depleted of  red  blood cells  (RBC)  and  most  of 
- 141  -the  polymorphonuclear cells  (PMN)  by  a  two-step procedure:  a 
buffy-coat  and  a  Ficoll-Metrizoat  (FM)  gradient 
centrifugation using  the  IBM  Blood  Cell  Processor  2991  as 
described by Gilmore et al.  (13). 
Mafosfamide<R>,  a  stable  substitute  cf  the  activated 
primary metabolite of  CY,  was  added at a  concentration of  60 
to  80  ug  per  2xl0 7  w~C and  was  incubated with agitation at 
37°C  for  30  min.  Cells were  washed,  resuspended with ABO 
compatible  human  plasma  and  transferred to  freezing  bags,  50 
ml  per  bag.  50  ml  of  cold  S-MEM  supplemented with  20%  DMSO 
were  added  to  each  bag. 
3lccd  stem cell  /  :nc.r~cw  cr.rc-:Jreseror;a~;cn  a.:1d  t,...c.nsfusio:n 
~he  cell  suspension  was  t~en  i~2ediately  frozen  at  a 
controlled rate of  l-2°C/~in from  +l0°C  to  -70°C/min  up  to 
-100°C  (BV-10  Biological  Freezer,  Cryoson  GmbH,  Federal 
Republic  of Germany).  The  frozen  bags  were  stored in liquid 
nitrogen.  Thawing  was  performed rapidly in a  42°C waterbath 
without the  DMSO  being  removed.  The  cell suspension was  then 
aspirated into  50  ml  syringes  and  immediately injected into 
the patient's central line  (Hickman  catheter)  at a  rate of 
10  ml/min. 
The  median total volume  of  cell suspension transfused  per 
patient was  1025  rnl  for ABSCT  patients  (range,  600-1520), 
and  400  ml  for all ABMT  patients. 
Pretransplant regimen 
The  hyperfractionated TBI  was  slightly modified according  to 
Shank et al.  (14).  The  median  total body  dose at body  center 
was  calculated to be  14.5  Gy  (range,  14.4-15.3)  for  ABSCT 
patients,  and  14.4  Gy  (range,  12.1-16.7)  for  ABMT  patients. 
120  cGy  per  fraction were  given  3  times  daily on  days  1,  2, 
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3,  and  twice  on  day  4,  four  hours  apart  for  11  fractions 
(total  12.1-13.7  Gy)  or  12  fractions  (total 13.8-14.9  Gy), 
three  fractions  per day.  The  dose  range  between  15.0  and 
16.7  Gy  included  12  fractions,  130  cGy  each.  A  23  MeV  linear 
accelerator source  (Saturne)  (38  cases)  or,  alternatively,  a 
Co 60  gamma  source  (3  cases)  was  used with  a  mid-line dose 
rate of  7-18  cGy  per min.  The  lung  dose was  limited to  9  Gy. 
Additional  boosts with  electrons  of  a  maximum  of  15  MeV 
(depending  on  the  chest wall  thickness)  were given to the 
previously shielded areas,  particularly the ribs,  to reach 
t~e total  maxim~~ dose.  Following  TBI  (days  -9,  -8,  -7,  -6) 
CY  was  given i.v.  on  each  of  4  consecutive  days  (-5,  -4,  -3, 
-2!  ~t  a  daily dose  of  50  mg/kg.  Afte~  cne  cay of  =est 
-:::-ansplanta  ticn ·.,.;as  perfor:::ed  en  day  0. 
~~o  ~ore  patien~s were  ~=ea~ed wit~ busulfan  (15  mg/kg)  and 
CY  (200  ~g/kg)  prior to  blood  stem cell  (1  case)  o~  bone 
~arrow transplantation  (1  case). 
Intensive care post transPlantation 
The  patients  were  kept  in  reverse  isolation  from  the 
beginning of  high  dose  CY  until  a  peripheral  PMN  cell 
concentration of  500  per  ul  was  reached.  Prophylactically 
they  all  received  acyclovir,  ketoconazole  and 
CMV-hyperimmunoglobulin  together  with  partial  antibiotic 
decontamination  of  the  gut  (15)  up  to  100  days  post 
transplantation.  When  fever  exceeded  38.5°C broad  spectrum 
antibiotics were  administered,  and,  when  fever  persisted for 
more  than  4  days  despite appropriate antibacterial treatment 
amphothericin  B was  added  systemically.  All platelet support 
was  HLA-A/B  matched  and  CMV  negative  if the patient was 
negative  as well.  All  blood  products  were  irradiated with  20 
Gy  to avoid  the risk of  GvHD  induction  . 
.  143  • Statistical evaluation 
Clinical  and  laboratory  data  were  obtained  from  the  bone 
marrow  transplant  data  base  and  analysed  by  standard 
statistical methods  using  the  SAS  software program.  Basic 
characteristics of  the patient groups  were  compared  by means 
of  chi-square tests.  In the  case of  uncensored quantitative 
variables  the usual  Mann-Whitney-Wilcoxon-Tet was  applied. 
Plotting  the  distribution  of  censored  variables  and 
estimating  median  values  was  carried out according  to the 
Kaplan-Meier method.  The  mai~ variable of  interest was  D?S, 
defined  as  ~he  ~ime from  transplantation to relapse.  T~=ee 
~a~ien~s died  ~i~hout relapse,  t~o  of  ~hem were  counted  as 
"e·vent.s..  =.nd  o::e  .. w-as  considered  as  a  censored  obser-.:_,·a tic:-1, 
due  ~o  ::.  aeneralized  Eernes  7i=~s 
~~fec~ion.  T~e comparison of .;3MT  and  ~3SCT  or  prognos~~= 
subgroups  wi~h respect  ~o  DFS  was  based  on  the  log  ran~ 
t:.est.  Theh  estimation  of  a  "cure  rate"  did  not  seem 
appropriate,  instead  we  calculated  rates  for  two-year 
disease-free survival with confidence intervals based  on  the 
standard errors  supplied by the Kaplan-Meier method.  Other 
censored  variables  such  as  hemopoietic reconstitution and 
duration of hospital  stay were  analysed in the  same  way,  but 
tests  were  based  ont eh  generalized Wilcoxon  statistics. 
Formal  significance  levels of  p  =  0.05  were  used  without 
adjustment  for multiple testing. 
The  probability  of  DFS  or 
day of  transplantation  (day 
1,  1989. 
relapse was  calculated  from  the 
0)  and  was  analysed as  of  June 
Harvesting  and  transfusion of cells 
To  guarantee  a  sufficient  blood  stern  cell  autograft,  its 
total  number  of pluripotent  stern cells should  be  comparable 
with  that  from  the  marrow.  Since  blood  stem  cell 
- 144  -concentration is  only  about  1/10  to  1/20  of  that in the 
marrow,  the total  number  of  blood  1~C harvested  had  to be 
adjusted. 
The  median  yield  of  ~-rnc  collected  by  a  single 
continuous-flow apheresis  was  5.4  x  10 9  (range,  0.2-14.5)  or 
13  x  10 4  CFU-GM  (range,  1-180).  The  total  number  of  blood 
derived  MNC  transfused  pe=  kg  b.w.  was  80.0  x  10 7  (range, 
17.3-140.9)  or  2.35  x  10
4  CFU-GM  (range,  0.2-4.1).  The 
marrow  stem cell graft,  o~ the other hand,  contained  4.7  x 
10 7  (=ange,  0.6-13.0)  ~C  a~ a  median.  The  respective median 
::~-:'J:·er  of  :mar::-ow  (C?U-G~1 -==a:1s£used  per  kg  b.w.  was  low  ·"-·i-:.!1 
:J.l~  X  10
4  0.005-:.o;  due  to  a 
C~U-G~ as  a  consequence  o~  ~afosfarnide<R)  purgi~g (15). 
~emocoietic  recons~it~tic:: 
The  total number  of pluri;otent stem  cells and  w~C as  well 
as  cell  composition  of 
characteristic  kinetics 
the 
of 
autograft 
hemopoietic 
determines  the 
reconstitution 
following  myeloablation and  ABSCT  or  ABMT.  As  Figure  19 
shows  on  a  daily blood  count  basis,  the reconstitution of 
peripheral  leukocytes  started  significantly  earlier 
following  ABSCT  compared  to ABMT.  The difference in speed of 
hemopoietic reconstitution of  peripheral  leukocytes  started 
significantly earlier following  ABSCT  compared  to ABMT.  The 
difference in speed  of  hemopoietic reconstitution within  28 
days  after transplantation was  highly significant each day 
from  day  1  on  (p  =  0.0001).  The  median  time it took  for  the 
peripheral  WBC  count  to reach  1000/ul was  10  days  (ABSCT) 
compared  to  28  days  (ABMT)  (p  =  0.0001)  (Figure  2)  or  14 
days  (ABSCT)  compared  to  42  days  (ABMT)  (P  =  0.0001),  which 
was  the median  time it took  for  the peripheral  PMN  count to 
reach  500/ul.  The  kinetic of  platelet reconstitution were  in 
favour  of  ABSCT  patients;  the median  time  to reach  a  stable 
20,000/ul  platelet  concentration  was  30  days  (ABSCT) 
- 145  -compared  to  46  days  (ABMT)  with  a  borderline significance  (p 
= 0.05).  Three  out  of  20  ABSCT  patients did  not  reach  a 
stable  20,000/ul  platelet  count  before  day  100  post 
transplant  compared  to  8  out of  22  evaluable ABMT  patients. 
Figure  19 
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Early transplant-related morbidity and mortality 
Transient supraventricular tachycardia  and  severe mucositis 
were  seen in almost all patients.  One  ABMT  patient died  of 
septicemia,  whereas  there was  no mortality among  the ABSCT 
patients.  The  median  hospital  stay was  45  days  for  ABSCT 
patients versus  73  days  for  ABMT  patients  (P  = 0.005). 
Due  to  the  rather large  volume  of  the  blood  stem cell 
autograft  (1025  ml  at  a  median)  transfused over  a  central 
line,  patients suffered  from  chills,  stomach  ache  and  muscle 
cramps  at the  lower  extremities.  Those  side effects  ceased 
shortly after transfusion  was  concluded,  and  were  not  as 
- 146  • severe  during  marrow  cell  transfusion,  when  an 
autotransplant at a  lesser volume  (400  ml)  was  carried out. 
Disease-free survival 
When  compared statistically,  there were  no  differences  to be 
observed in both the ABSCT  or ABMT  groups  as  far as  sex,  WBC 
concentration  at  diagnosis,  the  time  between  start  of 
remission  and  transplant,  and  F~~  subclassification  were 
concerned,  while  the median  age  of  ~~MT patients  was  less 
~han that of  -~SCT patients  (p  = 0.05)  (Table 1). 
~~e ~edian =elapse  time  for  the  20  A3SCT  oatients  was  14.3 
:no:-.:. ~:1  s ,  a::d  3 7%  ·.,.;ere  disease-free  t~o  years  af-cer 
-----nl~n~~~icn  (o~~  c-~;;c·enco  ;~-~~-~1  -..:...  ~..:...:..!::.~--·  L..-'-- -' ...J  ~  .._. ••  .J.._  J.  ._.  ...... J..l--- '""""- from  13%  ~o 60%). 
:n  ~he group  fo  23  ~3MT  patients  the two-year  D?S  rate was 
59%  (95%  confidence interval  from  38%  to  80%),  to date  no 
relapses  have  occured  later than  9  months  post transplant. 
As  can  be  seen in Figure  5  the  Kaplan-Meier  estimates  for 
DFS  in both groups  are  crossing and  the  long  rank test  is 
not  significant  (P  = 0.33).  Of  20  ABSCT  patients autografted 
in 1st CR,  11  have  relapsed;  of  23  patients autografted with 
bone  marrow,  9  have  relapsed  or  died too  early  to  be 
evaluated  (1  patient). 
Relevance  for  radiation accident management 
It is apparent  from  these clinical data,  that it is feasible 
to set  up  blood  stem cell banks  in  order  to collect and 
store  pluripotent  hematopoietic  stem  cells  from  the 
peripheral  blood  of  persons  who  are at  high  risk to be 
exposed  in  extraordinary  circumstances,  for  instance in 
radiation  accident  clean-up  operations.  Further  work, 
however,  is essential  in  this  field in  two  aspects.  It 
appears  of  interest to  develop  new  approaches  to  mobilize 
stem cells  into  the  blood  from  extramedullary sites.  In 
- 147  -patients,  the high yield of  blood  stem cells was  obtained  by 
pretreatment  with  cytotoxic  drugs,  such  as  ARA-C  and 
Dannorubicin.  Cyclophosphamide  has  also be  shown  in dogs  and 
man  to  produce  a  high  concentration  of  hematopoietic 
progenitor cells in the  blood within 10-14  days.  In dogs,  it 
has  been  shown  that  dextran  sulfate  (DS)  is capable of 
inducing  a  significant increase of  ciruclating progenitor 
cells within  3-4  hours  after DS  administration.  It  appears 
therefore useful  to explore the mechanisms  for  this  type  of 
mobilization  and  to transfer  the experience  gained to the 
clinical level.  A  second area requiring  further  intensive 
=esea=ch  is evident i£  one  considers  the  advances  made  i~ 
u~ilizi~g  recombinant  ~emopoietic  g=ow~h  factors  in the 
treatment  o£  hemoooietic  failure.  The  ~uesticn  is whether 
one  could utilize  ver1 smal  n~~~ers of  blood derived  stem 
cells  and  enhance  their  replication  and  differentiation 
potential  by  post-transfusion  application  of  such 
recombinant  grow~h factors.  In this case,  one might  be  able 
to collect a  sufficient number  of  pluripotent blood derived 
stem cells with one  single leukapheresis. 
- 148  -7.  Further research  needs  to  imorove existing and  develop 
further strategies to handle  persons accidentally exposed 
to ionizing radiation 
It is apparent  from  this report that  a  lot of  progress  has 
been  made  in trying to  improve  means  and  ways  to adequately 
take  case of  persons  accidentally exposed  to ionizing radia-
tion.  However,  a  lot of  man  work  has  to  be  done  which  may  be 
summarized  as  follows. 
~he Chernobyl  experience  should je fully  analysed  by esta-
blishing  apprcpria~e  ccllabora~icn projec~s with  the  scien-
·- is reported,  fer instance, 
~~at  t~ere were  many  ~ore ceoole exposed  to  ic~izing radia-
~ion the  cli~ical data of  whom  have  ~ot been adequately ana-
lysed.  There  are also  a  large  nw~~er of  persons who  partici-
pated in clean-up.operations  who  may  have  had  significant 
radiation exposures. 
The  goal  of  such  a  collaboration would  be  to set up  an in-
ternationally accessible  data base  of  persons accidentally 
exposed  to ionizing radiation  possibly  in a  continuous or 
protracted way.  This  type  of  research would  be  of great im-
portance for radiation protection planing in Europe. 
There is  a  great  need  to analyse all clinical  data that 
become  available in the future  of accidentally radiation ex-
posed persons.  There  are  - most  likely - a  relatively large 
number  of  persons  exposed  to  high dose  of  radiation that 
have  not  as  yet been  published in the international litera-
ture.  It  is  desivable to establish  an  international data 
base  for  a  many  cases  of  acute accidental  radiation exposure 
as  appropriate. 
On  this basis,  it  would  become  of  importance  to develop  an 
knowledge  based  expert  system  for assisting medical  doctors 
- 149  -in the decision making  in case of  radiation accidents.  This 
would  require  a  further analysis  of  the  pathophysiological 
mechanisms  of  radiation induced  changes  in cell renewal  sy-
stems  at risk employing  also biomathematical  computer  simu-
lation technics. 
Of  particular importance is the development  of  further bio-
logical markers  for  radiation  exposure.  Blood cell  changes 
need  to  be  complemented  by  more  sophisticated  methods 
mensing  d~~age and  complete  or incowplete repair at the  sub-
cell~la=  a~d ruolecula=  level.  T~is approach will  become  es-
se::.-=.:.al  especially  .:.£  ::.~e  Droble:n  of  medit:...-n  -:.o  lor:cr  te:::-:n 
-n.,o"l""o  .:  ... 
-··--- _.;:j  also  ;:,eea  :::cr  i:ranrove  exis-ci.:1g 
and  develop  ::.ew  approaches  to the  trea~uent of radiation in-
duced  health impair ments.  The  advent  of  recombinant  factors 
such  as-- IL-3  alone  or in combination  with erythropoitin 
signals  new possibilities to influence hematopoietic recove-
ry positively.  Therefore,  it  is mandatory to  do  more  re-
search  in  the field of  using  such  recombinant  factors  in 
cases  of radiation induced hemopoietic  failure. 
Finally,  it appears  essential to set  up  a  European  network 
of  radiation medicine  centres to  establish a  collaborative 
system for handling  radiation accident  cases if necessary. 
This  network  should also  take  over the  responsibility to 
train a  sufficient number  of  European  physicians  to partici-
pate  - if necessary  - in the  optimal  can of radiation acci-
dent victims. 
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1 GENERAL 
Hematopoiesis  1s  under  the  control  of  growth  and  differentiation 
factors  which  allow  the  organism  to  adapt  itself  to  the  new 
situations  by  consequently  modulating  its  own  response.  Some  of 
these  factors  are  well  known,  some  others  are  only  hypothetical. 
The  most  studied  factors  are: 
-the  Granulocyte-macrophage  colony  stimulating  factor 
(G~1 CSF) 
-the  Granulocyte  colony  stimulating  factor  (G  CSF) 
-the  growth  factor  for  the  red  cell  line:  Erythropoietin  (EPO) 
-the  growth  factor  for  undifferentiated  cells:  interleukin  3 
(IL  3). 
Those  factors  are  small  proteins  which  bind  to  specific  receptors 
on  the  membrane  of  the  target  cells.  They  stimulate  the 
proliferation  or  differentiation  of  hematopoietic  progenitors. 
Furthermore,  they  act  on  the  functions  of  mature  cells  (for 
exemple:  the  phagocytic  function  of  granulocytes  for  G  CSF)  . 
•  153  -Recent  advances  in  the  study  and  large  scale  production  of  these 
hematopoietic  growth  factors  have  allowed  their  use  for 
therapeutic  purposes.  The  main  field  of  clinical  investigations  are: 
- bone  marrow  toxicity  control  for  antitumoral  treatment  (such  as 
chemotherapy) 
-treatment  of  global  or  elective  aplastic  anemia 
-treatment  of  infection  related  leukopenia. 
GM  CSF  is  a  protein  acting  at  very  low  doses  (picomolar 
concentrations)  for  the  in  vitro  stimulation  of  colonies  of 
differentiated  granulocytes  and  monocytes  (GM  CFU:  Granulocyte 
Macrophage  colony-forming  unit).  The  successful  cloning  and 
expression  of  eDNA  encoding  human  GM  CSF  gene,  has  allowed  the 
production  of  recombinant  human  (rHu)  GM  CSF  which  is  now 
submitted  to  laboratory  studies  and  clinical  trials  for  few  years. 
The  recombinant  human  GM  CSF  bind  to  high  affinity  receptors  on 
the  membrane  of  the  responding  target  cells  and  possesses 
biologic  activity  for  the  proliferation  and/or  differentiation  of 
granulocyte,  mixed  granulocyte-macrophage,  pure  eosinophilic 
(CFU  eo)  and  mixed  cell  colonies  (CFU  mix)  from  human  normal 
blood,  bone  marrow  and  some  leukemia  cell  lines  (such  as  HL  60, 
where  GM  CSF  acts  as  a  weak  inducer  of  differentiation,  increasing 
the  number  of  cells  displaying  monocytic  or  eosinophile 
differentiation  patterns). 
In  the  presence  of  erythropoietin,  GM  CSF  stimulates  also  the 
growth  of  human  erythroid  burst  forming  unit  (BFU  E).  GM  CSF  has  a 
wide  range  of  effects:  in  vitro  and  in  animal  studies  it  enhances 
•  154  -'I 
the  functions  of  mature  granulocytes.  monocytes/macrophages  and 
eosinophils  on  which  its  receptors  are  also  present  in  small 
quantities.  In  functionnal  studies  GM  CSF  stimulates  neutrophil 
viability,  inhibit  neutrophil  migration  (in  vivo,  in  about  30%  of  the 
patients  cellular  migration  into  a  sterile  skin  window  appears  to 
be  reduced  after  GM  CSF  treatment),  and  stimulates  superoxyde  10n 
production  in  response  to  bacterial  chemo-attractant. 
Furthermore,  GM  CSF  stimulates  the  neutrophil  oxydative 
metabolism  involved  in  granulocyte  microbicidal  or  tumoricidal 
activities,  so  that  the  granulocytes  appear  to  be  activated  and  are 
more  efficient  in  bacteria  killing  after  GM  CSF  stimulation.  The 
phagocytosis  of  bacteria  and  cytotoxicity  are  also  stimulated  by 
G~1 CSF. 
GM  CSF  enbances  the  viability  of  eosinophils  and  act  on  the 
antibody  dependent  cell-mediated  cytotoxicity  (ADCC)  and  on 
antitumoral  activities  of  macrophages.  Furthermore  when 
associated  with  other  growth  factors  it  helps  to  the  development 
of  red  cell  progenitors  and  megakaryocytes  (thus  acting  on 
platelet  renewal).  The  GM  CSF  has  been  used  in  a  variety  of 
clinical  settings  in  order  to  reduce  the  time  of  aplasia  and  the  risk 
of  infections  during  the  chemotherapeutic  or  radiotherapeutic 
treatment  of  cancer  (solid  tumors)  patients,  during  the  treatment 
of  malignant  hematologic  diseases,  following  a  bone  marrow 
transplantation  (autologous  or  allogenic)  in  order  to  reduce  the 
aplastic  phases,  to  reduce  leukopenia  during  acquired 
immunodeficiency  syndrome  (but  also  other  infectious  disorders). 
for  the  treatment  of  diseases  involving  myeloid  disorders  (such  as 
- 155  -congenital  agranulocytosis.  aplastic  anemia  or  myelodisplastic 
syndrome).  The  beginning  of  the  clinical  trials  has  evidenced  the 
positive  aspects  of  its  use:  GM  CSF  was  found  to  be  well  tolerated 
and  able  to  induce  dose  dependent  increases  in  blood  leukocytes 
counts  (neutrophils  but  also  eosinophils  and  monocytes).  For 
ex em ple,  a  shortening  from  7. 4  to  3. 5  days  of  the  mean  neutropenia 
duration  was  observed  for  patients  submitted  to  a  chemotherapy 
for  solid  tumors  and  receiving  GM  CSF  doses  from  4  to  32 
microgramme/kg/day.  The  observed  hematopoietic  recoveries  are 
unstable  (less  than  two  weeks  after  the  end  of  the  treatment)  and 
for  most  of  the  patients  GM  CSF  infusion  must  be  extended  in  order 
to  maintain  a  high  level  of  leukocytes.  For  patients  with  severe 
idiopathic  aplastic  anemia  important  individual  variations  were 
observed:  a  granulocyte  peak  appeared  in  the  blood  betweenl  and 
21  days  (mean  time  4  days)  after  the  beginning  of  the  treatment.  A 
better  general  physical  condition  for  the  patients  and  a  reduced 
frequency  of  infections  have  been  often  reported  suggesting  that 
G~·1  CSF  has  also  corrected  some  defects  in  neutrophil  and 
monocyte  functions. 
Because  of  these  effects  GM  CSF  could  be  of  high  interest  for  the 
treatment  of  the  hematopoietic  syndrome  during  radiation 
accidental  exposure. 
The  GM  CSF  has  already  been  used  in  the  treatment  of  some 
patients  with  bone  marrow  failure  due  to  an  accidental  radiation 
exposure.  It  was  concluded  after  the  Gotania  accident  that  by 
initiating  GM  CSF  use  early  after  exposure  to  near  lethal  doses  of 
- 156  -radiations.  the  period  of  granulocytopenia  may  be  shortened  and 
survival  improved. 
The  optimal  schedule  of  GM  CSF  seems  to  be  5  to  15 
microgramme/kg/day  subcutaneously.  Side  effects  included  bone 
pains.  chills,  headhaches,  mild  myalgias  and  fever,  but  also  for 
higher  doses  (60  microgramme/kg/day),  capillary  leak  syndrome 
with  generalized  edema,  pleural  and  pericardia!  effusion  was 
reported  as  well  as  large  vessel  thrombosis.  It  was  reported  that  a 
high  dose  (64  microgramme/kg/day)  GM  CSF  assay  for 
myelodisplastic  syndrome  patients  had  initiated  rather  than 
prevented  the  onset  of  acute  myeloid  leukemia. 
\'Vh(!ther  GM  CSF  has  carcinogenic  potential  or  will  stimulation 
with  G~1  CSF  results  in  bone  marrow  exhaustion  or  stem  cell 
failure  were  some  of  the  questions  that  had  to  be  solved  before 
hemopoietic  growth  factors  could  be  used  on  a  large  scale  and  for 
radiopathology  purposes.  Taking  advantage  of  phase 1  and  2 
clinical  trials  as  well  as  compasionnate  need  cases  GM  CSF  cures. 
we  have  developed  during  this  contract  an  experimental  protocol  in 
order  to  study  the  long  term  and  side  effects  of  GM  CSF. 
Long  term  bone  marrow  cultures  (L  TBMC)  have  provided  a  powerful 
tool  to  demonstrate  important  cell-cell  interactions  together  with 
the  influence  of  hemopoietic  growth  factors  necessary  for  the 
m ai nte  nance  of  hemopoiesis. 
- 157  -In  order  to  study  the  long  term  interaction  between  GM  CSF 
hemopoietic  cells,  tumoral  cells  and  stromal  bone  marrow  cells. 
we  have  set  up  a  L  TBMC  assay  during  (and  after)  the  course  of  Gtvl 
CSF  clinical  trial  for  treatment  of  leukopenia  observed  after 
autologous  bone  marrow  transplantation  in  advanced  solid  tumor 
therapies.  L  TBMC  were  set  up  before  any  treatment  and 
sequentially  after  each  step  of  the  protocol  (double  autologous 
bone  marrow  transplantation  with  radiotherapy.  chemotherapy  and 
G M  CSF  infusion)  up  to  one  year  after  treatment.  Hemopoiesis  was 
assessed  by  granulocyte  macrophage  progenitors  (GM  CFU)  and 
mature  cell  production  in  the  supernatant  of  the  L  TBMC.  Stromal 
cells  were  studied  for  their  growth  and  differentiation  pattern. 
The  presence  of  abnormal  cells  was  studied  by  culture,  cytological 
or  immunological  methods.  Controls  were  assessed  using  bone 
marrow  samples  from  the  same  patient  before  treatment  and  from 
normal  donnors  with  matching  ages. 
Following  a  bone  marrow  transplantation  or  myelosuppressive 
therapy.  patients  with  severe  bone  marrow  failure  have  received 
G~1  CSF  as  compassionates.  As  the  bone  marrow  of  this  kind  of 
patients  may  be  closer  to  the  marrow  of  a  radiopathology  patient 
than  the  bone  marrow  of  solid  tumor  patients,  we  have  developed  a 
L  TBMC  assay  to  study  the  aplastic  bone  marrow.  Short  term  and 
side  effects  of  the  growth  factor  therapy  were  studied  during  this 
assay.  The  effects  of  repeated  growth  factor  therapies  were  also 
investigated. 
•  158  -i 
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Although  short  term  effects  of  G~1  CSF  were  well  documented 
through  in  vitro  and  animal  studies.  when  this  study  was 
initiated,  the  know ledges  about  long  term  in  vivo  effects  of  G!vf 
CSF  on  human  were  scarce.  Therefore,  we  have  designed  a  protocol 
to  study  paraclinical  long  term  effects  of  GM  CSF  during  the 
course  of  an  autologous  bone  marrow  transplantation  programme. 
and  paraclinical  and  clinical  side  effects  of  GM  CSF  during  a 
protocol  of  treatment  of  bone  marrow  failure.  These  two  main 
points  are  developed  below. 
- 159  -2 AUIQLOGQUS BONE MARROW TRANSPLANTATION STIJDY 
Granulocyte-macrophage  colony  stimulating  factor  (GM  CSF)  is 
under  clinical  trials  and  shows  promising  effects  over 
hematopoiesis.  Disseminated  neuroblastoma  are  treated  with 
massive  therapy  followed  by  two  autologous  bone  marrow 
transplantations  (ABMT).  As  a  small  amount  of  malignant  cells  1s 
still  present  in  the  marrow  of  these  children  after  the  induction 
treatment.  neuroblastoma  cells  are  magnetically  depleted  in  vitro 
with  specific  monoclonal  antibodies  before  grafting.  In  order  to 
shorten  granulopenia,  GM  CSF  is  administered  after  one  of  the  two 
ABMT  so  that  all  patients  received  GM  CSF  once. 
\Ve  have  previously  developed  a  long  term  bone  marrow  culture 
(L  TBMC)  system  with  potential  application  to  the  follow  up  of 
stage  IV  neuroblastoma  children  treated  with  high  dose 
radiotherapy  combined  to  chemotherapy  followed  by  autologous 
bone  marrow  transplantation.  The  effects  of  in  vivo  GM  CSF 
infusion  over  the  L  TBMC  system  were  assessed  during  the  clinical 
trial  in  order  to  study  the  interaction  with  neuroblastoma  cells, 
hematopoietic  and  stromal  bone  marrow  cells. 
Children  were  diagnosed  with  metastatic  neuroblastoma  and 
enrolled  in  this  prospective  study.  All  patients  were  treated 
according  to  the  SFOP  NB  87  induction  protocol  and  the  current 
LMCE  consolidation  regimen  which  have  been  described  already. 
- 160  -Briefly.  induction  chemotherapy  regimen  consisted  in  four 
alternating  chemotherapy  cycles  of  CADO  (Cyclophosphamide 
300mg/m2/day  on  dayslto  5.  Doxorubicin  60mg/m2/day  on  day  5. 
Vincristine 1.5mg/m2/day  on  days land  5)  and  VP/CIS  (Etoposide 
100mg/m2/day  on  dayslto  5  and  Cisplatinum  40mg/m2/day  on 
days 1  to  5)  starting  with  a  CADO  cycle.  Surgery  was  performed  at 
the  end  of  the  induction  chemotherapy  prior  to  bone  marrow 
harvest  for  graft.  Autologous  bone  marrow  was  purged  using  an 
immunomagnetic  depletion  technique  slightly  modified  by  Lopez  et 
al.  from  the  method  initialy  described  by  J.  Kemshead. 
Consolidation  regimen  was  performed  after  a  predetermined  plan: 
-Patients  in  complete  remission  (CR)  or  in  very  good  partial 
remission  (VGPR)  received  the  association  of  Vincristine, 
~1elphalan  and  a  12  Grays  fractionated  total  body  irradiation  (TBI) 
followed  by  autologous  purged  bone  marrow  rescue. 
-Patients  in  partial  remission  (PR)  underwent  the  double 
autologous  bone  marrow  transplantation  (ABMT)  programme  of  the 
L~vlCE  group  consisting  of  a  first  consolidation  made  of  BCNU  300 
mgfm2  on  day  1,  VM26  250  mgfm2  on  days  2  to  5,  Carboplatinum 
250  mg/m2  on  days  2  to  6.  A  second  bone  marrow  harvest  with 
immunomagnetic  depletion  was  performed  prior  to  a  second 
consolidation  made  of  Vincristine,  Mel ph alan  and  TB I.  These 
patients  received  as  part  of  a  double  blind  study  of  recombinant 
GM  CSF  14  microgramme/kg/day  as  a  continuous  infusion  of  CHO 
material(Sandoz)  during  14  days  following  either  the  first  or  the 
second  ABMT  (so  that  all  patients  received  GM  CSF  and  placebo 
once). 
- 161  -The  timing  for  bone  marrow  sampling  for  the  study  was  as  follow: 
a  sample  was  harvested  from  four  different  sites  of  the  iliac  bone 
under  anesthesia  at  diagnosis.  after  induction  chemotherapy 
(around  first  bone  marrow  harvest  for  ABMT).  between  the  two 
grafts  if  applicable.  The  post-graft  sampling  was  made  of  7 
samples  harvested  (when  possible  due  to  the  poor  condition  of 
some  of  these  patients)  at  2,  6.  9,  12,18,  24,  28  months  post  TBI. 
Information  about  long  term  survivors  were  obtained  by  studying 
the  marrow  from  patients  treated  by  other  induction  chemotherapy 
protocols  who  underwent  the  same  single  ABMT  consolidation 
regimen  as  CR  patients. 
Patients  were  between  2  and  4  years  old.  Ten  hematologically 
normal  patients  (stage  neuroblastoma  patients  with  comparable 
ages),  normal  bone  marrow  samples  from  healthy  allogenic  bone 
marrow  transplantation 
controls. 
donors  were  also  investigated  as 
Long  term  bone  marrow  culture  study  (L  TBMC)  were  as  follow. 
The  sample  (about  2  ml  over  heparine-Roche)  was  diluted  ( 113) 
with  Iscove's  medium  (Gibco)  and  centrifuged  over  ficoll  of 
density  l. 119  (Sigma)  10  minutes  at  200  g  followed  by  15  minutes 
at  400  g  to  get  rid  of  most  of  the  red  cells.  The  nucleated 
overlaying  cells  were  washed  three  times  ( 10  minutes  at  400  g)  1n 
Iscove's  medium  2%  foetal  calf  serum  (FCS-Boehringer)  and 
- 162  -cultured  (5%  C02.  at  33 OC)  after  the  viability  of  the  cells  had  been 
assessed  by  the  trypan  blue  exclusion  test  (2.106  viable  cells/ml 
1n  Jscove's  medium  10%  FCS,  10%  horse  serum- Boehringer,  10-6 
~1  hydrocortisone  hemisuccinate  - Sigma).  Half  of  the  supernatant 
was  removed  each  week.  the  collected  cells  were  counted 
(expressed  in  million  cells  per  millilitre,  C/ml)  and  the 
clonogenicity  of  granulocyte-macrophage  progenitors  (GM  CFU) 
was  tested  in  triplicate  among  the  non  adhering  cells  using 
conditioned  medium  of  the  human  563 7  cell  line  as  a  source  of 
hemopoietic  colony  stimulating  factors  ( 105  cells/ml  in  Is cove's 
medium,  0.3  %  agar  -Difco,  20%  conditioned  medium  of  5637  cell 
line,  15  %  FCS.  cultured  in  Petri  dishes  at  5%  C02,  3 7oC).  The 
presence  of  preadipocytic  cells  identified  among  the  stromal  cells 
by  fat  inclusions  (Fluorescence  of  Nile  red  dye  -Aldrich,  10  mg/ml, 
excitation  wavelength:  450-500  nm,  emission  wavelength  >580 
run)  was  also  monitored. 
Cultures  in  agar  without  conditioned  medium  from  5637  cells 
were  also  set  up  in  order  to  test  the  growth  of  other  cell  types 
(i.e.  tumor  cells).  All  the  semi-solid  cultures  were  scored  on  day 
11,  the  colonies  being  defined  as  groups  of  more  than  50  cells, 
clusters  as  groups  of  10  to  50  cells.  The  mean  counts  of  three 
Petri  dishes  containing  GM  CFU  colonies  was  expressed  as  the 
quantity  of  clonogenic  cells  to  the  number  of  viable  cells 
harvested  per  millilitre  of  LTBMC  supernatant,  on  the  day  of 
collection  and  agar  culture  (GM  CFU/ml). 
- 163  -Supernatant  samples  from  L  TB.tvlC  were  cytocentrifuged  ( 10 
minutes  at  200  g)  on  glass  slides.  The  cells  were  stained  to 
evaluate  the  presence  of  tumor  cells  in  the  culture.  Three 
dimensional  out  growth  of  potential  tumor  cells  occured  tn  the 
cultures  established  from  patients  with  advanced  bone  marrow 
metastatic  neuroblastoma.  They  were  removed  from  the  stroma 
layer  in  some  of  the  flasks  of  each  cultured  sample  by  flushing 
with  medium  and  subcultured  for  4  to  8  weeks,  in  order  to  initiate 
spheroid  growth  (Iscove's  medium.  15%  FCS,  0.2%  agar  at  5  %  C02, 
3 7°C).  The  spheroids  of  cells  obtained  were  freezed  down  or 
included  in  parafin  and  processed  for  histological  analysis  and/or 
assayed  for  neurone  specific  enolase  (NSE)  or  anti  GD2  response 
using  enzymo-immunological  assays  (DAKO).  Due  to  the  large 
variation  of  results  observed  between  various  batches  of  serum, 
all  the  horse  and  fetal  calf  serum  used  have  been  preselected 
through  long  term  and  short  term  cultures  of  normal  human  or 
mouse  bone  marrow  and  the  same  batches  has  been  used  during  all 
the  length  of  the  study. 
A.mong  the  12  studied  patients  only  5  have  completed  the  protocol. 
The  semilogarithmic  scaled  figures  show  the  quantity  of  cells  and 
the  pattern  of  clonogenicity  of  the  GM  CFU  among  supernatant  cells 
during  the  time  course  of  the  cultures.  Results  of  clonogenicity 
experiments  using  colonies  counts  or  c1 uster  plus  colonies  counts 
are  comparable.  In  most  of  the  experiments  of  secondary  semi-
solid  culture  from  neuroblastoma  patients  bone  marrow  cells,  as 
- 164  -well  as  some  colonies  or  clusters  of  tumor  cells  may  be  evidenced 
due  to  their  peculiar  morphology. 
The  quantity  of  viable  cells  and  the  clonogenicity  of  the  GM  CFU 
among  supernatant  cells  during  the  LTBtv1C  were  followed  for  at 
least  one  month.  The  settling  tumor  cells  could  be  subcultured  and 
characterized  as  spheroids.  The  interactions  between 
neuroblastoma  cells  and  the  bone  marrow  stroma  could  be 
evidenced  through  the  culture,  histological  and  immunocytological 
data.  When  available  fresh  stromal  layer  where  also  investigated. 
The  clinical  trials  of  GM  CSF  have  already  evidenced  its  usefulness 
in  the  treatment  of  granulopenia,  however  long  lasting  effects  on 
other  cells  (stromal  cells  or  tumoral  cells)  are  not  well 
documented.  The  human  LTBMC  assay  we  have  developed 
demonstrate  the  production  of  hemopoietic  stem  cells  for  several 
weeks  and  might  be  of  diagnostic  and  prognostic  value  to  assess 
neuroblastoma  invasi  vness  and  the  functions  of  the  bone  marrow 
during  treatment.  During  this  assay  no  long  term  effect  of  G~1  CSF 
was  evidenced  when  comparing  ABMT  and  placebo  versus  ABMT  and 
G M  CS F  for  each  patient 
(figures  la  to  Sa:  Cellularity  in  LTB1v1C  from  patient  1-5,  figures 
lb  to  Sb:  Clonogenicity  in  LTBMC  from  patient  1-5).  The  long  term 
bone  marrow  cultures  of  the  neurob las tom a  patients  are  impaired 
in  terme  of  cellularity  and  clonogenicity  when  compared  to  stage  I 
neuroblastoma  patients  with  comparable  age  as  controls  (figures 
6,  7.  8,  9:  Mean  cellularity  in  LTBMC  from  patients  at  diagnostic. 
~1ean  clonogenicity  in  LTBMC  from  patients  at  diagnostic,  ~1ean 
cellularity  in  LTBMC  from  controls,  1\.1ean  clonogenicity  in  LTBMC 
- 165  -from  controls).  The  results  of  the  cultures  for  patients  who  did 
not  received  GM  CSF  and  for  the  patients  who  received  it  are  very 
similar  suggesting  that  the  treated  patients  do  not  evidence  long 
term  effect  of  GM  CSF  on  the  bone  marrow  (figures  10,  11.  12.  13: 
Mean  cellularity  in  LTBMC  from  patients  after  ABMT.  Mean 
cellularity  in  LTBMC  from  patients  after  ABMT  and  GM  CSF.Mean 
clonogenicity  in  LTBMC  from  patients  after  ABMT.  Mean 
clonogenicity  in  LTBMC  from  patients  after  ABMT  and  GM  CSF). 
L  TBMC  from  normal  bone  marrow  donors  give  very  similar  results 
to  LTBMC  from  stage  I  neuroblastoma  controls.  Late  survey  (more 
than  10  months  after  total  body  irradiation  and  up  to  28  months) 
do  not  evidence  a  clear  GM  CSF  effect  either,  although  the  LTBMC 
evidence  the  long  lasting  impairment  of  the  marrow  functions 
following  the  therapies  (figures  14.  15,  16,  17:  Late  survey  of 
clonogenicity  in  LTBMC  after  ABMT  without  GM  CSF,  Late  survey  of 
cellularity in  LTBMC  after  ABMT  and  GM  CSF.  Late  survey  of 
cellularity  in  LTBMC  after  ABMT  without  GM  CSF.  Late  survey  of 
clonogenicity in  LTBMC  after  ABMT  and  GM  CSF). 
No  secondary  diseases  have  appeared  for  these  patients.  No  bone 
marrow  exhaustion  related  to  GM  CSF  treatment  was  reported.  We 
did  not  evidenced  any  effect  of  GM  CSF  on  preadipocytes  among 
stromal  cells  during  long  term  follow  up. 
Cloning  and  growth  of  neuroblastoma  cells  in  semi-solid  media 
have  been  reported  previously  and  the  fundamental  importance  of 
the  interaction  between  tumor  cells  and  hemopoietic  function  for 
diagnosis,  prognosis  and  follow  up  has  been  emphasized.  We  did  not 
evidence  any  action  of  GM  CSF  either  on  the  number  of  clonogenic 
•  166  • tumoral  cells,which  may  be  representative  of  the  quantitative 
growth  potential  of  the  tum or.  or  on  the  spheroid  sub cultures. 
which  may  be  closer  to  the  typical  growth  behavior  of  the  tumors. 
Histochemical  stainings.  cytological  examinations  and 
immunoenzymatic  assays  for  the  presence  of  NSE  and  GD2  did  not 
evidence  any  change  in  the  differentiation  pattern  of 
neuroblastoma  cells  following  growth  factor  therapy.  The  observed 
normal  initial  hemopoietic  cell  production  already  documented 
suggests  that  the  interaction  between  impaired  bone  marrow 
function  and  neuroblastoma  cell  growth  is  not  a  direct  inhibition 
of  the  hemopoietic  stem  cell  production. 
Results  evidP,nce  no  long  term  effect  of  GM  CSF  infusion  when 
compared  to  control  either  on  normal  (hematopoietic  or  stromal) 
cells  or  on  tumoral  cells.  The  assay  we  developed  might  be  of 
diagnostic  and  prognostic  value  to  assess  the  functions  of  the  bone 
marrow  during  treatment  and  to  assess  the  effect  of 
hematopoietic  growth  factors.  During  the  GM  CSF  clinical  trial  for 
solid  tumor  patients,  at  the  level  of  LTBMC,  we  have  not  evidenced 
adverse  or  positive  effects  of  GM  CSF  on  stromal  cells.  The  G~f  CFU 
clonogenicity  assays  and  the  production  of  mature  cells  1n  L  TB~1C 
supernatant  are  not  modified  either.  Abnormal  cells  do  not  appear 
more  frequently  suggesting  that  in  this  peculiar  disease  the 
tumoral  cells  are  not  sensitive  to  the  growth  factor.  No  abnormal 
bone  marrow  cells  was  evidenced  by  culture  technique.  This 
results  suggest  that,  in  this  protocol,  GM  CSF  has  no  long  term 
adverse  effects  on  the  bone  marrow  . 
•  167  • 3  HEMATOPOIETIC GROW[H EACfOR TREATMENT Of SECONDARY 
APLASIA  STUDY 
GM  CSr  was  used  as  a  treatment  in  21  compassionate  need  cases.  A 
study  of  short  term  side  effects  and  tn  vitro  effects  of  the  growth 
factor  was  set  up. 
Patients  had  marrow  failure  (less  than  500  blood  leukocytes/rom  3) 
following  allogenic  bone  marrow  transplantation  for  the  treatment 
of  aplastic  anemia,  chronic  or  acute  leukemias  (the  conditionning 
regimen  included  a  10  Gy  single  exposure  total  body  irradiation) 
and  was  associated  with  graft  versus  host  disease  ( 11  patients), 
cytomegalovirus  or  other  viral  infections  ( 10  patients),  veino 
occlusive  disorder  (in  one  case),  aspergillosis  or  candidosis  (3 
patients).  Patients  received  a  first  cure  of  0.216  mg  per  day  for  14 
days  subcutaneously.  The  treatment  was  continued  when  needed 
and  well  tolerated.  Vital  signs  monitored  were  weight,  systolic 
pressure,  diastolic  pressure,  radial  pulse.  respiratory  rate.  body 
temperature  and  maximal  temperature.  Karnofsky  performance  was 
scored.  Hematology  included  blood  leukocytes,  erythrocytes. 
platelets,  reticulocytes,  eosinophils.  monocytes.  lymphocytes. 
b asophils.  neutrophils,  hemoglobin.  hematocrit.  Biochemistry 
included  measurement  of  Sodium,  Potassium,  Creatinine.  Urea, 
Calcium.  Total  Bilirubin,  ASAT  (GOT).  ALAI  (GPT).  Gamma  GT. 
Alkaline  phosphatase,  Total  Cholesterol,  Total  Protein.  Albumine, 
Globuline.  Uric  Acid.  Glucose.  Overall  tolerability  and  efficacy  was 
- 168  -correlated  to  the  concomitant  medications  and  assessed  by 
investigators.  Attempt  to  established  long  term  bone  marrow 
cultures  for  some  of  these  patients  and  for  patients  with  severe 
aplastic  anemia  patients  who  did  not  received  GM  CSF  were 
realised.  The  sample  (about!  ml  over  heparine-Roche)  was  diluted 
( 113)  with  Iscove's  medium  (Gibco)  and  centrifuged  over  ficoll  of 
density  1. 119  (Sigma)  10  minutes  at  200  g  followed  without  stop 
by  15  minutes  at  400  g  to  get  rid  of  most  of  the  red  cells.  The 
nucleated  overlaying  cells  were  washed  three  times  ( 10  minutes 
at  400  g)  in  Iscove's  medium  2%  foetal  calf  serum  (FCS-
Boehringer)  and  cultured  (596  C02.  at  33°C)  after  the  viability  of 
the  cells  had  been  assessed  by  the  trypan  blue  exclusion  test 
(2.106  viable  cells/ml  10  Iscove's  medium  10  %  FCS,  10%  human  AB 
serum  - CNTS.  1  o-6  t-.1  hydrocortisone  hemisuccinate  - Sigma).  Half 
of  the  supernatant  was  removed  each  week,  the  collected  cells 
were  counted  (expressed  in  million  cells  per  millilitre.  C/ml)  and 
the  clonogenicity  of  granulocyte-macrophage  progenitors  (GM  CFU) 
was  tested  in  triplicate  among  the  non  adhering  cells  using 
conditionned  medium  of  the  human  563 7  cell  line  as  a  source  of 
hemopoietic  colony  stimulating  factors  ( 105  cells/ml  in  Iscove's 
medium,  0.3  96  agar  - Difco,  10%  conditioned  medium  of  5637  cell 
line,  15  %  FCS,  cultured  in  Petri  dishes  at  5%  C02•  37oC).The  ma1n 
probleme  encounter  was  the  very  low  quantity  of  cells  in  the 
sample  (we  had  to  use  Leighton  tubes  or  10  square  centimeters 
dishes  in  order  to  keep  a  high  concentration  of  cells  in  the  culture 
as  attempt  to  culture  the  cells  at  lower  density  were 
- 169  -unsuccessful)  and  its  sensitivity  to  the  toxic  effects  of  horse 
serum. 
Overall  tolerability  was  good  or  very  good  tn  l 7  cases.  moderate 
in  4  cases,  no  poor  tolerability  was  reported.  Efficacy  was  good  or 
very  good  tn  12  cases.  moderate  in  5.  slight  in  one  case  and  no 
efficacy  at  all  was  reported  in  3  cases.  The  large  heterogeneity  of 
the  indications  for  compassionate  need  case  do  not  allow  to  draw 
a  general  conclusion  from  this ..  study.  However  it  appears  that  the 
dose  used  during  this  assay  (which  was  about  8 
microgrammes/kg/day)  was  well  tolerated  and  had  a  positive  role 
on  leukopenia  in  most  patients  as  evidenced  by  the  results  of  the 
hematology  counts 
(figures  18,  19,  20,  21,  22:  Mean  leukocytes  counts  during  GM  CSF 
treatment,  Mean  erythrocytes  counts  during  GM  CSF  treatment, 
lv1ean  platelets  counts  during  GM  CSF  treatment.  t-.1ean  hemoglobin 
level  during  GM  CSF  treatment,  Mean  hematocrit  during  GM  CSF 
treatment)  The  observed  changes  on  platelets  and  red  cells  counts 
correlate  with  transfusion  of  these  elements  to  the  patients  and 
are  not  likeky  to  be  due  to  a  direct  positive  role  of  GM  CSF  on 
these  cell  lines.  When  a  patient  received  more  than  one  treatment 
it  appear  that  there  was  no  long  lasting  effects  on  leukocytes 
blood  counts  and  that  the  effects  of  the  cure  were  not  really 
cumulative  although  some  patients  had  higher  leukocyte  level 
during  the  repeated  cures  (figures  23a  to  23e:  Leukocytes  counts 
in  G M  CSF  treatments  of  five  patients).  Cell  production  exhaustion 
was  not  reported  in  response  to  GM  CSF  therapy  although  the  given 
- 170  -dose  had  to  be  enhanced  for  some  patients  tn  an  attempt  to  reach  a 
better  efficacy  (up  to  0. 638  mg  per  day).  The  growth  factor 
therapy  does  not  seems  to  act  on  the  other  studied  parameters. 
Study  on  bone  marrow  failure  using  a  long  term  bone  marrow 
culture  technique  has  laid  to  unclear  results:  we  have  been  able  to 
developpe  an  assay  for  aplastic  bone  marrow  (using  human  AB 
serunt  instead  of  the  classical  horse  serum  used  in  L  TBt-.1C.  a 
stromal  layer  was  established  in  a  majority  of  the  cultured 
samples  from  severe  aplastic  anemia  patients)  but  the  important 
individual  variability  and  the  poor  condition  of  the  patients  has 
not  allowed  us  to  evidence  any  gain  or  loss  from  GM  CSF  with  the 
techniques  we  used.  We  concluded  that  this  type  of  culture  is 
inappropriate  for  those  patients. 
- 171  -4 CONCLUSION 
Although  a  large  variety  of  clinical  trials  have  been  set  up. 
the  efficiency  of  human  recombinant  GM  CSF  therapy  in  the 
treatment  of  leukopenia  is  not  well  established  yet.  Our  results 
suggest  that  there  is  no  contraindication  to  the  use  of  Gtvt  CSF  for 
the  treatment  of  leukopenia  due  to  adverse  long  term  effect  of  GM 
CSF  or  because  of  the  rather  mild  side  effects  reported  during 
these  studies. 
~1ost  of  the  initial  studies  were  performed  in  vitro  and  1n  vivo 
with  glycosylated  G~1  CSF  produced  by  gene  expression  1n 
eukaryotic  cells  (namely  chinese  hamster  ovary  cells).  However 
the  GM  CSF  now  available  for  clinical  trials  is  obtained  from 
prokaryotic  strain  (E.  coli)  and  thus  non  glycosylated.  In  vitro 
studies  have  shown  that  non  glycosylated  growth  factors  (except 
erythropoietin  which  is  highly  glycosylated  in  its  natural  form) 
have  comparable  activities  to  glycosylated  forms.  However.  the 
presence  of  antibodies  to  non  glycosylated  GM  CSF  has  been 
observed  1n  the  serum  of  treated  patients.  The  selective 
immunization  could  hinder  the  efficacy  of  the  treatment. 
Furthermore,  a  lower  efficacy  for  blood  hematopoietic  stem  cell 
harvesting  (for  autologous  blood  stem  cell  transplantation)  has 
been  recently  reported.  The  differences  observed  between  in  vivo 
effects  of  non  glycosylated  versus  glycosylated  growth  factors 
suggest  that  further  studies  are  needed. 
- 172  -Granulocytes  colony  stimulating  factor  (G  CSF)  and  interlcukin  3 
arc  promtst ng  h cmo poieti c  growth  factors  entering  clinical  trial 
for  the  treatment  of  aplasia.  Other  growth  factors  are  gotng  to  be 
on  clinical  trial  and  some  of  their  properties  may  be  important  for 
radiopathology  patients  (such  as  interleukin  wh~ch  may  have  a 
radioprotective  effect,  interleukin  6  which  may  act  on  primitive 
stem  cells.  TGF  P  which  protect  experimental  animals  against 
sepsis).  Although  their  side  effects  are  rather  well  identified, 
long  term  effects  are  not  known,  and  may  be  of  peculiar 
importance  for  IL  3  which  is  known  to  stimulate  the  growth  of 
some  leukemia  cell  lines.  Furthermore  clinical  trials  for 
combination  of  growth  factors  (IL  3  plus  GM  CSF  for  example)  are 
going  to  be  set  up  and  the  side  and  long  term  effects  are  not  well 
documented.  The  assays  we  have  developed  will  be  adapted  to  the 
new  protocols  in  order  to  assess  their  long  term  effects.  New 
other  assays  should  be  developed  in  order  to  study  the  potential 
use  of  these  factors  for  overexposed  patients. 
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